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The global aim of this thesis was to assess retinal vascular reactivity in glaucoma patients 
using a standardised hypercapnic stimulus. There is a suggestion of disturbance in the 
regulation of retinal and optic nerve head (ONH) hemodynamics in patients with Primary 
Open Angle Glaucoma (POAG), although much of the work to-date has either been 
equivocal or speculative. Previous studies have used non-standardised hypercapnic stimuli to 
assess vascular reactivity. To explain, hypercapnia induces hyperventilation which disturbs 
arterial oxygen concentration, an effect that varies between individuals resulting in the non-
standardised provocation of vascular reactivity. Therefore, a normoxic hypercapnic 
provocation was developed to avoid additional and potentially uncontrolled vasoconstriction 
in what is thought to be a vasospastic disease. The development of a safe, sustained and 
stable normoxic hypercapnic stimulus was essential for the assessment of retinal arteriolar 
vascular reactivity so that repeated hemodynamic measurements could be obtained. 
Furthermore, most techniques used to measure vascular reactivity do not comprehensively 
assess retinal hemodynamics, in terms of the simultaneous measurement of vessel diameter 
and blood velocity in order to calculate flow. In this respect, this study utilized a technique 
that quantitatively assesses retinal blood flow and vascular reactivity of the major arterioles 
in close proximity to the ONH. The stimulus and vascular reactivity quantification technique 
was validated in healthy controls and then was clinically applied in patients with POAG. 
Newly diagnosed patients with untreated POAG (uPOAG) were recruited in order to avoid 
any confounding pharmacological effects and patients with progressive POAG (pPOAG) 
were also selected since they are thought to likely manifest vascular dysregulation. Finally, 
the results of the functional vascular reactivity assessment were compared to those of 
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systemic biochemical markers of endothelial function in patients with untreated and 
progressive POAG and in healthy controls. 
 
Overall summary  
A safe, sustained, stable and repeatable normoxic hypercapnic stimulus was developed, 
evaluated and validated. In terms of the physiology of retinal vascular regulation, the percent 
magnitude of vascular reactivity of the arterioles and capillaries was found to be comparable 
in terms of flow. The new stimulus was successfully applied in POAG and in healthy 
controls to assess vascular reactivity and was also compared to plasma levels of ET-1 and 
cGMP. In terms of the patho-physiology of POAG, the study revealed a clear impairment of 
vascular reactivity in the uPOAG and pPOAG groups. There were reduced levels of plasma 
ET-1 in the uPOAG and ntPOAG groups. In addition, treatment with Dorzolamide improved 
vascular reactivity in the ntPOAG group in the absence of any change in the expression of 
plasma ET-1 or cGMP. Future work will address this apparent contradiction between the 
outcome of the functional vascular reactivity assessment and the biochemical markers of 
endothelial function in newly diagnosed POAG patients treated with Dorzolamide. 
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Aims of chapters 
 Chapter 3: To determine the effect of hypercapnia on retinal capillary blood flow in the 
macula and ONH using scanning laser Doppler flowmetry (SLDF) in young healthy subjects. 
 Chapter 4: To describe a new manual methodology that permits the comprehensive 
assessment of retinal arteriolar vascular reactivity in response to a sustained and stable 
hypercapnic stimulus. The secondary aim was to determine the magnitude of the vascular 
reactivity response of the retinal arterioles to hypercapnic provocation in young healthy 
subjects. 
 Chapter 5: To compare the magnitude of vascular reactivity of the retinal arterioles in terms 
of percentage change of flow to that of the retinal capillaries using a novel automated 
standardized methodology to provoke normoxic, or isoxic, hypercapnia. 
 Chapter 6: To determine the magnitude of retinal arteriolar vascular reactivity to normoxic 
hypercapnia in patients with untreated POAG (uPOAG), progressive POAG (pPOAG) and 
controls. The secondary aim was to determine retinal vascular reactivity in newly treated 
POAG (ntPOAG, i.e. after treatment with 2% Dorzolamide, twice daily for 2 weeks). 
 Chapter 7: To compare plasma endothelin-1 (ET-1) and cyclic guanosine monophosphate 
(cGMP) between groups of patients with untreated primary open angle glaucoma (uPOAG), 
progressive POAG (pPOAG), newly treated POAG (ntPOAG) and controls. The effect of 
normoxic hypercapnia on plasma ET-1 and cGMP was also assessed. The functional 
measures of retinal blood flow and vascular reactivity were correlated with systemic 





Chapters 3, 4 and 5 were conducted on young healthy control subjects, where as Chapters 6 
and 7 were conducted on patients with glaucoma and healthy controls. 
 Chapter 3: Subjects breathed unrestricted air for 15 minutes (baseline) via a sequential gas 
delivery circuit and then the fractional (percent) end-tidal concentration of CO2 (FETCO2) 
was manually raised for 15 minutes by adding a low flow of CO2 to the inspired air.  For the 
last 15 minutes, FETCO2 was returned to baseline values to establish a recovery period. 
Heidelberg Retina Flowmeter (HRF) images centered on both the ONH and the macula were 
acquired during each phase. 
 Chapter 4: Subjects breathed air via a sequential gas delivery circuit for 15 minutes and the 
air flow was then manually decreased so that subjects inspired gases from the rebreathing 
reservoir until a stable 10-15% increase in FETCO2 concentration was achieved for 20 
minutes. Air flow rate was then manually elevated so that subjects breathed primarily from 
the fresh gas reservoir to return FETCO2 back to baseline for the last 15 minutes. Retinal 
arteriolar hemodynamics was assessed using the Canon Laser Blood Flowmeter (CLBF) 
during all three breathing phases. 
 Chapter 5: Normoxic, or isoxic, hypercapnia was induced using an automated gas flow 
controller (RespirActTM, Thornhill Research Inc. Toronto, Canada). Subjects breathed air 
with PETCO2 normalized at 38 mmHg. An increase in PETCO2 of 15% above baseline, whilst 
maintaining normoxia, was then implemented for 20 minutes and then PETCO2 was returned 
to baseline conditions for 10 minutes. Retinal and ONH hemodynamic measurements were 
performed using the CLBF and HRF in random order across sessions. 
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 Chapter 6: Retinal arteriolar vascular reactivity was assessed in patients with uPOAG, 
pPOAG (defined by the occurrence of optic disc hemorrhage within the past 24 months) and 
controls during normoxic hypercapnia. Using the automated gas flow controller, patients 
breathed air for 10 mins and PETCO2 was maintained at 38mmHg. Following this normoxic 
hypercapnia (a 15% increase in PETCO2 while PETO2 was maintained at resting levels) was 
induced for 15 mins and then for the last 10 mins PETCO2 was returned to baseline (post-
hypercapnia) to establish recovery blood flow values. Retinal arteriolar diameter, blood 
velocity and blood flow was assessed using the CLBF in both patient groups and controls. A 
similar paradigm was repeated in the newly treated POAG group (ntPOAG, i.e. after 
treatment with 2% Dorzolamide, twice daily for 2 weeks). 
 Chapter 7: Blood samples were collected from the cubital vein of all participants (uPOAG, 
pPOAG, ntPOAG and controls) during baseline conditions (PETCO2=38mmHg) and then 
during normoxic hypercapnia (i.e. a 15% increase in PETCO2 relative to the baseline) using 
the paradigm described for Chapter 6. ET-1 and cGMP was assessed using immunoassay. 
 
Results 
 Chapter 3: The group mean nasal macula capillary blood flow increased from 127.17 a.u. 
(SD 32.59) at baseline to 151.22 a.u. (SD 36.67) during hypercapnia (p=0.028), while foveal 
blood flow increased from 92.71 a.u. (SD 28.07) to 107.39 a.u. (SD 34.43) (p=0.042). There 
was a concomitant and uncontrolled +13% increase in the group mean PETO2 during the 
hypercapnic provocation of +14% increase in PETCO2. 
 Chapter 4: Retinal arteriolar diameter, blood velocity and blood flow increased by 3.2% 
(p=0.0045), 26.4% (p<0.0001) and 34.9% (p<0.0001), respectively during hypercapnia. 
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There was a stable +12% increase in PETCO2 during hypercapnia and a concomitant -6% 
decrease in PETO2. 
 Chapter 5: Using an automated gas flow controller the co-efficient of repeatability (COR) 
was 5% of the average PETCO2 at baseline and during normoxic hypercapnia. The COR for 
PETO2 was 10% and 7% of the average PETO2 at baseline and during normoxic hypercapnia, 
respectively. Group mean PETCO2 increased by approximately +14.4% and there was only a 
+4.3% increase in PETO2 during hypercapnia across both study sessions. Retinal arteriolar 
hemodynamics increased during hypercapnia (p<0.001). Similarly, there was an increase in 
the capillary blood flow of the temporal rim of the ONH (p<0.001), nasal macula (p<0.001) 
and foveal areas (p<0.006) during hypercapnia. A non-significant trend for capillary blood 
flow to increase in the macula temporal area (+8.2%) was noted. In terms of percentage 
change of blood flow, retinal capillary vascular reactivity (i.e. all 4 analyzed areas = 22.4%) 
was similar to the magnitude of arteriolar (= 24.9%) vascular reactivity.  
 Chapter 6: Retinal arteriolar diameter, blood velocity and flow did not increase during 
normoxic hypercapnia in uPOAG compared to controls. Diameter and blood velocity did not 
change in pPOAG during normoxic hypercapnia but there was a significant increase in blood 
flow (+9.1%, p=0.030). After treatment with 2% Dorzolamide for 2 weeks there was a 3% 
(p=0.040), 19% (p<0.001) and 26% (p<0.001) increase in diameter, velocity and flow, 
respectively, in the ntPOAG group. Group mean PETCO2 increased by approximately +15% 
in all the groups and there was only a +3% increase in PETO2 during hypercapnia. 
 Chapter 7: Plasma ET-1 levels were significantly different across groups at baseline (one 
way ANOVA; p=0.0012) and this was repeated during normoxic hypercapnia (one way 
ANOVA; p=0.0014). ET-1 levels were lower in uPOAG compared to pPOAG and controls at 
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baseline and during normoxic hypercapnia (Tukey’s honestly significant difference test). 
Similarly, ntPOAG group also showed lower ET-1 levels compared to the pPOAG and 
controls at baseline and during normoxic hypercapnia (Tukey’s honestly significant 
difference test). The cGMP at baseline and during normoxic hypercapnia across all groups 
was not different. In the control group, the change in ET-1 during normoxic hypercapnia was 
negatively correlated with change in retinal arteriolar blood flow (r = -0.52, p=0.04), that is, 
as the change in ET-1 reduced, the change in blood flow increased. A weak correlation was 
noted between change in cGMP during normoxic hypercapnia and the change in arteriolar 
blood flow (r = +0.45, p=0.08). 
 
Conclusions 
 Chapter 3: Hypercapnia resulted in a quantifiable capillary vascular reactivity response in 2 
of the 3 assessed retinal locations (i.e., nasal macula and fovea). There was no vascular 
reactivity response of the ONH. It is critical to minimise the concomitant change in PETO2 
during hypercapnia in order to obtain robust vascular reactivity responses. 
 Chapter 4: A technique to comprehensively assess vascular reactivity during stable and 
sustained hypercapnia was described. Retinal arteriolar diameter, blood velocity and blood 
flow increased in response to hypercapnia. The vascular reactivity results of this study served 
as a reference for future studies using the hypercapnic provocation and CLBF. Also, the 
concomitant change in PETO2 using the partial rebreathing technique was reduced compared 
to the manual addition of CO2 technique described in Chapter 3 but was still greater than 
optimal. 
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 Chapter 5: A new automated gas flow controller was used to induce standardised normoxic, 
or isoxic, hypercapnia. The magnitude of vascular reactivity in both retinal arterioles and 
capillaries in response to the new hypercapnic stimulus was robust compared to the previous 
stimuli. There was a clear ONH vascular reactivity response in this study, unlike the result 
attained in Chapter 3. Although theoretically it is predictable that the percent magnitude of 
vascular reactivity of the arterioles and capillaries should be similar, this is the first study to 
show that they are indeed comparable. The magnitude of hypercapnia was repeatable and the 
concomitant change in PETO2 was minimal and physiologically insignificant. 
 Chapter 6: The normal response of the retinal arterioles and capillaries to normoxic 
hypercapnia is impaired in both uPOAG and pPOAG compared to controls. Short term 
treatment with 2% topical Dorzolamide for two weeks improved retinal vascular reactivity in 
ntPOAG. However, it is still unclear whether this improvement is a direct effect of 
Dorzolamide or as a secondary effect of the decrease in intraocular pressure (IOP). 
 Chapter 7: We found a reduction in the plasma ET-1 at baseline and during normoxic 
hypercapnia in the uPOAG and in the ntPOAG groups. This is the first study to show a lower 
plasma ET-1 level in uPOAG. The fact that this finding was repeated after 2 weeks treatment 
with Dorzolamide in the ntPOAG group further validates these results. It also suggests that 
Dorzolamide treatment does not impact ET-1 and cGMP measures, although it clearly results 
in an improvement of vascular reactivity. Correlation results suggest that as the change in 
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1 Introduction 
The inner retina and optic nerve head (ONH), and also the choroid, are nourished by different 
blood supplies and therefore the measurement of all aspects of hemodynamic parameters 
using a single blood flow assessment technique is difficult. 
 
1.1 Anatomy and blood supply of the retina  
The inner, or neural, retina receives its blood supply through the common carotid artery, 
internal carotid artery, ophthalmic artery (OA) and finally the central retinal artery (CRA) 1. 
The CRA divides into four major arterioles usually at the surface of the ONH. The outer 
retina, or choroid, is nourished by the choriocapillaries via the common carotid artery, 
internal carotid artery, OA and the posterior ciliary arteries (PCAs) 2. The short PCAs 
(SPCA) supply the posterior choriocapillaries and the long PCAs supply the anterior 
choriocapillaries. The long PCAs and anterior ciliary arteries derived from the muscular 
branches of the OA combine to form the major circle of the iris (MCI) 1. The retinal venules 
drain blood from the retina into the central retinal vein. Venous blood eventually drains into 
the ophthalmic vein (mostly into the superior ophthalmic vein) to exit the orbit. The 
ophthalmic vein passes through the superior orbital fissure and drains into venous sinuses in 




1.2 Anatomy and blood supply of the ONH 
The ONH is stratified into 4 layers (Figure 1.1). The superficial nerve fibre layer (NFL) 
consists primarily of neurons and is predominantly supplied by the inner retinal circulation 
and, in part, by the SPCAs in the temporal area 4, 5. The prelaminar region in most eyes is 
seen clinically in the central optic cup. This layer comprises neurons and astrocytes. It 
receives its blood supply from the branches of the peripapillary choroid and from the SPCAs. 
The third layer is the lamina cribrosa (LC), consisting of fenestrated connective tissue and 
elastic fibres through which axons transit to and from the eye. The LC is principally supplied 
by the SPCAs. The retrolaminar region lies outside the globe and is posterior to the LC. As 
the axons leave the globe and exit the laminar cribrosa they are invested with myelin and the 
optic nerve increases in diameter. The lamina is nourished by both the pial vessels and the 
SPCAs 5-8. The venous drainage of the ONH is primarily through the central retinal vein and 
its branches 1, 3, 5. Hayreh S.S. (2001) and Buchi E.R. (1996) have reported that the 
prelaminar region of the ONH also drains through the choroidal veins 3, 5. The choroidal 
circulation drains through the vortex veins and empties into the superior ophthalmic and 




Figure 1.1 Blood Supply of the ONH. 
  
Abbreviations used in figure: A = arachnoid, C = choroid, CRA = central retinal artery, Col Br. = collateral 
branches, CRV = central retinal vein, D = dura, LC = lamina cribrosa, OD = optic disc, ON = optic nerve, ONH 
= optic nerve head, PCA = posterior ciliary artery, PR = prelaminar region, R = retina, S = sclera, SAS = 
subarachnoid space. 
Reprinted by permission, Progress in Retinal and Eye Research 20: 563-593, Copyright (2001). 
 
1.3 Regulation of blood flow in the retina and ONH  
The eye is supplied with autonomic nerves within the uvea and the posterior ciliary arteries 9, 
10. The retina lacks autonomic innervation and blood flow is regulated as a result of a 
myogenic driven negative feedback mechanism and by local tissue demands. In most tissues, 
arterioles are thought to be the major site for regulation of perfusion 5, 11, 12. However, there is 
also increasing evidence that the pericytes in retinal capillaries might also regulate perfusion 
at a local level 11, 13-16. 
 
Autoregulation is defined as the ability of a tissue to maintain perfusion despite changes in 
perfusion pressure. Guyton and co-workers (1964) expanded the original definition of 
autoregulation to include tissue responses to changes in blood gas concentrations, sometimes 
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referred to as metabolic autoregulation 17. The change in hemodynamic parameters in 
response to physiological provocation such as carbon dioxide (CO2) 
18-21, oxygen (O2) 
22-25, 
cold stress 26-30 or light flicker 31-35is often referred to as vascular reactivity, particularly in 
the cerebral blood flow literature.  
 
Regulation of blood flow in the eye is achieved through metabolic, myogenic, neural and 
hormonal mechanisms. Metabolic autoregulation is the regulation of the retinal and ONH 
vasculature by the local concentration of O2, CO2, potassium or hydrogen
 5, 12, 36. The 
mechanism of metabolic autoregulation is not well established but certain endothelial derived 
relaxing and constricting factors are thought to play an important role 11, 24, 36-42.  
 
An increase in blood pressure leads to vasoconstriction of arterioles, and vice versa and 
thereby maintains blood flow and this is termed as myogenic autoregulation. Myogenic 
autoregulation occurs secondary to the activation of stretch activated ion channels in vascular 
smooth muscle cells that, in turn, allow calcium ions to enter the smooth muscle cell to 
induce contraction. Myogenic autoregulation has been shown in both retinal 11, 43-45 and ONH 
circulation 46-48 in a variety of animal models.  
 
Neurogenic factors are also thought to control blood supply in certain vascular beds of the 
ocular vasculature 12 and also in response to light flicker simulation 49. However, the inner 
retina and the pre-laminar portion of the ONH lack autonomic nerve supply and the 
resistance of these vessels is altered primarily based on myogenic influences and local 
metabolic needs 1, 36. A few studies have shown that nitric oxide (NO), a potent neural 
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vasodilator, might play an important role in the regulation of inner retinal vessels 37, 50-56. 
However, earlier studies in pigs 57-59 and in humans 54 do not support the regulatory role of 
NO in the retina and ONH. 
 
Hormonal factors also participate in the regulation of blood flow by the signalling of blood 
vessel smooth muscle cells, endothelial cells and also pericytes 12, 60. In particular the renin-
angiotensin system activates angiotensin I (AT-I) to form angiotensin II (AT-II) by the action 
of angiotensin converting enzyme (ACE) 61, 62. AT-II infusion has been shown to decrease 
ONH blood flow in cats 63. Inhibition of ACE improved retinal endothelial function in rats 
with O2 induced diabetic retinopathy 
64 and in healthy humans 65. In addition, an enhanced 
increase in retinal capillary blood flow in response to flicker stimulation was shown in 
patients with reduced blood pressure (after treatment) compared to those with normal blood 
pressure 65. Epinephrine is produced by the adrenal medulla and can produce tissue 
vasoconstriction in the eye through adrenergic receptors 60, 66. However, the effect of 
epinephrine on retinal and ONH circulation is not well understood. High levels of circulating 
epinephrine fail to produce greater changes in the retinal vascular tone 67. Similarly, the role 
of other hormonal regulators such as vasopressin and natriuretic peptides are not well 
established in the retina and ONH 12. 
 
In the eye, the retina and the ONH have been generally shown to autoregulate up to an intra 
ocular pressure (IOP) increase of 30-40mmHg in clinically normal human subjects 68-71. Sehi 
and co-workers (2005) showed effective autoregulation of the ONH capillaries during diurnal 
changes in IOP and MOPP 72. In addition, Lovasik and co-workers (2003) showed that 
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choroidal blood vessels also autoregulate during an ocular perfusion pressure (OPP) increase 
of 43% achieved using isometric exercise 73. Several review papers have suggested a 
disturbance of autoregulation in primary open angle (POAG) 40, 74-79. There is, however, a 
lack of an adequate evidence base to prove the association between altered autoregulation 
and POAG. 
 
1.4 Vascular endothelial factors 
The vascular endothelium lines the lumen of blood vessels and, in terms of arterioles, is 
enveloped in the vascular smooth muscle cells 1, 60. It regulates blood flow by producing 
vasoactive substances such as Endothelial Derived Constricting Factors (EDCF) and 
Endothelial Derived Relaxing Factors (EDRF) (Figure 1.2). In healthy individuals, the 
endothelial factors respond to various provocative stimuli to maintain local blood flow, in the 
face of change in blood pressure by exercise 73, 80-83 or changes in IOP induced using a 
suction cup or after exercise 43, 69, 71, 80, 82. These factors also maintain the supply of nutrients 




Figure 1.2 Schematic representation of the vasoconstricting and vasodilating factors released by the vascular 
endothelium in response to local physiological provocations.  
Abbreviations used: AT = angiotensin, EDHF = endothelium derived hyperpolarising factor, ET = endothelin, 
NO = nitric oxide, PG = prostaglandin. 
 
The EDCFs include contracting factors such as prostaglandin H2 (PGH2) and thromboxane 
A2, derived from the cycloxygenase pathway as studied in the cerebral vasculature 
85-87. The 
cycloxygenase pathway, however, also produces prostacyclin by the activation of the enzyme 
phospholipase A2 and results in vasodilation through an increase in cyclic adenosine 
monophosphate (cAMP) 12. In addition, AT-I after conversion into AT-II by ACE can also 
result in vasoconstriction in the retinal circulation 87. 
 
Among the various dilating and constricting factors, evidence suggests that NO (EDRF) and 
endothelin-1 (ET-1) (EDCF) represent major players responsible for modulation of blood 
flow in the eye. A constant balance between these two opposing factors is critical for proper 
regulation of the vascular system 88-90. NO and ET-1 are continually secreted by the 
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endothelium. Up-regulation of ET-1 is thought to result in vasoconstriction, as will down-
regulation of NO, and vice versa. A possible disturbance of this balance between NO and 
ET-1 has been proposed in glaucoma, in particular in POAG, and this disturbance has been 
suggested to trigger a series of events that lead to the apoptotic loss of retinal ganglion cells 
and glaucomatous optic neuropathy (GON) 39, 41, 78, 91-93. 
 
1.4.1 Endothelial derived constricting factors 
The endothelial cells produce endothelin, a 21 amino acid peptide. There are three isoforms 
of endothelin, namely ET-1, ET-2 and ET-3 12, 41, 94. ET-1 is the primary constricting factor 
that has been widely studied and is thought to be produced in large amounts in the ocular 
circulation. ET-1 mainly causes vasoconstriction by the stimulation of the ET-A receptor that 
is present in the vascular smooth muscle cells and pericytes 60, 95, 96. ET-1 dependent 
vasoconstriction is thought to occur by an increase in intracellular calcium. Under normal 
conditions, at lower concentrations, ET-1 through the stimulation of the ET-B receptors, can 
result in vasodilatation via the NO/prostacyclin pathways 95.  
 
Recently, a link between IOP and factors that might drive glaucomatous optic neuropathy 
(GON) was investigated. The aqueous ET-1 concentration increased as a result of an increase 
in IOP in a rat model, suggesting a possible role of ET-1 in GON 97. Interestingly, higher ET-
B receptors have been located in pathological conditions in the astrocytes of both brain 98 and 
ONH 99, 100. Also, higher ET-B receptor immunoreactivity was observed in patients with 
glaucoma than in controls 100. Hyperoxia results in vasoconstriction of retinal blood vessels 
and this is thought to be primarily mediated by ET-1 24, 101, 102. Intravitreal injection of 
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endothelin has been shown to decrease retinal blood flow in animals 103, 104 and in humans 105. 
Endothelin can also reduce the bio-availability of NO, thereby leading to exaggerated 
vasoconstriction 89. ET-1 has been suggested to be present in higher amounts in the plasma 
and / or aqueous of patients with normal tension glaucoma (NTG) 106, 107 and in POAG with 
visual field progression 108, while there was no difference in ET-1 reported by another study 
in POAG 109 and in NTG 110. An increased aqueous level of ET-1 was also reported in 
glaucomatous dog models 111. Similarly, Tezel and co-workers (1997) showed higher levels 
of aqueous ET-1 in humans with POAG 112. However, other studies have failed to show 
higher levels of plasma ET-1 in NTG or POAG 26, 28, 109, 112 (Table 1.1a & 1.1b). Nicolela and 
co-workers (2003) were the first to investigate plasma ET-1 concentration following cold 
provocation and showed higher ET-1 levels in patients with open angle glaucoma after 
provocation 28. The discrepancy in the results of these studies might be due to the difference 
in the characteristics of the sample studied, differences in the procedures of the assay used 
(i.e. radioimmunoassay and enzyme immunoassay) and also individual variations in the 
cross-reactivities of the immunoassays. The findings of Kunimatsu and co-workers (2006) 109 
might differ from other studies in the respect that ET-1 levels were assessed in a Japanese 
population and also in patients of <60 years of age. It is thought that ET-1 levels might 
increase with age, however, this needs to be confirmed 112. 
  
Most of these studies have included patients receiving IOP lowering treatment prior to ET-1 
assessment. The influence of IOP lowering medications on endothelial vasoactive factors is 
not known, however, we cannot rule out the possible effect of treatment on these findings. 
Other vasoconstricting factors are present in the cerebral circulation such as prostaglandins, 
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superoxide anions and thromboxane A2 
113; however, there is no evidence of the involvement 
of these factors in the regulation of ocular circulation. 
Author & year Findings 
Kunimatsu S. 2006 No difference in ET-1 levels. 
Cellini M. 1997 Higher ET-1 levels. 
Kaiser HJ. 1995 No difference in ET-1 levels †. 
Sugiyama T. 1995 Higher ET-1 levels. 
 
Table 1.1 Summary of findings from various studies that investigated plasma ET-1 levels in NTG  
compared to controls and/or high tension glaucoma †.  
 
Author & year Findings 
Kunimatsu S. 2006 No difference in ET-1 levels. 
Emre M. 2005 
Patients with progressive visual fields  
had higher ET-1 levels. 
Nicolela MT. 2003 No difference in ET-1 levels. 
Hollo G. 1998 No difference in ET-1 levels †. 
Tezel G. 1997 No difference in ET-1 levels. 
  
Table 1.2 Summary of findings from various studies that investigated plasma ET-1 levels in POAG compared to 
controls and/or capsular glaucoma†. 
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1.4.2 Endothelial derived relaxing factors 
The vascular endothelium produces NO, a potent vasodilator, under basal conditions and also 
in response to physiological provocation 37, 50, 60, 90, 114. NO is formed from L-arginine by the 
enzyme nitric oxide synthase (NOS) 115, 116. There are three types of nitric oxide synthase 
(NOS) namely, endothelial NOS (eNOS), inducible NOS (iNOS) and neuronal NOS (nNOS). 
eNOS is the most widely available form in the vascular endothelium and is responsible for 
regulation of blood flow in a tissue 117, 118. The release of NO during physiological 
provocation results in the increased production of cyclic guanosine monophosphate (cGMP) 
leading to a decrease in calcium thereby causing vasodilatation 119-121.  
 
Previous research has already shown the effect of NO on the regulation of choroidal blood 
flow 54, 122. It is well established in the cerebral circulation that NO contributes to 
hypercapnia induced vasodilatation 123-127. However, a few recent studies do not support the 
above results 128, 129. The effect of NO on the ocular circulation, however, has not been as 
extensively studied. NOS inhibition was shown not to decrease the hypercapnia induced 
retinal vasodilatation in humans 124, while a positive role of NO during hypercapnic 
vasodilation was reported in cats 130. Recently, it was reported that NO plays a role in the 
recovery (i.e. post-vasoconstriction) of retinal arterioles after hyperoxia 131.  
 
Nitric oxide has a very short half-life and direct measurement is challenging. As a result, 
previous studies have investigated the presence of cGMP or levels of nitrites and nitrates in 
the aqueous and plasma as a surrogate to ascertain the level of NO expression. The findings 
of the levels of NO in glaucoma are inconclusive. There is some evidence for decreased 
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levels of NO in the plasma/aqueous of POAG 121, 132-134. However, other researchers have 
reported no difference in the plasma levels of NO 111, 135. Increased levels of nitrites have 
been noted in the aqueous and vitreous of dogs with POAG 111. Studies using other types of 
glaucoma, such as juvenile and neovascular glaucoma (NVG), showed that NO levels in the 
aqueous were higher in NVG, while they were lower in juvenile glaucoma 136. Similarly, Tsai 
and co-workers (2002) showed increased levels of nitrites in the aqueous of patients with 
NVG 111 (Table 1.2a & 1.2b). NVG, a secondary glaucoma, is generally associated with other 
systemic conditions, in particular diabetes 137. It is known that the ocular blood vessels are in 
a dilated state due to the hypoxic environment in NVG 138 and that is the possible reason for 
the increase in NO or its surrogate marker levels in NVG. 
Author & year Findings 
Kallberg ME. 2007 Increased levels of nitrites in dog models  
Galassi F. 2004 Decreased levels of cGMP 
Kosior-Jarecka E. 2004 Decreased levels of nitrites † 
Doganay S. 2002 Decreased levels of nitrites 
Kotikoski H. 2002 Trend to increase in nitrite & cGMP levels  
Tsai DC. 2002 Increase in NO levels † 
 
Table 1.3 Summary of findings from various studies that investigated aqueous NO levels (indirect markers of 




There is evidence of imbalance of NO or its surrogate markers in glaucoma compared to 
healthy controls. The measurement of indirect markers to represent NO has some 
disadvantages as it is hard to eliminate the influence of diet rich in nitrates that will 
artificially elevate nitrites, nitrates and or cGMP levels in the plasma. Previous reports lack 
details about any diet restrictions imposed in study patients other than the study by Galassi 
and co-workers (2004)121. It is yet to be confirmed whether the levels of nitrates, nitrites or 
cGMP reflect the presence of NO. 
Author & year Findings 
Galassi F. 2004 Decrease in cGMP levels. 
O’Brien C.1999* Decreased concentration of cGMP. 
Kotikoski H. 2002 Increase in cGMP levels. 
Tsai DC. 2002** Increase in NO levels†  
 
Table 1.4 Summary of findings from various studies that investigated plasma NO levels (indirect markers of 
NO such as cGMP and nitrites) in POAG, NTG* and NVG** compared to controls and/or patients with chronic 
angle closure glaucoma†.  
 
1.5 Physiological provocations and ocular vascular reactivity 
The hemodynamic response of ocular blood vessels to physiological provocation has been 
widely studied in the past. Measurement of hemodynamic parameters under normal 
circumstances may not provide adequate information about vascular regulation 139. In 
addition, it is clear that there is a wide variability in homeostatic hemodynamic variables 
 14 
amongst individuals, while the assessment of change in hemodynamics in response to some 
form of provocation results in a markedly reduced variability 140. There are various 
provocation techniques that are currently available to study the ocular hemodynamics in both 
normal and in pathological conditions. 
 
1.5.1 Blood pressure 
Blood pressure (BP) is the force exerted on the walls of the arteries as the heart pumps blood 
throughout the body. The maximum pressure exerted on the arteries during ventricular 
contraction is the systolic pressure and the minimum pressure during ventricular relaxation is 
the diastolic pressure. Average normal values of systolic and diastolic blood pressures are 
120 and 80mmHg in young healthy subjects. BP is measured using a sphygmomanometer 
and a stethoscope. Mean arterial pressure (MAP) can be calculated from the BP using the 
following relationship 
MAP = Diastolic pressure + 1/3 (Systolic-Diastolic) 
 
Previous research has shown that ocular blood flow remains stable with increase in BP 
during dynamic exercise 82. Another study showed a 2.5% decrease in retinal arteriolar 
diameter with change in MAP of 21.8mmHg relative to baseline in normal volunteers, i.e. 
suggesting a resistance to vasodilation in the face of a large increase in MAP. Not 
surprisingly, there was a weak correlation between increase in BP and decrease in retinal 
arteriolar diameter 48. 
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1.5.2 Intra ocular pressure  
IOP is the pressure induced by the constant renewal of aqueous humor from the posterior 
chamber of the eye. Aqueous humor is secreted by the non-pigmented epithelium of the 
ciliary body into the posterior chamber and passes through the pupil to drain through the 
anterior chamber via the trabecular meshwork and finally into the Schlemm’s canal. It is the 
resistance to outflow of aqueous humor at the site of the trabecular meshwork, along with the 
constant secretion of aqueous humor that generates the IOP. In addition, aqueous humor also 
drains through the anterior ciliary body into the suprachoroidal space known as the 
uveoscleral drainage but this represents only 20% of aqueous outflow. The distribution of 
normal IOP values is essentially Gaussian but with a positive skew and a range of 10-
21mmHg, with a mean of 15mmHg. The IOP exerts a uniquely high external tissue pressure 
on the retinal vessels which must be opposed with sufficient force to preserve lumen 
integrity. 
 
Riva and co-workers (1981) studied autoregulation of the retinal circulation using the blue 
field entoptic technique and showed that the retinal vessels autoregulated up to a 36% 
decrease in perfusion pressure (as defined below) 68. In a recent study, choroidal blood flow 
showed a negative correlation with increase in IOP and MAP. However, choroidal blood 
flow did not change until an IOP increase of 40mmHg was achieved using a suction cup 80.  
 
1.5.3 Ocular perfusion pressure (OPP) 
OPP is defined as the resultant pressure of blood entering the eye. It can be calculated using 
the following relationship: 
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OPP = 2/3 MAP – IOP 
An increase in OPP of 43% from baseline was found not to change choroidal blood flow 
measured using Laser Doppler Flowmetry 73. Also, other studies have shown effective 
autoregulation up to a 67% 141 and 69% 142 increase in OPP after isometric exercise. 
Conversely, some studies have shown that an increase in OPP after dynamic exercise results 
in an increase in ocular blood flow using the Scanning Laser Blood Flowmeter (SLDF) and 
the Pulsatile Ocular Blood Flowmeter (POBF) in healthy subjects i.e. no effective 
autoregulation within the autoregulatory range 56, 83. 
 
1.5.4 Flicker stimulation 
The retinal vasculature regulates blood flow as a result of various metabolic demands. The 
regulation of choroidal vessels in response to flicker stimulation is not well understood. 
Flicker of different frequencies can be produced using a photo stimulator that can emit 
flashes at a pre-determined time interval. Studies have shown that there is a significant 
increase in blood volume in the ONH during flicker stimulation 35, 143. A few studies have 
shown no change in retinal and choroidal perfusion in response to flicker 143, 144. The 
mechanism by which retinal vessels regulate their blood supply during flicker stimulation is 
not completely clear but it is thought to be due to coupling of neural activity with blood flow 
to increase ganglion cell activity 32, 145. It has been suggested that flicker stimulation of 
change in retinal blood flow is a measure of endothelial function, although the evidence to 
support this theory is currently equivocal. 
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1.6 Ocular blood flow measurement techniques  
1.6.1 Color doppler imaging (CDI) 
CDI is a non-invasive technique based on the principle of ultrasound that is used to measure 
blood velocity in extra ocular vessels i.e., OA, CRA and SPCAs. Sound waves from a 
stationary object reflect with an unchanged frequency, while those from moving particles 
have a shift in frequency. Blood velocity can be calculated from the frequency shift of the 
sound waves that reflect from the moving blood. This technique cannot measure the diameter 
of blood vessels and therefore the quantification of blood flow is not possible. Previously, 
disturbed homeostatic blood velocity in the CRA and/or OA, SPCAs in patients with POAG 
has been shown 146. Importantly, the angle at which the probe is held in relation to the eye 
will impact the velocity values since the measured Doppler shift depends upon the angle 
between the moving object and the reflected sound wave. Patients with POAG in response to 
hypercapnia have shown a decreased magnitude of vascular reactivity compared to ocular 
hypertensive patients and controls 147. 
  
1.6.2 Pulsatile ocular blood flowmeter (POBF) 
The POBF instrument measures the pulsatile component of the arterial blood flow and 
primarily reflects the choroidal circulation since this is by far the predominant circulatory 
component in the eye. IOP is sampled at 200Hz in 5-20seconds using a pneumatic probe 
attached to a disposable tip. The resulting pulsatile waveform provides information about 
IOP, systolic and diastolic time, ocular pulse amplitude and heart rate. The pulsatile ocular 
blood flow is automatically calculated by the instrument by the analysis of the IOP 
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waveforms between systolic and diastolic IOP assuming standard ocular rigidity and constant 
aqueous humor outflow. POBF measurements are influenced by axial length and refractive 
error. The blood flow measurements are not obtained through direct assessment of ocular 
blood flow. They are derived mathematically by estimating ocular pulse volume change on 
the basis of a preset equation relating ocular volume to IOP. This assumes a uniform and 
stable ocular rigidity. POBF measurements have been shown to be reduced in patients with 
NTG 134, 148. 
 
1.6.3 Blue field entoptic phenomenon 
This non-invasive psychophysical technique is used to measure retinal macular capillary 
velocity. The blue-field entoptic phenomenon can be best perceived at a narrow band of blue 
light of wavelength 430nm. The movement of white blood cells (WBC’s) can be seen as a 
flying corpuscle at 10-15 degrees around the fovea. To determine mean blood velocity, 
subjects are shown a stimulated particle field and asked to match a comparison field to the 
speed of their perceived moving corpuscles. In the past, retinal vascular reactivity in response 
to various provocation stimuli has been studied using this technique 19, 25, 149. The major 
limitation of this technique is that it is subjective, quantifies movement of only WBC’s and 
also has very poor reproducibility. 
   
1.6.4 Laser interferometry (Fundus pulsation technique) 
The laser interferometry is a technique used to determine the pulsatility of the choroidal 
blood flow 150. The eye is illuminated using a single mode-diode laser of wavelength 783nm. 
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The light is reflected from the front surface of the cornea and the retina. This results in an 
interference pattern from which the distance between the cornea and the retinal surfaces are 
calculated along the cardiac cycle. The maximum change in distance between the systolic 
and the diastolic phase is referred to as the fundus pulsation amplitude (FPA) 118, 151. The 
change in the interference pattern is measured in micrometers. A decrease in choroidal blood 
flow has been shown in POAG using the fundus pulsation technique152.  
 
1.6.5 Retinal vessel analyzer (RVA) 
The RVA measures retinal arteriolar and venular diameter in relative units. It consists of a 
fundus camera, a charge-coupled device and a computer. An area in the retina is defined by 
the examiner and the diameter of the vessel (arteriole, venule, or both) inside this region is 
determined using an algorithm that detects the edges of the vessel at a maximum frequency 
of 50Hz 153. The fundus is imaged onto the charge-coupled device (CCD) chip of the video 
camera. There are a total of 25 diameter measurements performed every second 19, 154. The 
system automatically stops the measurement if the readings are affected due to eye 
movements or blinks and restarts as soon as a clear fundus image is obtained 153. This 
instrument does not measure blood velocity and flow in the retinal vasculature, rather it 
infers a direct relationship between diameter and retinal blood flow. RVA has been used in 
clinically healthy subjects to assess retinal arteriolar and venular diameter in response to 
hypercapnia and hyperoxia 19, 154. There is lack of information on retinal vascular response in 
POAG using the RVA. 
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1.6.6 Laser Doppler effect 
The Doppler effect is the observed change in frequency, often termed frequency shift, that a 
light or sound wave undergoes when reflected from a moving object, relative to the 
frequency of the wave prior to reflection (or relative to neighbouring non-moving tissue). 
The velocity of the moving object is directly proportional to the change in frequency  
(Figure 1.3). 
Doppler effect can be approximated as: 
df / f  =  
v Cos a / c 
df is the frequency shift, f is the frequency of the light wave; v is the velocity of the moving 
object: c is the speed of light; a is the angle between the velocity vector of the moving object 
and the direction of observation. 
 
Figure 1.3 Schematic representation of the Doppler effect.  
Laser beam of frequency (f) strikes the red blood cells moving with a velocity (V) and the resulting Doppler-
shifted frequency (∆f ) is detected by the photodetector. 
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1.6.7 Heidelberg retina flowmeter (HRF) 
The principle of the HRF is based on the combination of confocal scanning laser and the 
Doppler effect. The HRF is used to measure blood velocity, volume and flow (arbitrary units) 
in the retinal and ONH capillaries (Figure 1.4). The fundus is illuminated using a diode laser 
source of 780nm wavelength with a power of 180µW. After the laser beam is centered on the 
area of interest, instrument focus is adjusted to produce maximal brightness within that area 
but without “pixel burnout”. The scan field is 10˚ wide and 2.5˚ high with a total area of 
2.88x0.72mm and a scan resolution of 256 pixels (horizontal) by 64 lines. Each line of 256 
pixels is sequentially scanned 128 times at a frequency of 4000Hz. The incident and reflected 
light interfere resulting in an oscillation, or “beat”, of the measured light intensity. The 
resulting “beat” is converted using a digitizer to obtain 256 pixels in each measurement line. 
The intensity of back-scattered laser light from the retina is measured as a function of time 
(to produce an intensity-time curve) for each pixel within the image. The intensity obtained 
at each pixel undergoes Fast Fourier Transformation (FFT) to generate a power spectrum (as 
a function of frequency). Volume, flow and velocity are calculated based on this power 
spectrum. The point in the power spectrum where the frequency is zero P(0; x,y) is the direct 
current (DC) value. The power spectra is corrected for noise and normalised to the DC 
component to avoid dependence of reflectance 155, 156. 
 
1.6.7.1 HRF calculation of volumetric blood flow 
Volume is calculated as an integral of the power spectrum over all frequencies and is 
proportional to the total number of red blood cells in the measured volume. Flow is 
calculated as the integral of power times the frequency and is proportional to the number of 
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red blood cells multiplied by their velocity.  Velocity is calculated using flow divided by 
volume, normalised by the DC value. The upper limit of the integral equation = 2000Hz and 
the lower limit =125. The upper limit in the equation is determined based on the Nyquist 
sampling theorem (sampling rate is twice the frequency i.e. the HRF samples at a rate of 
4000Hz in order to obtain all range of frequencies to calculate volume, velocity and flow). 
The lower limit is chosen such as to eliminate intensity variations that are due to eye 
movements, heart beat and respiration 155. 
 
Studies have shown SLDF measurements of the ONH and / or temporal retinal area to be 
lower in patients with POAG compared to controls 152, 157-159. There are a number of 
limitations noted in previous studies using this instrument. There is an artificial flow value 
produced even when no cells are moving 160, 161. Research from our lab has shown an 
artifactual increase in HRF flow values using a simulated light scatter model 162. However, 
the HRF can be used as a follow-up tool to measure flow at one site across time 160, 161. 
  
Figure 1.4 Photograph of the Heidelberg Retina Flowmeter. 
Laser head of the instrument mounted on a table and attached to a chin rest. 
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1.6.8 Bidirectional laser Doppler velocimetry 
The use of two photo-detectors separated by a known angle permits the quantification of 
absolute centre-line blood velocity, irrespective of the angle between the moving particle and 
incident beam 163, 164. The previous optical set-up described by Feke and Riva (1978) 165 did 
not measure absolute velocity due to the difficulty in determining the angles between the 
incident laser light and the moving blood cells. When an incident beam strikes the moving 
red blood cells (RBC) it is known that a vessel that exhibits Poiseuille flow will result in a 
frequency shift of up to a maximum ∆fmax 
163, 166. This shift ∆fmax corresponds to the 
maximum velocity at the centre of the vessel lumen. 
 
∆fmax = fmax2 – fmax1 = (α2 – α1).n/λ 
 
 where α1 and α2 are the angles between the velocity vector Vmax and K1 and K2, 
respectively. fmax1 and fmax2 are the maximum frequency shifts at K1 and K2, respectively, n 
is the refractive index of the medium and λ is the wavelength of the incident light (Figure 
1.5). 
Vmax = λ.∆f / n.∆α.cosβ 
 




Figure 1.5 Schematic representation of the bi-directional laser Doppler effect.  
Laser beam of frequency (f) strikes the red blood cells moving with a velocity (Vmax) and the resulting 
Doppler-shifted frequencies fmax1 and fmax2 is detected by two photodetectors separated by a known angle. 
 
In a vessel that exhibits Poiseuille flow, mean velocity can be calculated using the following 
relationship 167. 
Vmean = Vmax / 2 
Flow rate (F) = Vmax S/2 where S is the cross sectional area of 
the vessels at the measurement site. 
Retinal blood flow can be calculated based on the diameter and maximum velocity (Vmax) 
measured. 
F =  ½.π.D2/4. 1/T + Vmax(t) dt 
where Vmax(t) is maximum RBC velocity, D is vessel diameter, T is the observation period, 
and 1/T·∫Vmax(t) dt is the average of Vmax during T 168. This formula assumes that blood 
flow is according to Poiseuille flow and that the blood vessel exhibits a circular cross section. 
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1.6.9 Canon laser blood flowmeter (CLBF -Model 100) 
The CLBF simultaneously measures vessel diameter (µm) and blood velocity (mm/sec) to 
calculate the rate of blood flow (µL/min) 22, 168-171 (Figure 1.6). Retinal vessel diameter is 
determined by projecting a rectangular (1500×150 µm) green (543  nm) HeNe diode laser 
perpendicular to the vessel segment measurement site. Densitometry analysis of the cross-
sectional vessel image on the CLBF array sensor is used to calculate vessel diameter. The 
minimum point (Min1) in the central
 portion of the image is designated as the nominal vessel 
center with D1 being its signal level from the background
 level. When mirror reflection 
occurs from the vessel wall, the second minimum point is observed in the neighborhood of 
Min1
 with signal level D2. The maximum points on either side
 are detected as the vessel 
edges with D3 and D4
 signal levels. The half-height points (X1 and X2) are points
 on the image 
whose signal levels are (D1+D3)/2 and (D2+D4)/2,
 respectively. The width between X1 and X2 
is taken to represent the uncorrected vessel diameter and is converted into micron units after 
correction for axial and refractive magnification effects 171-173 (Figure 1.7). Diameter 
measurements are acquired every 4 ms during the first and last 60 ms of the 2secs velocity 
acquisition window. An integral “eye tracking” mechanism stabilizes the laser system on the 
selected measurement site. Light from the red laser is projected into the center of the green 
rectangle 161. The green laser is manually adjusted perpendicular to the vessel segment 
(Figure 1.8). The resulting cross-sectional image of the vessel is focused on the CLBF array 
sensor. The array sensor detects any lateral motion of the vessel and, via a negative feedback 
loop, controls the galvanometer steering system to stabilize the green tracking laser on the 
selected measurement site. This system also enables identification and post-acquisition 
rejection of velocity measurements impacted by significant saccades (Figure 1.9). 
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 A red diode laser (675nm, 80µm x 50 µm oval), positioned in the centre of the green laser, is 
used to acquire bi-directional velocity measurements every 0.02secs throughout the 2secs 
measurement window resulting in a velocity-time trace that depicts the systolic-diastolic 
variation of blood velocity (Figure 1.10). A vessel that exhibits Poiseuille flow will have a 
range of velocities and thus a range of frequency shifts up to a maximum frequency shift 
(∆fmax) that corresponds to the maximum velocity of the blood moving at the centre of the 
vessel lumen. ∆fmax can be referenced to the frequency of laser light reflected from stationary 
tissue to calculate relative change in velocity 165. By utilizing two photo-detectors separated 
by a known angle, the maximum frequency shift detected by each photo-detector is 
subtracted to allow the absolute quantification of centre-line blood velocity, irrespective of 
the angle between the moving particle and reflected beam 163, 164. The resulting Doppler 
signal is analysed using a previously described algorithm 163, 166. The frequency shift is 
determined as the frequency at which there is an abrupt reduction in the amplitude of the 
fluctuations in the Doppler-shift power spectrum. This determination does not depend on any 
presumed shape of the average power spectral density curve. 
 
Two sequential measurements (Path 1 & Path 2) of diameter and velocity are taken to ensure 
consistency and averaged to give one reading (Figure 1.10). Hemodynamic measurements 
are corrected for magnification effects associated with axial and refractive ametropia 27, 168. 
In combination with the average velocity (Vmean) over a pulse cycle and diameter (D), flow 
(F) through the vessel can be calculated using the formula: 
 
F = ½ (π x D2/4) (Vmax x 60 sec) 
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D= vessel diameter (µm) and Vmax = maximum centreline blood velocity across a cardiac 
cycle (mm/sec). 
 
Although the only instrument capable of measuring retinal blood flow in absolute units, the 
CLBF has a number of disadvantages. The measurement is limited to a single location in the 
vascular tree. In this respect, it can be assumed that all branches of the vascular tree react 
similarly to provocation 174. Also, the measurement is not continuous but limited to a 2 
second window. For this reason, we were aware from the infancy of the work described in 
this thesis of the need to develop a sustainable and stable provocation. The flow calculated 
using the CLBF assumes that blood flows according to Poiseuille flow (i.e. maximum 
velocity is in the centre of the vessel) and that blood vessel exhibits a circular cross section. 
 
Figure 1.6 Photograph of the Canon laser blood flowmeter (model 100).  
Fundus camera like laser head mounted on a table and attached to a chin rest (left). The measurements acquired 





Figure 1.7 Densitometry signal of a cross-sectional image acquired from a retinal arteriole.  
Min1, minimum point in the central portion of the image
 designated as the nominal vessel center; D1, signal 
level of Min1 from the background level; D2, signal level of the
 second minimum point in the neighborhood of 
Min1; D3 and
 
D4, signal levels of the maximum points on either side
 designated as the vessel edges; X1 and X2, 
the half-height points whose signal levels are (D1+D3)/2 and (D2+D4)/2, respectively. The
 width between X1 and 
X2 is taken to represent the
 uncorrected vessel diameter.  
 
 
Figure 1.8 Photograph of the fundus acquired using the Canon laser blood flowmeter.  
Photograph shows the ONH - optic nerve head, superior temporal arteriole and venule. A HeNe laser of 543nm 
wavelength is centered on the arteriole of interest and oriented perpendicular to the vessel segment for 








Figure 1.9 An example of a CLBF measurement showing poor velocity waveform due to eye movements.  
The middle line in the figure is the cursor that can be moved on either side to read velocity measurement at one 
particular point on the waveform. 
 
 
Figure 1.10 A typical measurement output that appears on the CLBF computer after data acquisition.  
1) relative velocity profile of the CLBF measurement, that is variation of the centreline blood velocity during 
cardiac cycle 2) quality index of the measurement (Q index) that provides information about the overall quality 
of a reading as a numerical score  3) eye tracking measures across the 2 seconds window,  in path 1 (left) and 
path 2 (right). The two paths represent measurements obtained at two different angles of incidence of the 
measurement beam. The diameter measurements and the co-efficient of variability (CoV) are shown at the 









1.7 Gas provocations 
The hemodynamic effect of gas provocations in healthy volunteers has been extensively 
studied. The results of the effect of gas provocations in patients with POAG are discussed 
later in this chapter. 
 
1.7.1 Respiration 
The process of supplying O2 to the cells in the body and the removal of CO2 is defined as 
respiration. The first stage of respiration is gas exchange where O2 and CO2 are transferred 
between the atmosphere and the pulmonary capillaries followed by exchange between the 
systemic blood and the tissue. The second stage is cellular respiration and this involves 
various chemical processes that break down food to release energy and CO2. 
 
1.7.2 Pulmonary anatomy 
The lungs are the primary organs of gas exchange. During each inspiration, air passes 
through the nose or mouth and initially reaches the pharynx. It then travels to the larynx 
through the vocal cords and reaches the trachea that branches into two bronchi. Each 
bronchus enters the lungs that branch into further smaller structures known as bronchioles. 
The terminal bronchioles then branch into smaller structures called alveoli that are the site of 
gas exchange. Each alveolus is surrounded by pulmonary capillaries that facilitate gas 
exchange. O2 from the inhaled air diffuses through the alveolus into the blood and CO2 is 
diffused from the blood into the alveolus 175. 
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1.7.3 Mechanism of breathing 
The primary muscle involved during inspiration is the diaphragm (a structure that separates 
the abdomen from the thoracic cavity). The process of inspiration contracts the diaphragm 
leading to the contraction of external intercostal muscles that are attached to the ribs. This 
results in upward and outward movement of the ribs thereby increasing the thoracic volume 
and decreases alveolar pressure during inspiration. Inspiration is followed by expiration 
which is generally a passive process. The diaphragm and the intercostal muscles relax and 
decrease the alveolar volume thereby forcing out air from the lungs 176. 
1.7.4 Ventilation and gas exchange 
The amount of air exhaled at a given time is defined as total ventilation (VE). During 
inspiration, the total amount of air does not participate in alveolar gas exchange. The 
component that is not part of gas exchange forms the physiological dead space (VDphysiol). 
The portion of air that remains in the airways gets exhaled first during expiration. Alveolar 
ventilation is defined as the volume of air that participates in alveolar gas exchange (VA). It 
can be calculated using the following relationship: 
VA = VE - VDphysiol 
 
1.7.5 CO2 exchange 
CO2 is eliminated by the process of ventilation. The minute ventilation of CO2 (VCO2) is the 
difference between the exhaled and the inhaled amount of CO2 in a minute. As the amount of 
CO2 inhaled is negligible, the CO2 in expired gas represents the alveolar concentration of 
CO2 (FACO2). The FACO2 is equal to FETCO2 i.e., the fractional concentration of CO2 in 
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expired air measured in percent. The partial pressure of arterial CO2 (PaCO2) can be derived 
from VCO2 and is usually 40mmHg ± 3mmHg. The measurement of PaCO2 requires 
sampling from an arterial blood line and has only been used by a few studies in the past to 
measure manipulated changes in arterial partial pressure of CO2. The surrogate marker of 
PaCO2 is PETCO2 (end-tidal partial pressure of CO2: the amount of CO2 present in each 
exhaled breath, measured in mmHg) and is considered to be directly proportional to PaCO2. 
However, it has been recently shown that there is a large variation between PETCO2 and 
PaCO2 measurements achieved using non-standardised gas provocations (i.e. use of non-
rebreathing circuit and manual addition of CO2 to inspired air) 
177-179. 
 
1.7.6 Normoxic/isoxic hypercapnia 
Breathing increased amounts of CO2 without any significant change in the partial pressure of 
O2 is defined as isoxic hypercapnia (i.e. PETO2 unchanged). Normoxic hypercapnia is the 
increase in PETCO2 while the PETO2 remains constant at physiological resting levels (change 
that does not result in any physiologically measurable impact). The increase in the systemic 
partial pressure of arterial CO2 has been shown to increase blood flow in retinal vessels in 
humans 19, 20, 154, 170, 180-182 but the majority of these studies have failed to adequately consider 
O2 control during hypercapnia. The use of a standardised and a repeatable normoxic/isoxic 
hypercapnic stimulus is essential to assess vascular reactivity in order to avoid any 
confounding effects of O2 induced vasoconstriction. In this thesis, a safe, sustained and a 
stable normoxic hypercapnic stimulus was developed to assess retinal arteriolar and ONH 
vascular reactivity in patients with POAG. It is established that an increase in the arterial O2 
causes reduction in blood flow 20, 22, 23, 183-186. Similarly, the concomitant change in PETO2 
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during hypercapnia can reduce the overall magnitude of vascular reactivity obtained in 
response to the increase in PETCO2. It is widely accepted in the cerebral literature that NO 
might be an important factor that causes vasodilation. A few studies have shown the 
involvement of NO (a potent vasodilator) that leads to an increase in the retinal 130 and 
choroidal blood flow 124 in hypercapnia induced vasodilation. However, the exact mechanism 
of action is still not clear. 
   
1.7.7 Isocapnic hyperoxia 
Breathing increased amounts of O2 without a physiologically significant change in partial 
pressure of arterial CO2 is defined as isocapnic hyperoxia. The partial pressure of arterial O2 
(PaO2) can be indirectly assessed by measuring the minimum amount of O2 in each exhaled 
breath (PETO2 in mmHg). A number of studies have shown vasoconstriction in ocular blood 
vessels in humans in response to an increase in arterial partial pressure of O2 
20, 22, 154, 181, 183, 
185-188 but many of these studies have not met isocapnic conditions. Addition of O2 typically 
results in hyperventilation and thereby results in a decrease in pCO2 
189. Isocapnic hyperoxia 
generally results in accumulation of reactive oxygen species (ROS) thereby causing oxidative 
stress. Hyperoxia induced hyperventilation is thought to occur due to the stimulation of 
central chemoreceptors in the brain stem as a result of the increase in ROS 190. It is critical to 
control the concomitant change in CO2 during hyperoxia in order to reduce variability in 
retinal vascular reactivity assessment 22. The use of non-iscocapnic hyperoxia can cause a 
compounded effect on vascular reactivity assessment 23, 181, 191.  ET-1, a potent 
vasoconstrictor produced by the vascular endothelium, is thought to play an important role in 
the regulation of the retinal vasculature to isocapnic hyperoxia 24, 38. 
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1.7.8 Manipulation of CO2 concentration in ocular blood flow studies 
Studies in the past have manipulated the levels of PETCO2 using various techniques in both 
humans and animals to assess its impact on ocular blood vessels. It is known that 
hypercapnia causes unpredictable hyperventilation and thereby affects PETO2 in an 
unpredictable manner between individuals. 175. Inhalation of CO2 enriched gas dilutes the 
inspired air and thereby reduces the O2 concentration in the lungs and thus in the blood. 
However, this effect on the lung O2 concentration is partly offset by the increased ventilation 
stimulated by hypercapnia, thereby resulting in an increased PETO2. The mechanism 
involved in hypercapnia induced hyperventilation is thought to be mediated by the CO2 
sensitive central and peripheral chemoreceptors. These receptors provide feedback to the 
brain stem respiratory control system regarding arterial CO2 levels. The increase in CO2 
during hypercapnia is detected by the chemoreceptors in the brain stem thereby resulting in 
hyperventilation 192. As increase in PETO2 has been shown to decrease ocular blood flow, it 
becomes important to simultaneously monitor PETO2 during changes in CO2. However, most 
of the previous studies lack information about PETO2 during hypercapnia 
182, 193, 194.  
 
In this respect, we initially set-out to develop a normoxic/isoxic hypercapnic stimulus and 
assessed its effect on retinal vascular reactivity in young healthy subjects with the ultimate 
aim of using the standardised stimulus in patients with glaucoma. In this thesis, the use of a 
sequential rebreathing circuit along with the automated gas flow controller still resulted in a 
minimal change in PETO2. Since the change in PETO2 was minimal, the term normoxic 
hypercapnia (i.e. change that did not have any measureable physiological impact) was 
adopted rather than isoxic hypercapnia (i.e. unchanged). This stimulus was used in this work 
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to assess retinal vasodilatory capacity in patients with POAG. We chose normoxic 
hypercapnia because of concerns about provoking vasoconstriction in patients with a disease 
that might be triggered or exacerbated by transient peripheral vasoconstriction. 
  
1.8 Summary 
The blood supply to the retina and the ONH vary in terms of supply vessels and, in 
combination with differing anatomical conditions, this poses difficulty in measuring the 
hemodynamics at both sites using one instrument. The retinal vasculature is shown to exhibit 
autoregulation. Retinal arterioles are a major site of vascular resistance, however, recent 
evidence suggests that pericytes can also regulate blood flow in the eye. ET-1 and NO are 
thought to be the two major factors responsible for vascular regulation. There is some 
evidence for an increased expression of ET-1 in POAG.  
 
The CLBF is the only instrument currently available that quantifies retinal arteriolar 
hemodynamics in absolute units. The CLBF measures diameter and blood velocity at a single 
point along the vessel. Also, the measurement is not continuous but limited to a 2 second 
window. Similarly, the HRF has been used in the past to assess ONH blood flow. This 
instrument has high measurement variability and requires repeated measurements to obtain 
valid blood flow values. Both the CLBF and the HRF has been used in this work to assess 
retinal and ONH vascular reactivity in patients with POAG. For this reason, we were aware 
from the infancy of this work of the need to develop a safe, sustainable and stable 
provocation. In this respect, we set-out to initially develop a normoxic/isoxic hypercapnic 
stimulus ultimately to assess retinal vasodilatory capacity in patients with POAG.  
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The majority of previous studies have quantified homeostatic blood flow in POAG/NTG. 
The studies that have looked at vascular reactivity of the retinal vessels have only used non-
standardised provocation techniques (i.e. use of a non-rebreathing circuit to induce 
hypercapnia). The use of non-rebreathing circuit has been shown only to increase PETCO2, 
while the arterial partial pressure of CO2 failed to increase. In this thesis, the use of a 
sequential re-breathing circuit along with the automated gas flow controller resulted in a 
minimal change in PETO2. Since the change in PETO2 was minimal, the term normoxic 
hypercapnia (i.e. change that did not have any measureable physiological impact) was 
adopted rather than isoxic hypercapnia (i.e. unchanged).  
 
We chose to use normoxic hypercapnia in our study because of the concerns about provoking 
vasoconstriction in patients with a disease that might be triggered or exacerbated by transient 
peripheral vasoconstriction. In addition, this work also aimed to determine plasma levels of 
biochemical markers of endothelial function in patients with untreated POAG, newly treated 
POAG (after Dorzolamide treatment), progressive POAG and age-matched controls both at 
baseline and during hypercapnic provocation.  We correlated these biochemical markers to 
functional vascular responses in the same group of patients. 
 
1.9 Glaucoma 
Glaucoma is a condition characterized by loss of visual field, damage to the optic disc and an 
associated increase in IOP. It is the second leading cause of blindness in the world 195 and 
also in Canada, according to the Canadian National Institute for the Blind (CNIB) 196.  A 
previous report showed an overall prevalence of 1.86% of open angle glaucoma (OAG) in 
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the US population 197. According to the CNIB, at least 300,000 Canadians currently have 
glaucoma and 50% of them are undiagnosed. Recent reports suggest that glaucoma can occur 
at any level of IOP, which is not considered as the only risk factor for glaucoma. The 
prevalence of OAG increases with age and there is a greater percentage of African 
Americans affected by the disease 198. A recent meta-analysis of the prevalence of OAG in 
patients over 40 years of age showed 4.2% in the African population, 2.1% in whites of 
European origin and 1.4% in Asians. A higher prevalence of OAG in females compared to 
males has also been reported 199.  
 
1.9.1 Classification of Glaucoma 
There are various classification schemes used in the past to define glaucoma sub-types. Some 
have classified based on the etiology, mechanism and onset, while others have identified 
based on just mechanisms of outflow obstruction. The use of an appropriate classification 
system becomes clinically important in order to manage and treat this condition. 
  
Glaucoma is primarily classified into three broad categories 1) Open angle 2) Angle closure 
and 3) Developmental glaucoma. The Open Angle and Closed Angle Glaucomas are further 
divided into primary and secondary glaucomas. Primary open-angle glaucoma (POAG) 
includes high tension and NTG. POAG usually presents with an increase in IOP in most 
cases due to obstruction of aqueous outflow. The etiology of this obstruction is generally at 
the sub-microscopic level and not due to any mechanical obstruction. POAG can also present 
with optic disc abnormalities and associated visual field loss without elevation of IOP in 
some patients and that is termed as NTG.  
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The secondary open angle glaucomas can occur due to a variety of ocular and systemic 
conditions.  There is usually mechanical obstruction to aqueous outflow and it can be at the 
level of pre-trabecular, trabecular or post-trabecular meshwork. Primary angle closure 
glaucomas consist of acute, sub-acute and chronic angle closure, while the secondary angle 
closure glaucomas include those with or without pupillary block. 
   
A malformation or an incomplete formation of the trabecular meshwork or Schlemm’s canal 
during gestation is suggested to cause developmental glaucoma. 
  
1.10 Risk factors of POAG 
Careful identification of risk factors that aid in the progression of glaucoma is imperative to 
effectively manage glaucoma using medical therapy. Some of the earlier large scale clinical 
trials have provided evidence about the baseline risk factors that are involved in the 
progression of POAG. 
 
1.10.1 Age 
Increasing age has been proposed as one of the major risk factor for the prevalence of ocular 
hypertension (OHT) and development of POAG. The results of large clinical trials such as 
the Ocular Hypertension Treatment Study (OHTS), Early Manifest Glaucoma Trial (EMGT), 
Blue Mountain Eye Study (BMES), Advance Glaucoma Intervention Study (AGIS) and the 
Collaborative Initial Glaucoma Treatment Study (CIGTS) 200-203 and some population based 
studies support this theory. 204, 205. 
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1.10.2 IOP 
IOP is consistently considered as the primary risk factor for POAG. The outcome of large 
scale clinical trials has provided information to help modify the treatment approach of 
patients with POAG and OHT. The results of the OHTS indicated that use of IOP lowering 
medications reduces the risk of glaucoma progression by approximately half, i.e. 9.5% to 
4.4% 206. IOP lowering is also effective in delaying progression of POAG in African 
American population. Further analysis revealed that for every 1mmHg increase in IOP there 
was a 10% increase in the risk of development of POAG 207. Similarly, the EMGT also 
showed effective decrease in the progression rate after decrease in IOP in OHT (i.e. 65% in 
untreated OHTs to 45% in the treated OHT group). Large diurnal and nocturnal fluctuations 
of IOP are also proposed to be a factor for progression of POAG 208. 
 
1.10.3 Cup-to-disc ratio 
Previous evidence suggests that increased cup-to-disc ratio is an independent risk factor for 
the progression of POAG. Based on the univariate analysis of the OHTS results, there is a 
25% increase in the hazards ratio for every 0.1 increase in horizontal cup-to-disc ratio and a 
32% increase for a 0.1 increase in vertical cup-to-disc ratio 203, 206. 
 
1.10.4 Central corneal thickness (CCT) 
There is also evidence for CCT as a risk factor for progression of POAG. According to the 




Studies have shown increased prevalence of POAG in the black race. However, it was not 
clear whether there are other associated factors that increase the prevalence in this race. The 
OHTS did not reveal any significant correlations to the progression of POAG and race using 
multivariate analysis 203, 206. Conversely, a random survey of the urban Baltimore and 
Maryland residents showed increased prevalence in the black population. The study also 
revealed prevalence of POAG at an earlier age in the black population compared to the 
whites 209.  
 
1.10.6 Family history 
A positive family history is proposed to be associated with the incidence of POAG; however, 
there is no strong association with the progression of POAG. The Barbados Eye Study and 
the Rotterdam Study 204, 210 showed increased incidence of POAG in patients with a strong 
family history but this finding was not observed in OHTS. 
 
1.10.7 Blood pressure 
A positive association between IOP and blood pressure has been noted. The results of the 
EMGT study that assessed predictors of long term progression of POAG showed that low 
blood pressure is an independent risk factor for progression 211. Similar findings have been 
suggested by other studies and this leads to a possible vascular disturbance in patients with 




Vascular dysregulation has also been proposed in diabetes. An increase in the prevalence of 
POAG has been noted in patients with diabetes. The BMES showed a 6.5% increase in 
POAG compared to 3.5% prevalence in patients without diabetes 214. The AGIS, Beaver Dam 
Study and EMGT also showed an association between diabetes and progression of POAG 202, 
211, 215, while few other studies failed to show any association 209, 216. 
  
1.10.9 Migraine 
The BMES showed an association between history of migraine in different age groups and 
the prevalence of POAG. The results also suggested that history of migraine decreased with 
increasing age 217. In the OHTS analysis, however, there was no correlation between 
migraine and progression of POAG 203. 
 
1.10.10 Vasospasm 
Presence of vasospasm is considered as risk factor for progression of POAG. However, this 
is not well established. Recently, the Canadian Glaucoma Study showed no association 
between vasospasm and progression of POAG 218. Conversely, another study that reviewed 
the potential risk factors suggests that vasospasm might be a risk factor in POAG 78, 94. The 




1.11 Etiology and patho-physiology of POAG 
Glaucomatous optic neuropathy is characterised by progressive changes in the ONH caused 
either by an increase in IOP or as a result of vascular dysregulation leading to visual 
impairment (or possibly a mixture of both these mechanisms) 219, 220. It is generally 
characterised by one or more of the following features; enlargement of the optic cup, optic 
disc hemorrhage, thinning of the nerve fibre layer, asymmetrical cupping and parapapillary 
atrophy. There are various theories suggested as the possible etiology for the occurrence of 
optic neuropathy in POAG. The most widely studied are the biochemical factors, mechanical 
theory and the vascular theory (Figure 1.11). However it is generally recognised that 
glaucoma is typically caused by a combination of these different theories, i.e. it is the ability 
of an individual ONH to maintain perfusion, no matter what the biomechanical and vascular 
stresses. For historical reasons the theories will be discussed separately. 
  
1.11.1 Biochemical factors 
Evidence suggests that structural alterations in POAG at the level of the trabecular meshwork 
could give rise to an increased resistance to the aqueous outflow resulting in an increase in 
IOP. It is possible that in POAG the balance between secretion of aqueous humor and the 
outflow resistance could be altered. A decrease in the number of endothelial cells in the 
trabecular meshwork with age has already been established 221. However, in patients with 
POAG there might be an exaggerated decrease in cells leading to obstruction of the aqueous 
outflow and thereby causing an increase in IOP. Histopathological evidence also suggests 
that the loss of endothelial cells results in the enlargement and fusion of the remaining cells 
221, thereby blocking or reducing the size of the trabecular meshwork pores. In addition, there 
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is deposition of sheath-derived plaque material in the anterior chamber of patients with 
POAG. 222, 223. However, it is not very clear whether the plaque formation could result in 
decreased aqueous outflow 224, 225. The presence of giant vacuoles lining the inner wall of 
Schlemm’s canal has also been thought to play a role in aqueous drainage 226 (Figure 1.12). 
In eyes with POAG, there is evidence for a decrease in the number of vacuoles thereby 
leading to a decrease in aqueous outflow. The presence of transforming growth factor β2 
(TGF) in the aqueous humor of patients with POAG might result in an increased deposition 
of extra cellular matrix leading to a decrease in aqueous outflow 227. The exact mechanism of 
decreased aqueous outflow is not well understood although there is histo-pathological and 
biochemical evidence of several factors resulting in GON. 
 
1.11.2 Mechanical theory 
An increase in IOP causes mechanical stress on the lamina cribrosa and the retinal ganglion 
cells affecting both antero-grade and retrograde axonal transport.  There are various 
neurotrophic factors that are transmitted from the lateral geniculate nucleus to the optic 
nerve. Compression of the lamina cribrosa results in axonal cell death due to lack of 
sufficient trophic factors. Using a biomechanical model, Sigal and co-workers (2007) have 
shown that the ONH predominantly undergoes compression followed by stretching and 
shearing as a result of an increase in IOP 228. Also, the extent of scleral rigidity has been 
shown to be a primary factor for the development of POAG 229, 230. However, in patients with 
NTG, the optic nerve is affected even within the normal range of IOP 231. 
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1.11.3 Vascular theory 
An instability in blood flow might play an important role in the obstruction of axoplasmic 
flow leading to GON. A wide range of change in IOP and BP are autoregulated by retinal 
vessels under normal conditions. The vascular theory suggests that there could be impairment 
of normal autoregulation in patients with POAG 78, 94, 232. There is evidence from previous 
studies that ONH blood flow is decreased in patients with POAG measured using fundus 
fluorescein angiography 233 and Doppler techniques 233, 234, as well as histo-pathological 
evidence 235. Atrophy of the peripapillary capillaries supplying the retinal nerve fibre layer 
(RNFL) has also been reported in POAG 236, 237. However, another study shows no 
correlation between atrophy of peripapillary capillaries and visual field 238. Similarly, 
Michelson and co-workers (1996 & 1998) showed significant decrease in juxtapapillary and 
retinal capillary blood flow 158, 239. The presence of vascular alteration in POAG is not well 




Figure 1.11 Flow diagram showing the possible factors responsible for the pathogenesis of POAG. 




Figure 1.12 Schematic representation of the juxtacanalicular layer and schlemms canal.  
A) Arrows show normal aqueous outflow (top). B) Accumulation of extracellular material (marked types I, II 
and III) along the juxtacanalicular tissue. Flow and partial blockade of aqueous outflow is shown by the arrow 
in glaucomatous eye (bottom). 






1.12 Clinical diagnosis of glaucoma 
The first important step in the diagnosis of any eye disease is to obtain a detailed ocular and 
systemic history of the patient. A positive family history of POAG is one of the major risk 
factors and it is therefore essential to rule out any possible genetic influence during history 
taking 240, 241. The clinical diagnosis of POAG is complex and outside the scope of this thesis. 
However, the following clinical tests are often undertaken to aid the clinician reach a 
diagnosis, including ONH and nerve fibre evaluation, gonioscopy, tonometry, fundus 
photography, measurement of CCT and visual field assessment. 
 
1.13 Diagnostic imaging techniques 
During the last decade, objective imaging techniques have been developed in order to 
effectively monitor the progression of POAG. The most common imaging techniques that are 
currently used to monitor progression of POAG are scanning laser tomography (SLT), time 
domain and spectral domain optical coherence tomography (OCT) and scanning laser 
polarimetry. 
 
1.14 Management of glaucoma 
1.14.1 Pharmacological agents 
In the absence of optic disc damage and visual field loss, most clinicians initiate IOP 
reducing treatments when the baseline IOP reaches 30mmHg or close to this level. In 
general, target IOP is usually decided based on the extent of optic disc damage, visual field 
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deterioration and risk factor assessment. There are various groups of drugs used to treat 
glaucoma namely, beta-blockers, adrenergic agonists, miotics, carbonic anhydrase inhibitors 
(CAI), prostaglandin analogues and hyperosmotic agents. 242. 
  
1.14.2 Laser 
Laser iridectomy is usually performed in angle closure glaucoma with pupillary block. On 
many occasions, a prophylactic iridectomy is indicated to avoid potential pupillary block. 
Argon or disruptive Nd:YAG laser is delivered using a slit lamp to create an iridectomy. 
Argon Laser Trabeculoplasty (ALT) is a technique used primarily to treat POAG. This 
technique lowers intraocular pressure by improving aqueous outflow 243. Recently, Selective 
Laser Trabeculoplasty (SLT) has been used as it targets only specific trabecular cells 244, 245. 
 
1.14.3 Surgical management 
Filtering surgery is the most common technique to treat POAG. During the surgery a piece of 
the cornea or sclera is removed to help in the drainage of aqueous humor. In addition, anti-
metabolites are used during filtration surgery to avoid post-operative fibrosis of episcleral 
and sub-conjunctival tissue. The most commonly used anti-metabolites are mitomycin 
(MMC) and 5-Flurouracil. In conditions when filtration surgery fails, aqueous shunts are 
implanted to provide a pathway for the aqueous to drain into an exterior reservoir. In 
addition, cyclodestructive procedures are also used in patients where all other conventional 
therapy failed to decrease IOP. This procedure destroys the ciliary body to reduce aqueous 
production leading to reduction in IOP. 245. 
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1.15 Effect of IOP lowering medications on ocular blood flow 
The currently available IOP lowering medications primarily decrease IOP to a target level. 
Recently, the possible involvement of vascular dysregulation in the development of 
glaucoma, in particular in POAG, has been widely studied. As a result, there is an interest 
and need to define any possible effect on ocular hemodynamics of the different groups of 
medications used to lower IOP. However, the results of these studies are still contradictory. 
 
1.15.1 Beta-blockers 
Beta-blockers decrease IOP by reducing aqueous production The most commonly used beta 
blocker is timolol maleate and the majority of the studies using this medication on animal 
models have shown either no effect 246, 247 or a decrease in choroidal blood flow 248. Studies 
have shown no change in ocular blood flow in POAG/NTG after treatment with timolol 249-
253. Similarly, Betaxolol treatment in patients with POAG did not show any change in 
pulsatile ocular blood flow 254. Another study showed a significant increase in retrobulbar 
hemodynamics in POAG with betaxolol compared to the other beta blockers 255. 
Levobunolol, a non-selective beta-blocker, also showed an increase in POBF in patients with 
POAG 256, 257. These studies, however, failed to correlate the effect of IOP decrease on ocular 
blood flow changes. Similarly, treatment with carteolol showed a decrease in resistance index 
of CRA in POAG 255. 
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1.15.2 Parasympathomimetic agents 
Pilocarpine is one of the most commonly used parasympathomimetic and it decreases IOP 
through alteration of the trabecular meshwork configuration to facilitate an increase in 
aqueous outflow. In healthy volunteers treatment with pilocarpine showed no change in 
retrobulbar blood velocity of the CRA 258. A similar result was seen using the POBF in 
patients with POAG 259. 
 
1.15.3 Alpha agonists 
The primary mode of action of alpha agonists is to decrease IOP by a reduction in aqueous 
production without any alteration to the aqueous outflow. Intravenous administration of 
clonidine increased retinal arteriolar diameter measured using the RVA but decreased blood 
velocity and blood flow assessed using the laser Doppler velocimetry 260 in healthy 
volunteers. Using topical apraclonidine decreased blood velocity of the OA was noted in 
POAG 261. Few studies have also looked at the treatment effect of brimonidine but have 
shown no change in ocular blood flow in POAG 262-266. 
 
1.15.4 Prostaglandin analogues 
This group of drugs decrease IOP by increasing the uveoscleral outflow. Studies in patients 
with POAG after treatment with latanoprost showed no effect on the retrobulbar blood 
velocity 267 and pulsatile ocular blood flow after correcting for the decrease in IOP 268. 
Similarly, no effect was seen with a combination of timolol and latanoprost treatment in early 
POAG using the SLO 269 and CDI/SLDF 270. Interestingly, treatment with latanoprost 
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demonstrated an initial increase in POBF but no significant change after 6 months of 
treatment 271. More recent studies have shown increase in ONH and retinal blood flow using 
the HRF in newly diagnosed POAG 272 and a decrease in end-diastolic velocity of the OA in 
POAG 273.  
 
1.15.5 Carbonic anhydrase inhibitor 
Carbonic anhydrase enzyme is responsible for the production of aqueous humor by the non-
pigmented ciliary epithelium. These isoenzymes are also found in corneal endothelium, 
retina and the ciliary processes. The CAI decrease IOP by inhibition of the carbonic 
anhydrase in the eye, thereby decreasing the production of aqueous humor. 
 
1.15.5.1 Acetazolamide 
Intravenous administration of acetazolamide in healthy volunteers showed an increase in 
choroidal blood flow 274 and an increase in ocular pulse amplitude 275 measured using the 
FPA. The effect of this drug on patients with glaucoma is not well studied. 
 
1.15.5.2 Dorzolamide 
Dorzolamide is not used as a “first line” treatment in patients with POAG, mainly due to the 
weak IOP lowering effect compared to the other group of IOP lowering drugs. Over the last 
decade, researchers have widely studied the possible hemodynamic effect of this drug in 
patients with POAG, an investigation concept that has been encouraged by the manufacturer. 
However, the results of these generally poorly controlled studies are contradictory.  In 
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normal individuals, a single drop treatment of Dorzolamide did not show any short-term 
change in retinal arteriolar hemodynamics assessed using the CLBF 276 and a similar result 
was observed after 3 days of treatment 277. Another study showed a significant increase in 
ocular pulse amplitude in both normal subjects and patients with OHT 278. In general, most 
previous studies have shown an increase in the retinal hemodynamics with topical 
Dorzolamide treatment in patients with POAG. Dorzolamide treatment for 4 weeks in POAG 
demonstrated a trend to increase diastolic velocity of the SPCAs 279 and a decrease in the 
retinal arteriovenous passage time (AVP) 269, 280, 281. Assessment of neuroretinal rim blood 
flow and FPA showed an increase after 2 weeks treatment with topical Dorzolamide 253, 
while there was an increase in ONH blood flow using the SLDF after 4 weeks treatment with 
a fixed combination of Dorzolamide and Timolol 282. However, Bergstrand and co-workers 
(2002) observed no effect after 2 weeks Dorzolamide treatment in retrobulbar hemodynamics 
283. Treatment with Dorzolamide is shown to stabilise and/or increase ocular perfusion in 
normal subjects during hypercapnia 284. Intravenous injection of Dorzolamide 500mg in pigs 
resulted in retinal arteriolar dilation assessed using fundus photographs and also an increase 
in optic nerve oxygen tension 285. The majority of previous studies have only assessed 
homeostatic blood flow in previously treated patients or in patients without an adequate drug 
wash-out period. The effect of previous treatment on retinal hemodynamics is poorly 
understood. In addition, a combination of drugs has been used in the past that will not give 
adequate information about the vascular effect of one drug. As a result, we set out to 
investigate the effect of treatment with Dorzolamide on retinal vascular reactivity (i.e. in 
response to normoxic/isoxic hypercapnia) in untreated POAG.  
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1.15.5.3 Brinzolamide 
There is lack of adequate research on the treatment effect of Brinzolamide in patients with 
POAG. Sampolesi and co-workers (2001) showed no effect of Brinzolamide in advanced 
stages of POAG assessed using the SLDF 266. Similarly, there was no effect on the 
retrobulbar hemodynamics after 2 weeks brinzolamide treatment in healthy subjects but there 
was a decrease in AVP time noted 286. 
 
1.16 Summary 
The etiology of POAG is multi-factorial and previously two major theories were proposed, 
i.e. mechanical and vascular theories. Recent evidence suggests that the etiology of POAG is 
a combination of the two theories. However, the current treatment options available for 
POAG are only targeted to decrease IOP. The vascular beneficial effects of some of the IOP 
lowering medications have been studied. Some recent evidence suggests that CAI might 
improve ocular blood flow. However, those studies have not assessed the function of the 
retinal vessels in untreated POAG (uPOAG). The assessment of vascular reactivity in 
response to provocation is essential for a better understanding the patho-physiology of the 
disease. Accordingly, the work presented in this thesis is aimed at investigating the effect of 
normoxic hypercapnia on retinal arteriolar and ONH capillary vascular reactivity in uPOAG 
and also followed these patients after treatment with 2% Dorzolamide for 2 weeks. In 
addition, retinal and ONH vascular reactivity was also quantified in response to normoxic 
hypercapnia in patients with progressive POAG (pPOAG) as this group of patients have been 
suggested to more often exhibit ONH vascular dysregulation. 
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1.17 Autoregulation and vascular reactivity in glaucoma 
A few recent studies have concentrated on the assessment of homeostatic levels of ocular 
blood flow and also the response of the retinal, choroidal and ONH vasculature to various 
physiological provocations including inspired gas, light flicker, cold stress testing and 
changes in perfusion pressure. The results of these studies have provided some basic 
understanding of the possible vascular abnormalities associated with GON. In addition, the 
vascular abnormalities seen in POAG are thought to be associated with the imbalance of 
certain vasoactive substances such as ET-1 and NO that are primarily produced by the 
smooth muscle cells of the vascular endothelium 51, 287. 
 
1.17.1 Homeostatic blood flow in POAG 
Recent developments in blood flow measurement techniques have made the quantification of 
hemodynamic parameters possible 288. However, the measurement of blood flow in the eye is 
still challenging partly because of poor signal-to-noise ratio. The design and the principle of 
the various blood flow measurement techniques used to assess ocular hemodynamics in 
glaucoma have been described in detail elsewhere 74, 288. The majority of previous research 
has suggested a decrease in blood flow in various ocular tissue beds in patients with 
POAG/NTG. A decrease in perfusion assessed by measuring the retinal mean transit time has 
been found that is similar in both POAG and NTG 289. 
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1.17.1.1 Pulsatile ocular blood flowmeter and fundus pulsation amplitude 
Kerr and co-workers (2003) reported decreased levels of POBF-derived choroidal blood flow 
in uPOAG in comparison to patients with OHT and controls 18. Other studies have also 
reported similar findings in patients with POAG 290-294. Assessment of choroidal 
hemodynamics using FPA is in agreement with previous studies showing a decrease in 
pulsation amplitude in POAG 118, 152, 295. 
  
1.17.1.2 Scanning laser Doppler flowmetry 
Using the SLDF, a decrease in blood flow in the ONH has been shown in patients with 
POAG 152, 157-159, 291, 295, 296, NTG 297 and glaucoma suspects 298. Boehm and co-workers 
(1999) have shown regional variation in blood flow in healthy individuals using the HRF 
with the temporal neuroretinal rim of the ONH showing reduced blood flow compared to the 
nasal area 299. Also, the area of blood flow reduction in the ONH corresponded to visual field 
defects in patients with NTG 300. Sehi and co-workers (2005) determined the association 
between diurnal variation in IOP and MOPP to that of HRF measured ONH rim blood flow 
and showed an inverse correlation of blood flow to diurnal variation in IOP in untreated 
POAG 72. These findings likely indicate a vascular abnormality in POAG and NTG, 
however, none of the above studies have determined retinal or ONH vascular reactivity in 
response to physiological provocations such as CO2 or light flicker. The assessment of retinal 
and ONH vascular regulation provides additional information about ocular physiology and 
can be disturbed in the absence of disturbance of homeostatic retinal blood flow. Also, there 
is lack of a comprehensive assessment of ocular vascular hemodynamics in all the studies. 
Inner retinal blood flow might be normal in the presence of disturbed outer retinal blood 
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flow, or vice versa. More importantly, all the studies share the same limitation of using a 
surrogate parameter to indicate differences in blood flow, rather than measuring blood flow 
per se. 
 
1.17.1.3 Color Doppler imaging 
Using the CDI, a decrease has been found in retrobulbar hemodynamics in the OA and/or 
CRA in POAG 296, 301-305 and NTG 304, 306-309. However, in patients with non-progressive 
POAG 310 and NTG 311 no difference was found in retrobulbar blood velocity compared to 
controls. CDI has a number of significant limitations, including the requirement for an 
experienced operator to obtain reliable measurements, its inability to quantify volumetric 
blood flow and also the difficulty to differentiate responses between the CRA and SPCA 288. 
Proper positioning of the probe on the eye is critical as the resulting blood velocity value 
depends on the angle between the incident beam and the direction of blood flow. 
 
Another confounding factor that has been overlooked by the majority of the CDI-based and 
other studies is that homeostatic blood flow was assessed in treated POAG and/or in patients 
who had only recently stopped IOP lowering medication without an adequate washout 
period. The vascular effects of IOP lowering medications remain controversial. One study 
has shown no effect of medications on ocular blood flow 249, while other studies report 
change in ocular blood flow as a result of IOP lowering medication 256, 312, 313. The average 
wash-out period for IOP lowering medications is 4 weeks, in order to return to original IOP 
levels 314, 315. However, there is lack of adequate evidence to support the assumption that any 
secondary vascular effects induced by these drugs return to baseline conditions after the 
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required wash-out period to normalize IOP. Also, the use of IOP lowering medications can 
influence MOPP resulting in disturbances of vascular regulation 18. The presence of any 
residual vascular effects can thereby mask or exaggerate a true difference in measured 
baseline blood flow results. In addition, Costa and co-workers (2003) reported a negligible 
effect of IOP lowering medications on ocular blood flow 314. A more recent review on the 
impact of systemic medications on ocular blood flow reported beneficial vascular effects in 
various ocular beds 316. Another study showed that ONH blood flow was regulated with IOP 
lowering medications 317 in early POAG and failed to exhibit such a regulation of blood flow 
in advanced POAG. Nevertheless, it remains questionable as to whether a wash-out period of 
2-4 weeks will normalize hemodynamics in POAG. 
 
1.18 Regulation of blood flow in POAG 
Autoregulation is the ability of a tissue to maintain constant blood flow despite constant 
changes in perfusion pressure 318, 319. This original definition has been modified to include 
other types of blood flow regulation such as metabolic regulation. The vascular endothelium 
is thought to release certain vasoactive factors that regulate blood flow in response to 
changes in trans-mural pressure and is termed as myogenic regulation. Metabolic 
autoregulation occurs in order to regulate blood flow to maintain adequate and optimal levels 
of critical nutrients such as O2, CO2 and K
+ and to ensure the removal of unwanted metabolic 
waste products In the eye, the inner retina and the superficial ONH vascular beds have been 
shown to autoregulate to an IOP increase of 30-40mmHg in clinically normal human subjects 
68-71. Also, an abnormal vascular regulation has been suggested to occur in POAG 40, 74-76. 
There is however, a lack of definitive evidence to suggest altered autoregulation in POAG. 
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1.18.1 Regulation of blood flow to perfusion pressure provocation 
The ONH blood flow regulation to myogenic provocation has been studied using various 
hemodynamic measurement techniques. Using laser Doppler flowmetry, the blood flow in 
the ONH did not show a significant change in normal controls or patients with NTG after 3 
weeks wash-out of topical medications to a 28% increase in perfusion pressure during 
exercise 91. In NTG patients, however, there was an increase of vascular resistance to the 
alteration in perfusion pressure that might indicate some autoregulatory disturbance 91. A 
similar result was found in a study that measured change in choroidal pulsation using the 
fundus pulsation technique and ONH blood flow using the Laser Doppler Flowmetry in 
response to a 20mmHg change in IOP in patients with POAG 320. Similarly, altered 
autoregulation has been suggested to occur to changes in IOP in patients with POAG, as 
indicated by macular leucocyte velocity measured using the blue field entoptic phenomenon 
321. A short term increase in IOP has been shown to cause a reduced regulatory change in 
retinal arteriolar and venular diameter in POAG when assessed using the RVA in POAG 322.   
 
1.19 Vascular reactivity response to provocations in glaucoma 
The change in hemodynamic parameters in response to physiological provocation such as 
CO2, O2, cold stress or light flicker is defined as vascular reactivity or metabolic 
autoregulation; this functional assessment of the ocular vasculature is thought, but not 
proven, to reflect vascular regulation capacity. Relatively few studies have been undertaken 
on the assessment of vascular reactivity in response to provocation in patients with glaucoma. 
However, several recent studies have provided some in-sight into the retinal vascular 
response in glaucoma. 
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1.19.1 Hypercapnia 
Hypercapnia is the increase in the arterial partial pressure of CO2 achieved by inspiring 
increased amounts of CO2. In normal control subjects breathing CO2 causes vasodilation and 
thereby leads to an increase of inner retinal and superficial ONH blood flow 19, 170, 180, 182, 188, 
323. The mechanism involved in the vasodilation response of blood vessels to hypercapnia is 
controversial. Studies have shown a positive role of NO in humans 124 and animal models 130. 
Conversely, an absence of the role of NO during hypercapnia induced vasodilation has been 
reported in animal models 58, 59.  
  
Hosking and co-workers (2004) showed an increase in blood velocity of the SPCA in 
response to hypercapnia measured using CDI in POAG, although a similar response was not 
found in the OA 146. Patients with uPOAG have been shown to demonstrate a normal 
increase in the blood velocity of the CRA to hypercapnia but a decrease in blood velocity in 
the OA 147. Interestingly, others have found an exaggerated response to hypercapnia in the 
CRA and short PCAs in NTG compared to control subjects 307; the authors explain that this 
might be due to the reduced baseline blood velocity in the patient group compared to 
controls. A recent study has shown a decrease in the choroidal blood flow and an increase in 
ONH blood flow measured using the laser Doppler flowmeter in female subjects with 
vasospastic symptoms, such as cold hands and/or feet, in response to hypercapnia 92 
although, there was no increase in ONH blood flow in subjects without vasospasm. There 
was also a significant change in blood pressure during hypercapnia in all the groups, that is 
men, women without vasospasm and women with vasospasm. The reason for these 
unexpected results is unclear. The authors speculate that there might be either an increased 
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response of the ONH to hypercapnia in vasospasm or a lack of adequate autoregulation 
causing an increase in blood flow due to the associated change in blood pressure. 
 
The majority of the hypercapnia studies have used a simple manual addition of CO2 rather 
than a re-breathing circuit. The use of a standardised provocation is essential to minimise 
variability in the magnitude of vascular reactivity and the re-breathing circuit helps to 
minimise this variability 177. Breathing CO2 results in an unpredictable increase in ventilation 
and thereby an unpredictable increase in PETO2 
176. The use of normoxic/isoxic hypercapnia 
is important in the assessment of retinal vascular reactivity in order to avoid the confounding 
effects of varying O2, i.e. resulting in vasoconstriction. It has recently been shown that the 
use of a non-rebreathing circuit and the addition of CO2 to inspired air to induce hypercapnia 
results in an increase in PETCO2 to target levels, however, the arterial partial pressure of CO2 
remains unchanged 177. This potential problem is avoided by the use of a sequential gas 
breathing circuit and a newly developed automated gas flow controller 21, 177. 
 
Recently, our laboratory has validated a normoxic hypercapnic stimulus that is induced using 
an automated gas flow controller 21(see Chapter 5). Using this technique, partial pressures of 
CO2 and O2 can be manipulated independent of each other. This standardised stimulus is 
currently used in our laboratory for investigating the retinal arteriolar and ONH functional 




Hyperoxia is the increase in the arterial partial pressure of O2. The ocular vasculature 
responds to this increase in O2 level by vasoconstricting which results in a decrease in blood 
flow in healthy humans 22, 23, 154, 182. The response to hyperoxia in glaucoma has not been 
widely studied. This is likely due to the theory of a pre-existing vasospasm in glaucoma and 
that breathing O2 would further decrease the blood supply to an already compromised ONH. 
Recently, retrobulbar velocities in patients with POAG have been shown to remain unaltered 
in response to hyperoxia suggesting that the pre-existing vasospasm prevents further decrease 
in blood velocity in this group 146. There is also evidence that glaucoma might be associated 
with reduced blood velocity in cerebral vessels, in particular, the middle cerebral artery and 
also a decrease in the magnitude of cerebral vascular reactivity to hyperoxia in POAG 324. 
  
The increase in PETO2 during hyperoxia can generally result in a concomitant change in 
PETCO2. Most previous studies have used non-standardised hyperoxic stimuli, including use 
of a non-rebreathing valve and the manual addition of small amounts of CO2. This resulted in 
a high intrasubject variability. Gilmore and co-workers (2004) used a sequential re-breathing 
circuit and induced isocapnic hyperoxia to assess retinal vascular reactivity 325. As a result, 
they demonstrated a reduced variability of PETCO2 and this produced less variable vascular 
reactivity responses of the retinal vasculature to hyperoxia. However, although now 
experimentally feasible, the use of isocapnic hyperoxia has generally been avoided in 
patients with POAG due to the risk of further constriction of the vasculature of the retina and 
ONH.  
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1.19.3 Flicker stimulation 
The retinal and ONH blood vessels respond to flicker provocation with an increase in 
diameter and blood flow 31, 143, 326, 327 and a recent study has shown decreased vasodilation in 
response to flicker in patients with type 2 diabetes 328. The mechanism of vasodilation 
response during flicker is not well understood. In the cerebral vasculature, however, it is 
believed that there is a tight neural coupling between the local metabolic demand and blood 
flow 329. In addition, there are various vasoactive factors identified in the cerebral response to 
flicker stimulation, such as CO2, potassium, adenosine and NO, that have been suggested to 
play a role in the vasodilatory response during neuronal driven activity in both the cerebral 
and retinal vessels 330, 331. It is suggested that the increase in blood flow in the ONH in 
response to flicker stimulation in healthy individuals might be an effect of increased retinal 
activity 49, 332. However, the mediators responsible for the vasodilation during this neural 
activity are still not clear, although NO might play an important role 53.  
 
Recently, the response of the retina and the ONH to flicker stimulation has been widely 
studied in POAG. Horn and co-workers (2006) investigated temporal contrast sensitivity in 
patients with glaucoma and normal controls and showed a delayed recovery time after flicker 
stimulation in the patient group compared to controls 34. Vascular reactivity of the retinal and 
ONH blood vessels measured using laser Doppler flowmetry in response to flicker 
stimulation was reduced in patients with treated early OAG but did not show any 
deterioration in patients with OHT33.  
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It has also been shown that short term increases in IOP in a group of normals does not alter 
the dilation response to flicker stimulation 327. This is in agreement to previous experiments 
in animal models 32, 53. However, these findings cannot be directly compared to patients with 
glaucoma because the long term effect of increased IOP has not been studied. Recently, an 
abnormal autoregulatory response to flicker and pattern stimulation has also been reported in 
early OAG 49. 
 
1.19.4 Cold stress test 
Cold provocation is a technique used to assess the function of the autonomic nervous system 
(ANS). Disturbance in the ANS might be present in glaucoma, in particular in NTG 333-335. 
Cold provocation generally produces vasoconstriction, decrease in peripheral blood flow and 
an increase in blood pressure  
 
Previous studies in patients with POAG showed no significant alteration in ocular blood flow 
assessed using the SLDF and trans-cranial Doppler technique in the peripapillary retina 28 or 
in the OA 29. Recently, patients with POAG have been shown to exhibit a decrease in blood 
flow at the temporal neuroretinal rim in response to cold provocation, while no change was 
found in ocular blood flow in non-glaucomatous subjects 336. The mechanisms responsible 
for the regulation of blood flow during cold provocation are not well understood. However, 
Nicolela and co-workers (2003) have shown increased levels of plasma ET-1 in POAG after 
cold provocation 28. This increase in ET-1 might be responsible for the vasoconstriction of 
peripheral blood flow in response to cold in POAG. The use of IOP lowering medications in 
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patients with POAG and vasospasm helped to improve ONH rim blood flow compared to 
those without vasospasm 337. 
 
A limiting factor in our interpretation of virtually all vascular reactivity studies is our lack of 
understanding of the impact of the provocation upon the cellular vasoactive factors that 
control ocular vasoconstriction and vasodilation. 
    
1.20 Conclusions  
The retina and the ONH autoregulate to a wide range of changes in ocular perfusion pressure. 
The vascular endothelium derived vasoconstricting and vasodilating factors play an 
important role in regulating the blood flow in the eye. Studies have used a number of 
techniques to assess ocular blood flow, however, previous studies have not performed a 
comprehensive assessment of retinal hemodynamics. The measurement of all aspects of 
hemodynamics is important to assess the autoregulatory status of the retina and ONH. The 
CLBF is the only instrument currently available that quantifies retinal arteriolar 
hemodynamics in absolute units. The CLBF measures diameter and blood velocity at a single 
point along the vessel and in this respect, it can be assumed that all branches of the vascular 
tree react similarly to provocation. Also, the measurement is not continuous but limited to a 2 
second window. As glaucoma is a condition primarily affecting the ONH, assessment of the 
vascular reactivity of the ONH will provide a better understanding of the pathophysiology of 
the disease. In this work, the HRF will be used to assess ONH vascular reactivity in some 
patients with uPOAG, pPOAG and controls. The HRF has relatively high measurement 
variability and requires repeated measurements in order to obtain valid blood flow values. 
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For this reason, this work aimed to develop a safe, sustainable and stable provocation. We 
set-out to develop a normoxic/isoxic hypercapnic stimulus ultimately to assess retinal 
vasodilation capacity in patients with POAG. 
  
Over the last few years, retinal vascular reactivity has been widely studied using various 
provocation techniques. Studies have used gas provocations, cold stress test and flicker 
stimulation to assess regulation of vascular reactivity. Under normal conditions, the retinal 
and the ONH vessels respond by an increase in diameter, velocity and blood flow to 
hypercapnia and a decrease in all the hemodynamic parameters in response to hyperoxia. 
There is a particular lack of adequate information on the regulation of retinal and ONH blood 
flow in disease such as patients with POAG, especially in untreated POAG. In addition, the 
few studies that have looked at the effect of hypercapnia in POAG have either not used a 
standardised hypercapnic stimulus or failed to monitor any concomitant changes in PETO2. In 
our study we used a newly developed automated gas flow controller to induce normoxic 
hypercapnia via a sequential rebreathing circuit and this resulted in a robust vascular 
reactivity response in both normal controls and in patients with uPOAG and pPOAG. 
 
Vascular dysregulation is suggested to be a factor in the progression of POAG. Current 
treatment for POAG involves the use of medication to lower the IOP. Recent studies have 
focused on the effect of certain IOP lowering medications on retinal and ONH blood flow. 
There is a need for more research on the assessment of hemodynamic characteristics of 
patients with POAG and also to establish a treatment modality to address any possible 
vascular disturbance. Previous studies have assessed the vascular effects of IOP lowering 
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medications by using a combination of drugs. However, it is difficult to determine any 
beneficial effect of an individual medication. Accordingly, in our study we investigated the 
effect of treatment with 2% Dorzolamide for 2 weeks on retinal arteriolar vascular reactivity 
in patients with newly diagnosed POAG. 
 
The vascular endothelium releases both vasoconstricting and vasodilating factors such as ET-
1 and NO respectively.  Previously it has been shown that an exaggerated amount of ET-1 at 
baseline in patients with POAG thereby leading to vasospasm. In this work we therefore 
assessed plasma levels of ET-1/NO at baseline and during normoxic hypercapnic provocation 
in uPOAG, pPOAG and controls. Conversely, the results of this work show that there is a 
decrease in the plasma ET-1 at baseline in uPOAG. We also correlated functional vascular 
response in the above patients to endothelial biochemical markers. The approach to correlate 
between functional retinal vascular response and vascular endothelial biochemical markers 
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Vascular dysregulation is suggested to be involved in the pathogenesis of GON, in addition 
to increased IOP. Previous studies have shown a decrease in homeostatic blood flow in both 
retinal and ONH vasculature in patients with POAG. However, there is paucity of 
information on the response of ocular blood vessels to provocations that assess vascular 
reactivity. The ultimate aim of this thesis was to determine the magnitude of retinal and ONH 
vascular reactivity in patients with untreated POAG (uPOAG). In addition, the thesis also 
aimed to establish the relationship between functional vascular reactivity and biochemical 
markers of endothelial function in POAG. There were a number of steps and considerations 
that required careful evaluation and validation in achieving these ultimate aims: 
 
2.1 Development of a safe, sustained and stable normoxic/isoxic 
hypercapnic provocation 
Increase in inspired carbon dioxide (CO2), which results in hypercapnia, is an appealing 
provocation to employ in patients with POAG in order to avoid vasoconstriction in what is 
often considered to be a vasospastic disease. In particular, only a few studies have used 
hypercapnia to assess retinal vascular reactivity, partly because of obvious safety concerns in 
terms of administration of increased amounts of CO2 in human volunteers. Some of these 
studies have shown a decreased magnitude of vascular reactivity in retinal vessels in patients 
with POAG. However, most have failed to use standardised hypercapnic stimuli to assess 
retinal vascular reactivity. The majority of the studies have used a non re-breathing circuit to 
induce hypercapnia by the manual addition of CO2 to the inspired gases. Hypercapnia 
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induces hyperventilation which, in turn, alters arterial oxygen (O2) concentration, and the 
magnitude of this change varies between individuals resulting in a non-standardised 
provocation. The maintenance of normoxia / isoxia during hypercapnic provocation is 
important for the assessment of vascular reactivity in order to avoid confounding effects of 
O2 induced vasoconstriction. The use of a non-rebreathing valve system to induce 
hypercapnia by manual addition of CO2 to inspired air (known as the dynamic end-tidal 
forcing, DEF technique) has been shown to only raise PETCO2 to the target level; however, 
using this technique there is a large difference between the PETCO2 and the arterial 
concentration of CO2 (PaCO2). The sequential rebreathing circuit by the use of a rebreathing 
valve has been shown to avoid this problem and thereby closely matches both PETCO2 and 
PaCO2 values. In this thesis, a sequential rebreathing circuit and an automated gas flow 
controller (RespirActTM, Thornhill Research Inc., Toronto Canada) were used to 
independently alter PETCO2 and stabilize PETO2 and to induce normoxic/isoxic hypercapnia 
in patients with POAG. The development of a sustained and stable normoxic hypercapnic 
stimulus was essential for safety reasons. 
 
2.2 Quantitative assessment of retinal hemodynamics 
Various blood flow assessment techniques have been used in an attempt to quantify retinal 
hemodynamics. However, the majority of instruments that have been used to-date were not 
able to truly assess retinal blood flow in absolute units. Typically, these instruments would 
assess a component of retinal hemodynamics that was then assumed to reflect change in 
retinal blood flow. The Canon Laser Blood Flowmeter (CLBF, model 100, Canon, Tokyo, 
Japan) is the only instrument that quantifies retinal blood flow in absolute units. The CLBF 
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simultaneously measures diameter and blood velocity at a single point along a major retinal 
vessel. In this respect, the CLBF measurement is not continuous but rather is limited to a 2 
second window. For this reason, we were aware from the infancy of this work of the need to 
develop a sustained and stable normoxic / isoxic hypercapnic provocation to induce retinal 
vascular reactivity so that repeated hemodynamic measurements could be obtained. Similar 
consideration was given to the Heidelberg Retina Flowmeter (HRF, Heidelberg Engineering 
GmbH, Heidelberg, Germany) which was used in this work to assess the impact of normoxic 
/ isoxic hypercapnia on retinal capillary and ONH vascular reactivity. The HRF has a 
relatively high measurement variability which demands repeated measurements over a 
sustained period of time in order to attain a valid estimate of the hemodynamic parameter 
value. 
 
2.3 Evaluation, validation and repeatability 
Chapters 3, 4 and 5 of this thesis focus on the development of a safe, sustained and stable 
normoxic / isoxic hypercapnic stimulus and define the physiological response of the retinal 
and ONH vasculature to the provocation. The objective of Chapter 3 was to develop a safe, 
sustained and stable hypercapnic stimulus to assess retinal capillary and ONH vascular 
reactivity using the HRF. Accordingly, the manual addition of CO2 to inspired air was 
delivered via a sequential rebreathing circuit to induce hypercapnia. This stimulus was tested 
in young clinically healthy individuals. The hypothesis was that retinal and ONH capillary 
blood flow would increase during hypercapnia. Although the hypercapnic stimulus arguably 
resulted in a physiologically insignificant change, there was still an increase in PETO2 during 
hypercapnia. 
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In order to minimize the change in PETO2, the objective of Chapter 4 was to utilize the 
sequential rebreathing circuit to induce normoxic / isoxic hypercapnia by +15% PETCO2 
relative to baseline and to assess retinal arteriolar vascular reactivity using the CLBF in 
young healthy controls. The rate of flow of inspired air was simply decreased until subjects 
began to partially rebreathe expired air from the rebreathed gas reservoir, thereby elevating 
PETCO2 in a controlled manner. The requirement for a safe, sustained and stable hypercapnic 
stimulus was maintained. The hypothesis was that arteriolar diameter, blood velocity and 
blood flow would increase during normoxic / isoxic hypercapnia. The partial rebreathe 
technique resulted in an improved control of PETO2 during hypercapnia but nevertheless 
there was still a statistically significant decrease in the magnitude of PETO2. 
 
The results of Chapters 3 and 4 catalysed the development of an automated gas flow 
controller (RespirActTM, Thornhill Research Inc., Toronto Canada) which was used in 
conjunction with the sequential rebreathing circuit. Using this system, PETCO2 and PETO2 
can be independently controlled and set values are robust to changes in respiration rate and 
tidal volume. The objective of Chapter 5 was to assess retinal arteriolar and retinal capillary 
and ONH vascular reactivity in response to a normoxic / isoxic hypercapnic provocation 
induced using the automated gas flow controller and sequential rebreathing circuit in young 
healthy controls. The hypothesis was that the magnitude of vascular reactivity would be 
equivalent in percentage terms in the retinal arterioles and the downstream capillaries since 
the retinal circulation is a closed system.  This technique resulted in much improved and 
better PETO2 control during hypercapnia but nevertheless a statistically significant increase 
was still recorded. Since the change in PETO2 was now minimal, the term normoxic 
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hypercapnia (i.e. change that did not have any measureable physiological impact) was 
adopted for all future descriptions of the provocation rather than isoxic hypercapnia (i.e. 
unchanged). The normoxic hypercapnic provocation was demonstrated to be repeatable. 
 
2.4 Judicious selection of glaucoma patients to investigate vascular 
reactivity 
The objective of Chapter 6 was to apply the evaluated and validated normoxic hypercapnic 
stimulus in patients with POAG. The majority of previous studies have assessed retinal 
hemodynamics in patients with POAG who were receiving at least one IOP lowering 
medication and often multiple medications, or who had undergone an insufficient wash-out 
period prior to assessment. As a result, we set out to investigate retinal arteriolar and ONH 
vascular reactivity to normoxic hypercapnia in newly diagnosed untreated POAG (uPOAG) 
and in healthy controls. Patients with uPOAG were recruited in order to exclude the potential 
confounding effects of IOP lowering medications on the assessment of retinal vascular 
reactivity. Patients with progressive POAG (pPOAG) and who were receiving treatment were 
also assessed since they are thought to most likely manifest vascular dysregulation. The 
hypothesis was that patients with uPOAG and pPOAG would manifest a reduced magnitude 
of retinal arteriolar and ONH vascular reactivity compared to healthy controls. 
 
Previous studies have also investigated any possible beneficial effects of certain IOP 
lowering medications on ocular blood flow. In particular, studies have shown that treatment 
with Dorzolamide might improve retinal blood flow. However, none of the earlier studies 
have quantified the vascular reactivity in uPOAG at baseline and then followed the same 
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patient group after a short period of treatment, that is, newly treated POAG (ntPOAG). A 
second objective of Chapter 6 was to determine the effect of treatment with 2% Dorzolamide, 
twice daily for 2 weeks on retinal and ONH vascular reactivity in uPOAG. The second 
hypothesis of Chapter 6 was that treatment with Dorzolamide will improve retinal and ONH 
vascular reactivity in uPOAG.  
 
2.5 Relationship between functional vascular response and biochemical 
measures in POAG  
There is a suggestion that the potent vasoconstrictor ET-1 released by the vascular 
endothelium is present in higher amounts in the aqueous and plasma of patients with POAG 
and, in particular, in those with NTG. There is also evidence that patients with POAG exhibit 
reduced plasma cGMP levels which is thought to be a surrogate marker of NO expression. 
However, there is lack of research on the presence of these biochemical markers of 
endothelial function in uPOAG and pPOAG. The objective of Chapter 7 was to compare 
plasma levels of ET-1 and cGMP (i.e. endothelial derived markers) to the magnitude of 
retinal vascular reactivity in patients with uPOAG and pPOAG and in healthy controls in 
order to ultimately validate the functional measurement. The primary hypothesis was that 
plasma ET-1 will be present in higher amounts at baseline in uPOAG and pPOAG compared 
to age-similar controls and that hypercapnia would reduce the presence of ET-1 in all groups. 
In addition, cGMP was hypothesized to be lower in uPOAG and pPOAG compared to age-
similar controls at baseline and that hypercapnia would increase plasma cGMP levels. In 
addition, the effect of treatment with 2% Dorzolamide for 2 weeks on plasma ET-1 and 
cGMP levels was also investigated. The secondary hypothesis was that treatment would 
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decrease ET-1 in patients with uPOAG, thereby explaining the restoration of vascular 




3 The Impact of Hypercapnia on Retinal Capillary Blood Flow 
Assessed by Scanning Laser Doppler Flowmetry 
 
Venkataraman ST, Hudson C, Fisher JA, Flanagan JG. The impact of hypercapnia on retinal 
capillary blood flow assessed by scanning laser Doppler flowmetry. Microvasc.Res. 
2005;69:149-155. 
Reprinted by permission from Elsevier publishers. 
 
3.1 Abstract 
Aim: To determine the effect of hypercapnia on retinal capillary blood flow using scanning 
laser Doppler flowmetry (SLDF).  
Methods: One randomly selected eye of each of 10 normal healthy subjects (mean age 25 
years, SD 2.3) was studied. Subjects breathed unrestricted air for 15 minutes before 
(baseline) and after raising fractional (per cent) end-tidal concentration of CO2 (FETCO2) for 
15 minutes by adding low flows of CO2 to air entering a sequential gas delivery circuit 
attached to a nasal mask. Five good quality baseline SLDF images were acquired both of the 
optic nerve head (ONH) and of the macula. Subsequently, a minimum of 7 sequential images 
were acquired during hypercapnia. Five further images were acquired of the ONH, or of the 
macula, after returning to unlimited air breathing. The respiratory parameters of subjects 
were continually monitored.  
Results: The group mean increase in end-tidal CO2 was 14.13% (SD 4.10) relative to 
baseline. The nasal macula (p=0.028) and foveal (p=0.042) areas showed a significant 
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increase in retinal capillary blood flow in response to hypercapnia while no significant 
change was noted in the ONH or temporal macula areas. Change in blood flow significantly 
correlated with change of FETCO2 and/or end-tidal PO2 for 3 of the 4 locations.  
Conclusions: Hypercapnia provoked a significant increase in retinal capillary blood flow in 
2 of 4 retinal locations. Hypercapnia also induced a change in respiratory parameters that 
significantly correlated with change in retinal capillary blood flow in 3 of the 4 locations. 
 Keywords: Hypercapnia, retinal capillary blood flow, laser Doppler flowmetry. 
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3.2 Introduction 
Change of retinal perfusion induced by the perturbation of inspired oxygen (O2), or carbon 
dioxide (CO2), can be used to provide a measure of the magnitude of retinal vascular 
reactivity. Hypercapnia represents a potent vasoactive stimulus 1, 2. The change of fractional 
(per cent) end-tidal CO2 concentration (FETCO2) reflects the change in the partial pressure of 
arterial CO2 (PaCO2) 
3. An increase in FETCO2 has been demonstrated to produce 
vasodilatation in animals and humans of both the cerebral and retinal circulations using 
various measurement techniques 1, 2, 4-10. A 1 mmHg change in PaCO2 produces a 3% 
increase in ocular blood flow in primates 4. 
  
Scanning laser Doppler flowmetry (SLDF i.e. the combination of a laser Doppler flowmeter 
and a scanning laser system) provides a two-dimensional, quantifiable perfusion map of 
retinal capillary blood flow 11. SLDF can be used to non-invasively visualise and quantify 
retinal capillary blood flow 11-13. Previous studies have quantified the impact of hypercapnia 
on SLDF measurement of retinal capillary blood flow 5, on similar hemodynamic techniques 
8 and on contrast sensitivity 14. All of these studies utilised non-standardised stimuli and/or 
poorly defined methodology 5, 8, 14. In particular, in the study by Harris et al (1994a), any 
concomitant change of end-tidal O2 concentrations are not reported 
15.  They state that isoxic 
conditions are maintained during hypercapnia although evidence to support this is absent and 
the gas delivery system used does not seem capable of achieving isoxic hypercapnia. 
Furthermore, the period of hypercapnia was brief, i.e. approximately 3 minutes 14, which 
would impose severe methodological limitations on any experimental design.  
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The aim of this study was to non-invasively assess the magnitude of vascular reactivity of the 
retinal, and superficial optic nerve head, capillaries in young clinically normal subjects by 
SLDF, in response to a standardized hypercapnic provocation. The development of a 
standardized stimulus will provide conditions under which changes in vascular response can 
be compared in a given subject from one time period to the next, between subjects and 
between research groups. Unique to this study, the use of a sequential re-breathing technique 
16 facilitated the control and manipulation of stimulus parameters.  
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3.3 Materials and methods 
3.3.1 Subjects   
The study protocol was approved by the University of Waterloo, Office of Research Ethics.  
All subjects signed a consent form prior to participation after explanation of the nature and 
possible consequences of the study according to the tenets of the Declaration of Helsinki.  
Ten clinically normal young subjects of mean age 25 years (SD 2.35, range 22-29) were 
recruited (3 males : 7 females). Exclusion criteria included habitual smoking, treatable 
respiratory disorders (e.g. asthma), cardiovascular disease, systemic hypertension, refractive 
error greater than ± 6.00DS and greater than ± 1.50DC, ocular pathology and family history 
of glaucoma or diabetes. All subjects had Snellen visual acuity of 20/20 or better. The study 
eye was randomly selected. Subjects were asked to abstain from caffeine containing food and 
drinks 2 hours prior to the second visit. 
         
3.3.2 Visits  
Subjects attended for two visits. During the first visit, both eyes were dilated and an ocular 
examination was undertaken to ensure eligibility criteria for the study. Intraocular pressure 
was measured for both eyes using Goldmann tonometry. Retinal tomograph images were 
acquired using the Heidelberg Retina Tomograph (HRT; Heidelberg Engineering GmbH, 
Dossenheim, Germany) centered at both the optic nerve head and macula. HRT assessment 
was performed in order to calculate the optimal retinal location (i.e. x, y) and dioptric setting 
(i.e. z) for subsequent capillary blood flow measurement at both the optic nerve head and 
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macula 17. Using this technique, a preset location and focus was defined for the subsequent 
acquisition of SLDF images during the subsequent visit. 
 
3.3.3 Scanning laser Doppler flowmetry 
The light reflected by moving red blood cells in the retina undergoes a frequency shift while 
light reflected from surrounding tissue is unchanged. Using SLDF, the intensity of back-
scattered laser light from the retina is measured as a function of time (to produce an intensity-
time curve) for each pixel within the image. The two coherent components of light interfere 
resulting in an oscillation, or “beat”, of the measured light intensity. The frequency of the 
intensity oscillation is equal to the Doppler frequency shift. Fast Fourier transformation of 
the intensity-time curve generates a power spectrum of the Doppler shift to derive parameters 
of blood flow, volume and velocity 18 at each pixel within the image.  
 
SLDF measurements were undertaken using the Heidelberg Retina Flowmeter (HRF; 
Heidelberg Engineering GmbH, Dossenheim, Germany, software version 1.03W). The HRF 
uses a 780nm wavelength infrared diode laser to measure the intensity, and thereby calculate 
the Doppler shift of back-scattered light. The instrument has a spatial resolution of 
approximately 10µm and a depth resolution 300-400µm 19, 20. The laser scanning system of 
the HRF enables the measurement of a 10° horizontal x 2.5° vertical (i.e. approximately 
2.7mm x 0.7mm) field with a resolution of 256 pixels x 64 lines, respectively. Each line of 
256 pixels is scanned 128 times at a repetition rate of 4000Hz. The resulting image 
acquisition time is 2.048 sec. 
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The focus settings for each subject were kept constant throughout the experiment.  HRF 
images of both the ONH and the macula were acquired. Subjects fixated a green light with 
the non-study eye. The fixation light was mounted on a stand at a distance of 3 meters. A 
periscope was placed in front of the non-study eye when imaging the macula in order to 
permit the subject to view the fixation light. 
  
3.3.4 Procedures 
At visit 2, intraocular pressure was measured in the non-study eye prior to the introduction of 
the hypercapnic stimulus (to avoid disturbance of image quality in the study eye) and in both 
eyes on completion of the breathing protocol. The results were compared to those attained at 
visit 1 to ensure consistency. The total duration of visit 2 was 45 minutes. Subjects 
accommodated to the circuit for 10 minutes to allow stabilization of cardio-vascular 
parameters e.g. respiration rate, heart rate and blood pressure. Subjects were then fitted with 
a nasal mask connected to a sequential re-breathing circuit (Hi-Ox SR, Viasys Healthcare, 
Yorba Linda, CA). The sequential re-breathing circuit allowed the manipulation of inspired, 
and thereby expired, gases as described by Vesely and co-workers (2001) and Gilmore and 
co-workers (2004) 16, 21. The circuit comprised a non-rebreathing valve and fresh gas and re-
breathed gas reservoirs that were interconnected by two one-way valves and a single PEEP 
valve (Figure 3.1). The nasal mask was attached to the sequential re-breathing system that, in 
turn, was connected to the gas supply. Flow from the gas tanks was controlled using 
rotometers (Flowmeter 56073-11-01-000, Controls corp. of America, Virginia beach, 
Virginia). Inspired gases were reduced until FETCO2 rose approximately 15% relative to 
baseline, a level previously documented to be safe 22. Subjects were instructed not to open 
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their mouth during the procedure in order to achieve control of inspired gas concentration. 
Should the subjects experience discomfort from the hypercapnia, however, they would be 
able to breathe through their mouth (and the study would be aborted).  It was predetermined 
that the procedure would be abandoned if: i). There was an increase in diastolic blood 
pressure of ≥ 15mmHg; ii). Absolute diastolic blood pressure reached or exceeded 
100mmHg; and iii). Pulse rate reached or exceeded 150 beats/min. 
 
Figure 3.1 Schematic representation of the sequential rebreathing system. 
 
During the initial 15 minutes of data collection, subjects breathed bottled air entering the 
mask at a rate of 6.0 to 8.0 litres per minute (LPM) allowing the development of a stable 
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resting FETCO2. FETCO2 was stabilized (preventing any changes with increases in minute 
ventilation) by setting the air flow equal to the subjects’ resting minute ventilation (i.e. the air 
flow at which the fresh air reservoir just collapsed). Five good quality baseline SLDF images 
were acquired both of the optic nerve head (ONH) and of the macula (site order 
systematically alternated between subjects). During the next 15minutes, 0.3 to 0.4 LPM of 
CO2 was added to 5.0 to 7.0 LPM of inspired air to increase FETCO2 by approximately 15% 
from baseline. A minimum of 7 sequential SLDF images were acquired at both locations 
once a stabilized increase of FETCO2 was attained (site order maintained relative to baseline). 
During the final 15 minutes, subjects once more breathed bottled air at a rate of 6.0 to 8.0 
LPM and were allowed to return to their resting FETCO2 level. At this point, five further 
SLDF images were acquired of the ONH, or of the macula (systematically alternated between 
subjects). Tidal gas concentrations, including inspired and expired O2 and CO2 levels, were 
continuously sampled from the nasal mask using a rapid response gas analyzer (Cardiocap 5, 
Datex-Ohmeda, Helsinki, Finland). Over the entire procedure, systolic and diastolic blood 
pressure, heart rate, respiration rate, pulse rate and oxygen saturation were monitored using 
the critical care monitor. 
 
Capillary blood flow values of neuro-retinal rim, nasal macula, fovea and temporal macula 
were generated using the Automated Full Field Perfusion Image Analysis (AFFPIA) 
software. The AFFPIA software has been described in detail elsewhere 23. This analysis was 
used to extract blood flow values from SLDF images. Using this technique, erroneous blood 
flow data due to saccades and large blood vessels were excluded. The AFFPIA enabled the 
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use of a circle to be centered on the desired retinal measurement site (i.e. the fovea or ONH) 
to derive capillary blood flow values for specified retinal areas (Figure 3.2). 
 
  
Figure 3.2 Scanning laser Doppler flowmetry image of the left macula of an individual showing the AFFPIA 
analysis circle centered on the fovea.  
Using the AFFPIA, capillary blood flow values of the fovea (all valid pixels within the circle), nasal macula (all 
valid pixels nasal to the fovea) and temporal macula (all valid pixels temporal to the fovea) were generated. A 
similar methodology was used to generate capillary blood flow values for the ONH. 
 
3.3.5 Statistical analysis 
Repeated measures Analysis of Variance (ANOVA) was performed on each of the dependent 
variables using Statistical Analysis System (SAS). The dependent variables were retinal 
capillary blood flow, end-tidal CO2 and O2 gas concentrations. The within-subject factors 
were retinal measurement site (i.e. ONH, nasal macula, fovea and temporal macula) and time 
(i.e. baseline, hypercapnia and post-hypercapnia). Pearson’s correlation co-efficient analysis 
was undertaken to determine any significant relationship of the change over time in blood 
flow to change of the gas parameters. Probability values of mean correlation were determined 
and an R ≥ 0.2 with a corresponding p<0.05 were considered to demonstrate a moderate or 
greater relationship. Student’s two-tailed paired t-test was used to compare baseline and 
hypercapnic measures of systolic and diastolic blood pressure, heart rate, oxygen saturation 
and respiration rate. 
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3.4  Results 
The repeated measures ANOVA demonstrated that group mean nasal and foveal capillary 
blood flow increased significantly (p=0.028 & p=0.042, respectively) as a result of 
hypercapnic provocation. The Pearson correlation co-efficient showed that change in blood 
flow significantly correlated with change of FETCO2 and/or end-tidal PO2 for 3 of the 4 
locations. Change of ONH capillary blood flow showed significant correlation with change 
of FETO2, while nasal macula blood flow showed significant correlation with both FETCO2 
and FETO2.  Similarly, change of foveal blood flow significantly correlated with change of 
FETCO2 (Table 3.1). 
   
Gas Parameters ONH (p) Macula Nasal (p) Foveal (p) Macula Temporal (p) 
FETCO2 0.1808 0.0382 
* 0.0377 * 0.2075 
FETO2 0.0363 
* 0.0053 * 0.7063 0.1724 
 
Table 3.1 Statistical significance values for correlation between change in relevant gas parameters over time and 
change in blood flow in the optic nerve head, macula nasal, foveal and macula temporal areas of the retina. 
 (FETCO2; end-tidal CO2. FETO2; end-tidal O2).  * represents significance at the p<0.05 level. 
 
Seven of 10 subjects showed an increase in ONH capillary blood flow during hypercapnia 
compared to baseline. Nine subjects showed an increase in both the nasal macula and foveal 
capillary blood flow, while 8 subjects showed an increase at the temporal macula during 
hypercapnia compared to baseline (Figure 3.3). The group mean ONH capillary blood flow 
demonstrated an insignificant trend to increase from 190.15 a.u (SD 74.93) at baseline to 
209.57 a.u. (SD 73.44) during hypercapnia (p=0.325). The group mean nasal macula 
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capillary blood flow increased from 127.17 a.u. (SD 32.59) at baseline to 151.22 a.u. (SD 
36.67) during hypercapnia (p=0.028), while foveal blood flow increased from 92.71 a.u. (SD 
28.07) to 107.39 a.u. (SD 34.43) (p=0.042). Temporal macula blood flow demonstrated an 
insignificant trend to increase from 120.21 a.u. (SD 40.28) to 140.54 a.u. (SD 41.00) 
(p=0.068), respectively. 
 
A sustained increase in FETCO2 was achieved in all subjects. A representative example 
demonstrating the change in FETCO2 over the course of the experiment is shown in Figure 
3.4. The group mean magnitude of fractional (i.e. %) end-tidal concentrations of CO2 and O2 
for baseline, hypercapnia and post-hypercapnia (± SD) are presented in (Table 3.2). Group 
mean FETCO2 significantly increased from 5.37% (SD 0.45) at baseline to 6.13% (SD 0.44) 
during hypercapnia (p<0.0001); this resulted in a group mean relative increase (i.e. to 
baseline) in end-tidal CO2 of 14.13% (SD 4.10). The end-tidal fractional concentration of O2 
(FETO2) increased from 14.59% (SD 0.5) at baseline to 16.48% (SD 1.0) (p=0.0005) but was 





Figure 3.3 Normalised blood flow for each individual of the optic nerve head (open diamond; 5 plot symbols 
are overlapping), (macula nasal open triangle, 4 plot symbols are overlapping), foveal (open circle, 2 plot 
symbols are overlapping) and macula temporal (open inverted triangle, 5 plot symbols are overlapping) 








Figure 3.4 FETCO2 plotted against time for a single individual. 
 
Condition FETCO2 (%) FETO2 (%) 
Baseline 5.37 ± 0.4 14.59 ± 0.5 
Hypercapnia 6.13 ± 0.4 16.48 ± 1.0 
Post-hypercapnia 5.24 ± 0.4 15.19 ± 0.6 
p-value (Re-ANOVA) <0.0001 =0.0005 
 
Table 3.2 The group mean magnitude of fractional (i.e. %) end-tidal concentrations of CO2 and O2 for baseline, 
hypercapnia and post-hypercapnia (± SD).  
(FETCO2; end-tidal percentage concentration of CO2. FETO2; end-tidal percentage concentration of O2).  
   
There was no necessity to abandon the procedure in any subject as a result of increase in 
blood pressure or pulse rate. There was no significant change in systolic or diastolic blood 
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pressure and oxygen saturation during the hypercapnic provocation relative to baseline. 
Respiration rate (p=0.005) and heart rate (p=0.049) showed a significant increase during 
hypercapnia relative to baseline (Table 3.3). 
 
 















    Baseline 73.1 ± 5.6 110.8 ± 9.0 67.7 ± 6.4 12.7 ± 2.8 98.56 ± 0.43 
  Hypercapnia 75.3 ± 7.5 113.3 ± 11.0 66.6 ± 9.0 14.7 ± 3.3 98.94 ± 0.47 
Post-hypercapnia 72.4 ± 6.4 108.9 ± 9.6 69.2 ± 5.8 13.0 ± 2.9 98.98 ± 0.48 
       p-value =0.049 >0.05 >0.05 0.005 >0.05 
 
Table 3.3 The group mean percentage heart rate, systolic and diastolic blood pressure, respiration rate and 
oxygen saturation (± SD) as a function of condition (i.e. baseline, hypercapnia and post-hypercapnia).  
 
3.5 Discussion 
In this study, we describe the changes in retinal blood flow resulting from a 15% change in 
end-tidal fractional CO2 concentration. Capillary blood flow in the nasal macula and fovea 
significantly increased during hypercapnia. ONH and temporal macula blood flow, however, 
did not show a significant increase. The increase in foveal blood flow during hypercapnia 
might be due to a possible vascular regulatory mechanism exhibited by the underlying 
choroidal vessels as this has been shown by previous researchers 24.  Also, the difference in 
retinal vascular response to hypercapnia for the 4 locations (i.e. 2 locations exhibited a 
significant increase in blood flow while 2 did not) may be explained by variations in the 
relative contribution of the underlying choroid to the measured signal 25. The choroidal 
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vasculature is thought to possess a less efficient regulatory mechanism 5. Change in blood 
flow significantly correlated with change of FETCO2 and/or FETO2 for 3 of the 4 locations. 
The difference in the magnitude of response to hypercapnia in various areas of the retina and 
ONH could also possibly be due to the inherent variability of capillary blood flow 
measurements using the HRF. Topographical variation in vascular reactivity to gas 
perturbation, however, in different areas of the retina has been noted in previous studies. Roff 
and co-workers (1999) showed a significant increase in retinal capillary blood flow of the 
superior temporal quadrant compared to baseline using SLDF, but not in the inferior 
temporal quadrant, in normal subjects undergoing 15% increase in FETCO2 
5. Chung and co-
workers, (1999) also found that hypercapnia resulted in a localized significant increase of 
retinal capillary blood flow in the superior temporal quadrant but not in the inferior temporal 
quadrant 7. Similarly, topographical variation in cortical vascular reactivity to gas 
perturbation, has been noted. For example, cerebral plasma volume (CPV) has been assessed 
using magnetic resonance imaging during normocapnia and hypercapnia (partial pressure of 
CO2 approximately 65mmHg) in the dorsoparietal neocortex and striatum of each 
hemisphere in cerebellum and in extra cerebral tissue of rats.  CPV showed a significant 
increase in the neocortex, striatum of the cerebellum but not in the extra cerebral tissue 26.  
 
This study described a safe way of administering CO2 to young subjects using a sequential 
re-breathing circuit. There was no significant change in blood pressure and oxygen 
saturation, however, there was a significant increase in heart rate and respiration rate during 
hypercapnia relative to baseline, as found in previous studies 5, 27. Participants were able to 
sustain hypercapnia for 15minutes without any major discomfort during the provocation. A 
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sustained and a stable increase in FETCO2 was achieved in all subjects. An important further 
advantage of using the sequential re-breathing circuit is that absolute FETCO2 levels can be 
manipulated whilst minimizing the variability of FETCO2 
21, thus providing stable stimulus 
conditions for provocation. As a result, a smaller magnitude of change of FETCO2 will result 
in statistical significance.     
 
Inhalation of CO2 enriched gas, as in our study, dilutes and thereby reduces the O2 
concentration in the lung and thus in the blood. As O2 is a vasoactive molecule in the ocular 
vasculature, changes in blood O2 concentration will influence the vascular response to blood 
CO2 concentration. However, this effect on the lung O2 concentration is partly offset by the 
increased ventilation stimulated by hypercapnia. In our study, the small increase in FETO2 
concentration was statistically significant but of no physiological significance, since it 
represented only 1/760 of the range of a full scale of atmospheric O2 concentration (from 1 to 
760 mmHg).  Previous studies utilizing hypercapnic provocation to assess ocular vascular 
reactivity have not reported taking any measures to maintain FETO2 constant. In fact, most 
have failed to monitor or report the FETO2 concentration 
5, 7, 14, 28.  
 
An increase in intra-ocular pressure and transient loss of perfusion to the optic nerve head are 
some of the factors that may contribute to the development of glaucomatous optic neuropathy 
29, 30. In particular, vascular dysregulation is thought to be associated with patients with 
normal-tension glaucoma (NTG) 31. Endothelin-1 (ET-1) is a 21-residue amino acid peptide 
with vasoconstrictive properties that is elevated in patients with NTG and primary open angle 
30, 32-34. Under normal conditions, the vasoconstrictive effect of ET-1 is balanced by the basal 
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release of NO although many other vasoactive factors undoubtedly contribute to the dynamic 
control of vascular perfusion 31, 35. Interestingly, an exaggerated increase in end-diastolic 
flow velocity of the ophthalmic artery has been observed in response to hypercapnia in NTG 
patients compared to normal subjects, suggesting a possible over-expression of ET-1 at 
baseline and an overall dysregulation of vascular tonus control in patients with NTG 36. NO 
is produced primarily by the isoforms of nitric oxide synthase (NOS) present in the vascular 
endothelium 37. The release of NO in both vascular smooth muscle cells and pericytes 
triggers the release of cyclic guanosine monophosphate leading to dephosphorylation of 
myosin light chain resulting in vasodilatation 38-40. Inhibition of NOS reduces the magnitude 
of vascular reactivity in blood vessels in response to hypercapnia 37.  In addition, alteration in 
the extra cellular pH at the level of retinal pericytes may play a role in hypercapnic 
vasodilatation 41.  We intend to utilise the methodology developed in this study in patients 
with NTG and compare the results gained to age-matched normal controls. We anticipate that 
this methodology in combination with biochemical assays of endothelial derived constricting 
and relaxing factors will reveal the role of NO in vascular dysregulation associated with 
glaucoma. This work is in progress in our laboratory. 
 
3.6 Conclusions 
Hypercapnia provoked a significant increase in retinal capillary blood flow in 2 of 4 retinal 
locations. In addition, change in blood flow significantly correlated with change of FETCO2 
and/or FETO2 for 3 of the 4 locations. Hypercapnic provocation typically results in changes 
in PO2 which in turn can affect vascular reactivity. In our study, the use of the sequential re-
breathing circuit resulted in a physiologically insignificant change in PO2 that is, a near 
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isoxic hypercapnic provocation.  We plan to modify our hypercapnic provocation to allow 
the maintenance of isoxic conditions during achievement of multiple levels of FETCO2 and 
apply it to assess the vascular reactivity of the retinal vasculature in normals and individuals 
with vasospastic disorders. 
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4 Novel Methodology to Comprehensively Assess Retinal 
Arteriolar Vascular Reactivity to Hypercapnia 
 
Venkataraman ST, Hudson C, Fisher JA, Flanagan JG. Novel methodology to 
comprehensively assess retinal arteriolar vascular reactivity to hypercapnia. Microvasc.Res. 
2006;72:101-107. 
Reprinted by permission from Elsevier publishers 
 
4.1 Abstract 
Purpose: 1). Describe a new methodology that permits the comprehensive assessment of 
retinal arteriolar vascular reactivity in response to a sustained and stable hypercapnic 
stimulus. 2). Determine the magnitude of the vascular reactivity response of the retinal 
arterioles to hypercapnic provocation in healthy, young subjects.  
Methodology: Eleven healthy subjects of mean age 27years (SD 3.43) participated in the 
study and one eye was randomly selected. A mask attached to a sequential re-breathing 
circuit, and connected to a gas delivery system, was fitted to the face. To establish baseline 
values, subjects breathed bottled air for 15 minutes and at least 6 blood flow measurements 
of the supero-temporal arteriole were acquired using the Canon Laser Blood Flowmeter 
(CLBF). Air flow was then decreased until a stable increase in fractional end-tidal CO2 
concentration (FETCO2) of 10-15% was achieved. CLBF measurements were acquired every 
minute (minimum of 6 measurements) during the 20 minute period of elevated FETCO2. 
FETCO2 was then reduced to baseline levels and 6 further CLBF measurements were 
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acquired. Respiratory rate, blood pressure, pulse rate and oxygen saturation were monitored 
continuously.  
Results: Retinal arteriolar diameter, blood velocity and blood flow increased during 
hypercapnia relative to baseline (p=0.0045, p<0.0001 & p<0.0001, respectively). Group 
mean FETCO2 showed an increase of 12.0% (SD 3.6) relative to baseline (p<0.0001). 
Conclusions: This study describes a new methodology that permits the comprehensive 
assessment of retinal arteriolar vascular reactivity in response to a sustained and stable 
hypercapnic stimulus. Retinal arteriolar diameter, blood velocity and blood flow increased 
significantly in response to a hypercapnic provocation in young, healthy subjects. 




Vascular reactivity is the magnitude of change of hemodynamic parameters to a provocative 
stimulus, for example, an increase in partial pressure of oxygen or carbon dioxide in the 
blood. It has been shown that both the retinal and the cerebral vessels react similarly by 
constricting to oxygen (O2) and by dilating to carbon dioxide (CO2) 
1-4. Hypercapnia, that is 
an increased partial pressure of CO2 (PaCO2) in systemic arterial blood, is known to be a 
potent vasodilatory stimulus. For the purpose of non-invasive studies in healthy subjects at 
rest, the end-tidal partial pressure of CO2 (PETCO2) is considered to be within 2 mmHg of the 
arterial PCO2 (PaCO2) and tracks it closely when PETCO2 is varied 
5.  In this paper, we will 
also refer to FETCO2 which is the fractional end-tidal concentration of CO2 ; PETCO2 =  
FETCO2 x barometric pressure.  
 
The vascular reactivity response of the retina to a 10 - 15% increase in FETCO2, achieved by 
the use of various methods of modulating inspired CO2, has been quantified using laser 
Doppler based techniques 6-9. The response of the ocular vasculature to breathing a mixture 
of 95% air and 5% CO2, or 95% O2 and 5% CO2 (i.e. carbogen), has also been assessed using 
the Oculix and Retinal Vessel Analyser (RVA) 1, 10, blue field entoptic technique 11 and the 
Pulsatile Ocular Blood Flowmeter (POBF) 12. In addition, Harino and co-workers 13 
determined change in macular blood velocity, by rebreathing into a bag to elevate FETCO2, 
using the blue field entoptic technique. Recently, our group has determined the effect of 
hypercapnia, induced using a sequential re-breathing circuit, on retinal capillary blood flow 9. 
Unlike previous studies, the use of a sequential re-breathing circuit permitted a sustained and 
a stable increase in FETCO2 with minimal concomitant change in end-tidal PO2 
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concentrations. In addition, all of the hemodynamic assessment techniques detailed above 
assess only one aspect of hemodynamics (i.e. vessel diameter or effectively blood velocity). 
 
The determination of quantitative retinal blood flow necessitates the simultaneous 
measurement of vessel diameter and blood velocity. The Canon Laser Blood Flowmeter 
(CLBF), model 100 (Canon, Tokyo, Japan), is the only retinal hemodynamic instrument that 
can simultaneously measure vessel diameter and centerline blood velocity, and therefore for 
the first time, quantify volumetric blood flow in absolute units 14. It utilizes bidirectional 
photodetectors to quantify centerline blood velocity, densitometry to measure vessel diameter 
and an eye tracker system to minimize the impact of eye movement 15, 16. Using the CLBF 
and a sequential re-breathing circuit, our group has recently defined the timeline response of 
the retinal arterioles to isocapnic hyperoxia 17 and have demonstrated that retinal blood flow 
varies directly with the arterial PCO2, as reflected in the PETCO2 
18. However, the magnitude 
of the vascular reactivity response to hypercapnia has not been systematically addressed in 
previous work.  
 
The aims of the study were to: 1). Describe a new methodology that permits the 
comprehensive assessment of retinal arteriolar vascular reactivity in response to a 
standardized, sustained and stable hypercapnic stimulus with minimal concomitant change in 
end-tidal PO2. The concomitant change in end-tidal pO2 during hypercapnia is a problem that 
previous studies have typically ignored. 2). Determine the magnitude of change in vessel 
diameter, blood velocity and flow of the retinal arterioles in response to sustained and stable 
hypercapnic provocation in young, healthy subjects. The magnitude of retinal arteriolar 
 149 
vascular reactivity will be used as a reference for future studies that investigate the impact of 
disease upon this hypercapnic provocation. A sequential re-breathing circuit was used to 
induce a stable, sustainable change in FETCO2 
18, 19. 
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4.3 Materials and methods 
4.3.1 Sample 
The study was approved by the University Health Network, Research Ethics Board, 
University of Toronto and by the University of Waterloo, Office of Research Ethics. All 
subjects signed a consent form prior to participation after explanation of the nature and 
possible consequences of the study according to the tenets of the declaration of Helsinki. 
Eleven healthy subjects (7 males and 4 females) of mean age 27years (SD 3.43, range 24 – 
36years) participated in the study. One eye was chosen randomly for the study. All subjects 
had a visual acuity 20/20 or better. Exclusion criteria included habitual smoking, treatable 
respiratory disorders (e.g. asthma), cardiovascular diseases, systemic hypertension, a 
refractive error greater than ± 6.00DS and ± 1.50DC, any ocular pathology, no immediate 
family history of glaucoma or diabetes or medications with known effects on blood flow (e.g. 
anticonvulsants, muscle relaxants, or anti-inflammatory medications). All participants were 




Subjects attended for two visits. During the first visit, both pupils were dilated using 
Mydriacyl 1% (Alcon Canada Inc. Mississauga, Canada) and a health profile and ocular 
examination were performed to ensure eligibility for the study. The study eye was then 
randomly chosen and one CLBF image was acquired of a supero-temporal arteriole to 
determine a suitable measurement site. The site of CLBF measurement was approximately 1 
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disc diameter distant from the edge of the optic nerve head along a relatively straight 
segment of the supero-temporal arteriole and distant from any bifurcations. The measurement 
site selected at visit 1 was stored in the memory of the PC for subsequent imaging at visit 2. 
At the first visit, intra ocular pressure was measured in both eyes, followed by axial length 
measurement of the study eye. During the second visit, intra ocular pressure was measured 
only in the non-study eye to maintain the optical quality of the cornea for CLBF imaging. At 




4.3.3.1 Quantitative retinal blood flow assessment 
The principle underlying the quantitative retinal blood flow assessment technique is based on 
the Doppler effect. Laser light scattered from a stationary object such as a vessel wall 
remains unaltered in frequency, while light reflected by a moving red blood cell undergoes a 
frequency shift (∆f). This shift in frequency is proportional to the velocity of the moving 
particle. A vessel that exhibits Poiseuille flow will have a range of velocities and thus a range 
of frequency shifts up to a maximum frequency shift (∆fmax) that corresponds to the 
maximum velocity of the blood moving at the centre of the vessel lumen. ∆fmax can be 
referenced to the frequency of laser light reflected from stationary tissue to calculate relative 
change in velocity 20. By utilizing two photo-detectors separated by a known angle, the 
maximum frequency shift detected by each photo-detector is subtracted to allow the absolute 
quantification of centre-line blood velocity, irrespective of the angle between the moving 
particle and reflected beam 21, 22. The resulting Doppler signal is analysed using a previously 
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described algorithm 21, 23. The frequency shift is determined as the frequency at which there 
is an abrupt reduction in the amplitude of the fluctuations in the Doppler-shift power 
spectrum. This determination does not depend on any presumed shape of the average power 
spectral density curve. 
 
Briefly, the CLBF simultaneously measures blood velocity (mm/sec) and vessel diameter 
(µm) to calculate the rate of blood flow (µL/min). The operating principles of the quantitative 
blood flow assessment technique have been described in detail elsewhere 17, 24-27. 
Hemodynamic measurements are corrected for magnification effects associated with axial 
and refractive ametropia 25, 26. In combination with the average velocity (Vmean) over a pulse 
cycle and diameter (D), flow (F) through the vessel can be calculated using the formula: 
     F = ½ . π . D2/4. Vmean . 60 
where Vmean is the time average of the centerline blood velocity.  
 
4.3.3.2 Sequential re-breathing circuit 
The sequential re-breathing circuit design has been described in detail elsewhere 9, 17. It 
comprises a fresh gas reservoir and an expiratory gas reservoir. Each reservoir is connected 
to a face mask with separate one way valves. The face mask covers the mouth and nose of 
the subject. In turn, the two reservoirs are inter-connected using a positive end-expiratory 
pressure (PEEP) valve which allows subjects to breath exhaled gas (i.e. re-breathe CO2 
enriched gas) when the fresh gas reservoir is depleted 18, 28. This unique feature permits the 
sustained and stable manipulation of FETCO2 in a subject by adjusting the air flow into the 
circuit and is independent of the minute ventilation.  
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4.3.4 Procedures 
Subjects rested for 10 minutes prior to the start of the procedure to achieve stable baseline 
cardiovascular and respiratory parameters. A commercially available face mask (HiOxSR 
Viasys Healthcare, Yorba Linda, CA), securely sealed to the subjects face using Tegaderm 
(Health Care, Minnesota, USA), was connected to the sequential re-breathing circuit.  Flow 
from a gas tank containing air was controlled using generic rotometers as flowmeters. The 
relative concentrations of inhaled and exhaled O2 and CO2 were sampled continuously using 
a critical care gas monitor (Cardiocap 5, Datex-Ohmeda, Helsinki, Finland).  
 
For the first 15 minutes, subjects breathed bottled air at a flow equal to their minute 
ventilation ensuring a stable FETCO2 and at least six CLBF measurements at the 
predetermined arteriolar measurement site were acquired. During the next 20 minutes, air 
flow was reduced until a stable increase in FETCO2 of approximately 10-15% relative to the 
baseline value was achieved. CLBF measurements were acquired every minute (minimum of 
6 measurements). The sequential gas delivery circuit, with a constant inflow of air, assured 
stable conditions during repeated CLBF measurements since it maintained the FETCO2 
constant, independent of changes in ventilation.  During the final 15 minute period, air flow 
was again increased to restore FETCO2 to the baseline level and at least 6 CLBF 
measurements were acquired. Pulse rate, blood pressure, respiration rate and finger oxygen 




4.3.5.1 CLBF velocity waveform analysis 
CLBF analysis software was used to analyze each acquired velocity waveform. A 
standardized protocol was used to remove aberrant portions of each waveform due to eye 
movements or improper vessel tracking. The maximum number of acceptable cycles for each 
acquisition was included in the analysis, while a minimum of one complete systolic-diastolic 
cycle was required for inclusion of a given waveform.  
 
4.3.5.2 Statistical Analysis 
Group mean hemodynamic and systemic parameter values of each individual were calculated 
for each condition (i.e. baseline, hypercapnia and post-hypercapnia). A repeated measures 
Analysis of Variance (reANOVA) of the mean hemodynamic and systemic parameters was 
performed using Statistical Analysis System (SAS v.8.02). The dependent variables were 
retinal arteriolar diameter, blood velocity, blood flow, systolic and diastolic blood pressure, 
pulse rate, respiration rate and oxygen saturation. Time (baseline, hypercapnia and post-
hypercapnia) was the within subject factor. Fisher’s least significant difference (LSD) 
protected post-hoc test was used to determine the level of significance for each hemodynamic 
parameter that was found to have changed significantly by re ANOVA.  
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4.4 Results 
A sustained and stable hypercapnic provocation was achieved in all subjects (p<0.0001). 
There was a 12.0 ± 3.6 % relative increase in FETCO2 during hypercapnia. The group mean 
magnitude of FETCO2 and fractional (i.e. %) end-tidal concentrations of O2 (FETO2) for 
baseline, hypercapnia and post-hypercapnia (± SD) are presented in (Table 4.1). There was 
also a concomitant statistically significant decrease in the FETO2 during hypercapnia in all 
subjects (Figure 4.1). 
   
 
Table 4.1 The group mean fractional concentration of expired CO2 and O2 (± SD) as a function of condition (i.e. 
baseline, hypercapnia and post-hypercapnia) expressed as per cent.  
The repeated measures ANOVA p-value, indicating the significance of the change of expired CO2 and O2 over 
the course of the provocation, is shown on the bottom row (FETCO2; end-tidal percentage concentration of CO2; 
FETO2 end-tidal percentage concentration of O2). 
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Figure 4.1 Change in FETCO2 (open circles) and FETO2 (open squares) of a single individual over the course of 
the study.  
The black arrows represent the start and end of the hypercapnic stimulus. 
   
During hypercapnia, group mean (± SD) retinal arteriolar diameter increased from 108.7 ± 
10.8 µm to 112.2 ± 10.9 µm ) (p=0.0045) (Figure 4.2A) and group mean blood velocity also 
increased from 28.1 ±  4.1 mm/sec to 35.4 ±  4.9 mm/sec (p<0.0001) (Figure 4.2B). The 
resulting group mean arteriolar blood flow increased from 7.9 ± 1.9 µl/min to 10.7 ±  2.9 
µl/min (p<0.0001) (Figure 4.2C). The magnitude of increase in retinal arteriolar diameter, 
blood velocity and blood flow during hypercapnia relative to baseline was 3.2 ± 1.4 %, 26.4 
± 7.0 % and 34.9 ± 8.1 %, respectively. Baseline magnitudes of group mean retinal arteriolar 
diameter, blood velocity and flow were not significantly different from recovery values. 
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Figure 4.2 Box plot of group mean change in: A). Retinal arteriolar diameter; B). Blood velocity; and C). Blood 
flow as a function of condition (i.e. baseline, hypercapnia and post-hypercapnia). 
 
Subjects did not complain of any discomfort prior to, during or post-hypercapnia. There was 
no significant change observed in the systolic and diastolic blood pressure, respiration rate, 
and oxygen saturation during hypercapnia relative to baseline (Table 4.2). However, the 
group mean pulse rate increased slightly from 72 beats/min to 75 beats/min during 
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Table 4.2 The group mean (± SD) pulse rate, systolic and diastolic blood pressure, respiration rate and oxygen 
saturation as a function of condition (i.e. baseline, hypercapnia and post-hypercapnia).  
The repeated measures ANOVA p-value, indicating the significance of the change of each parameter over the 




This study describes a new methodology that permits the comprehensive assessment of 
retinal arteriolar vascular reactivity in response to a standardized, sustained and stable 
hypercapnic stimulus with minimal concomitant change in end-tidal PO2. As far as we are 
aware, this improvement in the standardization of the hypercapnic provocation is unique 
amongst the ocular blood flow literature. It also establishes the magnitude of response of the 
retinal arterioles to hypercapnic provocation in healthy, young subjects. We have previously 
demonstrated that retinal blood flow varies directly with the arterial PCO2, as reflected in the 
PETCO2 
18. However, this is the first study to systematically quantify the magnitude of 
increase in retinal arteriolar vascular reactivity in terms of change in vessel diameter, blood 
velocity and flow, during sustained and stable hypercapnia.  
 
The magnitude of increase in retinal arteriolar diameter following hypercapnic provocation 
found in this study is similar to previous work. Dorner and co-workers 1 determined the 
impact of breathing 5% CO2 and 95% air on retinal arteriolar diameter, macular leucocyte 
velocity and temporal retinal vein velocity using the RVA, blue field entoptic technique and 
Oculix, respectively. An increase in retinal arteriolar diameter of 4.2 % (SD 1.6) was 
reported in their study following an approximately 21% increase in FETCO2, in general 
agreement with our study.  
 
Capillaries act primarily as exchange vessels while the arterioles drive the vascular reactivity 
response i.e. diameter is adjusted in the arteriolar resistance vessels by smooth muscle in the 
vessel wall resulting in gross downstream regulation of blood flow 29. The magnitude of 
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response produced by retinal capillaries during hypercapnic provocation is less 9 compared to 
the magnitude of change in retinal arteriolar hemodynamics found in the present study. Using 
a similar sample of subjects, we have recently 9 demonstrated a significant increase of 
capillary hemodynamics in the macular nasal and the foveal areas of the retina during 
hypercapnia using scanning laser Doppler flowmetry (SLDF) but no change was observed in 
the optic nerve head (ONH) and temporal macular areas. The regional differences in capillary 
response might be due to variations in the relative contribution of the underlying choroid to 
the measured signal 30. Also, the measurement of capillary hemodynamics using SLDF has a 
less favorable signal-to-noise ratio. The strong statistical outcomes in this study (e.g. 
p<0.0001) indicate that the arteriolar vasodilation amongst the sample is consistent and the 
variability of the CLBF measurements merely represents the spread of homeostatic 
hemodynamic values. 
 
An increase in the arterial blood CO2 concentration has also been shown to vasodilate retinal 
capillaries in humans. Sponsel and co-workers 11 found a 26% increase in perimacular 
leukocyte velocity using the blue field entoptic technique after breathing carbogen. Roff and 
co-workers 8 demonstrated a mean increase of 11% and 13% in blood velocity and flow 
using SLDF during hypercapnia but no change was observed in the ophthalmic and central 
retinal arteries determined by color Doppler imaging. Another study that used the SLDF to 
assess the hemodynamic response of the retinal vessels in young subjects showed a 15.4% 
and 21.2% increase in blood velocity and flow, respectively, in the superior retina in 
response to a 15% increase in FETCO2 
6. The reason for the differences in magnitude of the 
capillary response between studies is probably explained by differences in magnitude of 
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hypercapnia, the stability of the provocation and the variability of SLDF measurements. In 
contrast to previous work, the present study assessed the magnitude of the response of the 
retinal arterioles (i.e. the site of vascular resistance) to a sustained and stable hypercapnic 
provocation.  
 
A similar magnitude of increase in retinal blood flow in response to hypercapnia has been 
shown in monkeys 31. In addition, assessment of cerebral vascular reactivity during elevated 
PaCO2 levels have also shown vasodilatation in both humans and animals 
2, 4, 32. Alterations 
in the hemodynamic parameters of retinal and cerebral blood vessels might be mediated by 
changes in extra cellular pH and/or release of vasoactive mediators particularly nitric oxide, 
but also including prostacyclin and prostaglandins, produced by the vascular endothelium 33-
36.  
 
Factors that regulate the tone of the retinal vasculature include endothelin derivatives and 
nitric oxide, both produced by the vascular endothelium 37, 38. In hypercapnia induced 
vasodilatation, nitric oxide produced by the enzyme nitric oxide synthase is thought to be a 
major mediating factor 39. Nitric oxide produces vasodilatation by the release of 3’5’-cyclic 
guanosine monophosphate (cGMP) in the smooth muscle cells leading to a decrease in 
intracellular calcium and dephosphorylation of myosin light chains 34. Inhibition of nitric 
oxide synthase activity has been shown to result in a decrease of hypercapnia induced 
vasodilation in humans 35. 
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In this study, sustained and stable hypercapnia was achieved with the aid of a sequential re-
breathing circuit. The magnitude of hypercapnia was safe since it was well within the range 
experienced on a day-to-day basis.  Subjects experienced no discomfort and there was no 
physiologically significant change observed in the blood pressure and heart rate during the 
provocation (Table 4.2). Only pulse rate increased by 2 to 3 beats / minute during 
hypercapnia, in agreement with previous studies 7, 13. The concomitant decrease in FETO2 
during the hypercapnic period was secondary to change in FETCO2. In our study, the small 
change in FETO2 was statistically significant but nevertheless physiologically irrelevant. 
Hypoxia-stimulated changes in blood flow in a tissue occur in response to changes in blood 
oxygen saturation (SaO2). In this study, the change in FETO2 was too small to affect the SaO2. 
Furthermore, the SaO2 was in the normal range in our subjects and was far from the threshold 
of the vascular response which for cerebral vessels is known to be at 88 % oxygen saturation 
40.  
 
Harino and co-workers (1995) used the blue field entoptic technique to assess macular 
leukocyte velocity and a total re-breathing technique to achieve an increase in FETCO2 of 
33% leading to a concomitant decrease in FETO2 of approximately 37%. In our study, 
however, FETCO2 increased only by 12% with a concomitant 6% decrease in FETO2. This 
relatively subtle increase in FETCO2 was sufficient to demonstrate a substantial increase in 
retinal arteriolar hemodynamics. Interestingly, other studies that have used hypercapnic 
provocation have failed to report any change of FETO2 concentration 
41, 42, although we 
anticipate such change to be greater than a 6% decrease in FETO2 since none of the previous 
studies have utilized a sequential re-breathing circuit. Change in FETO2 will act as a 
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confounding factor for vascular reactivity measurements during hypercapnia 43. Furthermore, 
we have developed in-house a computer driven gas flow controller that enables the 
independent manipulation of FETCO2 and of FETO2, thereby facilitating and automating the 
attainment of isoxic hypercapnia 44. On-going work will define the retinal vascular reactivity 




This study describes a new methodology that permits the comprehensive assessment of 
retinal arteriolar vascular reactivity in response to a standardized, sustained and stable 
hypercapnic stimulus. It also defines the magnitude of response of the retinal arterioles to the 
hypercapnic provocation in healthy, young subjects. Retinal arteriolar diameter, blood 
velocity and blood flow increased by 3.2% (SD 1.4), 26.4% (SD 7.0) and 34.9% (SD 8.1), 
respectively, in response to a 12.0% (SD 3.6) rise in FETCO2.  These values may be used as a 
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5 Retinal Arteriolar and Capillary Vascular Reactivity in 
Response to Isoxic Hypercapnia  
 
 
Venkataraman ST, Hudson C, Fisher JA, et al. Retinal arteriolar and capillary vascular 
reactivity in response to isoxic hypercapnia. Exp.Eye Res. 2008. Dec; 87 (6): 535-542. 
Reprinted by permission from Elsevier publishers. 
 
5.1 Abstract 
The aim of the study was to compare the magnitude of vascular reactivity of the retinal 
arterioles in terms of percentage change to that of the retinal capillaries using a novel, 
standardized methodology to provoke isoxic hypercapnia.   
Ten healthy subjects (mean age 25yrs, range 21–31) were recruited. Subjects attended for a 
single visit comprising two study sessions separated by 30 minutes. Subjects were fitted with 
a sequential re-breathing circuit connected to a computer-controlled gas blender. Each 
session consisted of breathing at rest for 10min (baseline), increase of PETCO2 (maximum 
partial pressure of CO2 during expiration) by 15% above baseline whilst maintaining isoxia 
for 20 minutes, and return to baseline conditions for 10 minutes. Retinal hemodynamic 
measurements were performed using the Canon Laser Blood Flowmeter and the Heidelberg 
Retina Flowmeter in random order across sessions. 
Retinal arteriolar diameter, blood velocity and flow increased by 3.3%, 16.9% and 24.9% 
(p<0.001), respectively, during isoxic hypercapnia. There was also an increase of capillary 
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blood flow of 34.8%, 21.6%, 24.9% (p≤0.006) at the optic nerve head neuroretinal rim, nasal 
macula and fovea, respectively. The co-efficient of repeatability (COR) was 5% of the 
average PETCO2 both at baseline and during isoxic hypercapnia and was 10% and 7% of the 
average PETO2 (minimum partial pressure of oxygen at end exhalation), respectively. 
The magnitude of retinal capillary vascular reactivity was equivalent to the arteriolar 
vascular reactivity with respect to percentage change of flow.  The magnitude of isoxic 
hypercapnia was repeatable.  
Keywords: Retina, blood flow, laser Doppler flowmetry, hypercapnia, PETCO2, PETO2. 
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5.2 Introduction 
Vascular reactivity is the magnitude of change in retinal hemodynamic measurements to 
provocative stimuli, such as that elicited by change in arterial blood partial pressure of 
carbon dioxide (PaCO2) or oxygen (PaO2). As the measurement of PaCO2 is invasive and 
painful, the partial pressure of CO2 in end-tidal gas (PETCO2) is often used as a surrogate for 
PaCO2
1. Previous research has used various techniques to raise PETCO2 including the 
addition of CO2 to inspired air 
2-15, and the total rebreathing of exhaled gas 16. Each of these 
methods is associated with a variable concomitant change in end-tidal PO2 (PETO2).  Inhaling 
CO2 results in an unpredictable increase in ventilation and thereby an unpredictable increase 
in PETO2 
17.  Previous studies have failed to consider concomitant changes in PaO2 during 
hypercapnia and the derived vascular reactivity values thereby represent change induced by 
manipulation of PaO2 as well as PaCO2.  In our experience, inducing a 10-15% increase in 
PETCO2 by the manual addition of CO2 to inspired air increased PETO2 by 13% 
13, while 
PETO2 was reduced by 6% when using a manually controlled partial re-breathing technique 
14.  
  
We have developed a partial re-breathing approach that utilizes computer control of inspired 
gases to achieve consistent changes in PETCO2 and in PETO2 in a subject independent of each 
other and independent of minute ventilation, in order to primarily study retinal and cerebral 
vascular reactivity (RespirActTM, Thornhill Research Inc., Toronto Canada). The aim of the 
current study was to compare the percentage change of the magnitude of vascular reactivity 
of retinal arterioles to that of the retinal capillaries using a novel, standardized methodology 
to provoke isoxic hypercapnia.  The magnitude of vascular reactivity in response to isoxic 
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hypercapnia is hypothesized to be equivalent in retinal arterioles and capillaries since the 
retinal circulation is a closed system, i.e. any percentage change in flow in the arterioles 
would be expected to be similarly reflected in the downstream capillaries. In addition, it is 
critical to use a repeatable magnitude of PETCO2 elevation during hypercapnia to reduce the 
variability in vascular reactivity assessment. A secondary aim therefore was to assess the 








5.3 Materials and methods 
5.3.1 Sample 
The study was approved by the Research Ethics Boards of the University Health Network, 
University of Toronto, and the Office of Research Ethics, University of Waterloo. All 
subjects provided signed informed consent prior to agreeing to participate, after explanation 
of the nature and possible consequences of the study according to the tenets of the 
Declaration of Helsinki. Ten healthy subjects (8 females) of mean age 25 years (SD 3.2, 
range 21-31 years) participated in this study. Subjects had corrected visual acuity of 6/6 or 
better. Exclusion criteria included respiratory disorders, cardiovascular diseases, systemic 
hypertension, habitual smoking, refractive error greater than ± 6.00DS and ± 1.50DC, any 
ocular disease, immediate family history of glaucoma, and/or diabetes, and medications with 
known effects on blood flow (e.g. antihypertensive medication and medication with activity 
at autonomic receptors, smooth muscles, or those affecting NO release).  
 
5.3.2 Instrumentation 
5.3.2.1 Gas delivery system 
A sequential gas delivery (SGD) breathing circuit (Hi-Ox80, ViasysHealthcare, Yorba Linda 
CA) was assembled by placing a rebreathing bag on the expiratory port of a commercial 3-
valve oxygen delivery system. This breathing circuit has been described in detail elsewhere 
13, 14, 18, 19. The SGD allows subjects to breath exhaled gas (i.e. re-breathe CO2 enriched gas) 
when the fresh gas reservoir is depleted 20. 
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Algorithms have previously been derived relating subject minute CO2 production and O2 
consumption, gas flow and composition entering the SGD circuit to values of PETCO2 and 
PETO2 
21. These algorithms have been set up in a computer-controlled gas blender to provide 
the gas flow to the SGD (RespirActTM, Thornhill Research Inc., Toronto Canada) (Figure 
5.1).  The software allows the user to choose a series of target PETCO2 and PETO2 and the 




Figure 5.1 Schematic representation of the gas flow controller attached to a sequential gas delivery system. 
 
5.3.2.2 Retinal blood flow assessment 
5.3.2.2.1 Scanning Laser Doppler Flowmetry of Capillaries 
The principle and details of the SLDF have been detailed elsewhere 2, 13, 22. It is based on the 
principle of the Doppler effect. SLDF measurements were undertaken using the Heidelberg 
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Retina Flowmeter (HRF; Heidelberg Engineering GmbH, Dossenheim, Germany, software 
version 1.03W). The HRF-derived assessment of capillary flow and vascular reactivity 
represents an indirect measurement of vascular function since it measures the frequency of 
the intensity oscillation attributable to red blood cell movement in a volume of tissue. 
 
5.3.2.2.2 Laser Doppler Flowmetry of Arterioles 
The principle and technical details of the Canon Laser Blood Flowmeter (CLBF; Model 100, 
Canon, Tokyo, Japan) have been detailed elsewhere 14, 18, 23-28. It is based on the principle of 
bi-directional laser Doppler velocimetry and simultaneous vessel densitometry. The CLBF 
simultaneously measures blood velocity (mm/sec) and vessel diameter (µm) to calculate the 
rate of blood flow (µL/min).  
 
5.3.3 Procedures 
Subjects were asked to refrain from caffeine-containing food or drinks for 24 hours prior to 
the study. Subjects were rested for 15 minutes prior to the start of the breathing paradigm. 
The study was performed during a single visit using two sessions separated by at least 30 
minutes in order to measure retinal vascular reactivity with both the CLBF and the HRF: the 
order of use of the instruments was systematically varied between sessions.  Each session 
lasted approximately 40 minutes. 
 
All participants underwent Heidelberg Retina Tomograph (HRT) imaging before the start of 
the protocol to determine the difference in the focus between the temporal rim of the optic 
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nerve head (ONH) and the peripapillary retina. This data was then used to establish the 
optimal focus setting during the HRF imaging of the temporal rim, thereby optimizing the 
sampling of the anterior ONH capillaries 29. The HRF focus and sensitivity settings were 
maintained constant during all phases of the breathing paradigm. 
 
The mask of the breathing circuit was sealed to the face using adhesive tape (Tegaderm, 3M 
Health Care, St Paul, MN, USA). Initially air flow was set to exceed minute ventilation and 
thus prevent rebreathing.  Tidal gas concentrations were monitored continuously. When 
PETCO2 became stable (less than 2 mmHg change over 2 min), end-tidal and mixed exhaled 
O2 and CO2 partial pressures were calculated from gas sampled from the face mask and the 
exhaled gas reservoir, respectively.  CO2 production was calculated automatically by the 
computer-controlled gas blender as the product of air flow entering the breathing circuit and 
the mixed expired concentrations of CO2 
30 31. O2 consumption was calculated as the product 
of air flow and the difference in O2 concentration in air and mixed exhaled gas.  Three gas 
stages were implemented at each session.  In the first stage, gas flow into the breathing 
circuit was adjusted to provide a PETCO2 of 38 mmHg at resting PETO2 (baseline) and this 
stage was maintained for 10 min (or longer if stability of end-tidal gases or systemic 
parameters could not be attained). In the second stage, PETCO2 was raised by 15% while 
maintaining isoxia for 20 min.  In the third stage, PETCO2 was returned to baseline levels for 
a further 10 min while again maintaining isoxia. An example of the change in PETCO2 over 
time and the concomitant stable PETO2 in one subject is shown in (Figure 5.2). 
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Figure 5.2 Change in PETCO2 (upper) and simultaneous constant PETO2 (lower) in one individual using the gas 
flow controller.  
The arrows in the PETCO2 graph represent start and end of isoxic hypercapnia. 
 
Retinal blood flow measurements were acquired at each stage. At least 3 good quality HRF 
images each centered on the ONH and at least 3 images centered on the macula were 
acquired at each stage. HRF images of the ONH were acquired to subsequently calculate 
temporal neuroretinal rim capillary blood flow, while macular images were acquired to 
calculate capillary blood flow for the nasal, foveal and temporal areas. At the other session, 5 
CLBF measurements of a relatively straight segment, distant from bifurcations of the 
superior or inferior temporal arteriole were acquired at each stage. Blood pressure was 
monitored every 2.5 minutes while pulse rate and oxygen saturation was measured every 
minute during the breathing period using a rapid response critical care gas analyzer 




5.3.4.1 Gas parameters analysis 
The gas parameters were analysed using Lab view software (National Instruments, version 
7.1). Tidal concentrations of CO2 and O2 were measured continuously.  PETCO2 and PETO2 
were calculated breath-by-breath as the maximum PCO2 value and minimum PETO2 value, 
respectively, during exhalation.  PETCO2 and PETO2 values were averaged over the time of 
blood flow measurement at each stage. 
 
5.3.4.2 SLDF image analysis 
Capillary blood flow values of the temporal ONH neuroretinal rim, macula nasal, foveal and 
macula temporal areas were analysed using the Automated Full Field Perfusion Image 
Analysis (AFFPIA) software version 3.3 22. The analysis software comprised two concentric 
circles of variable radius, up to a maximum of 2.5°, that were placed in the measurement 
areas. Capillary blood flow was calculated within the areas defined by the measurement 
circles. Using this technique, capillary blood flow values of the various macular areas were 
calculated using the total area within a 2.5° diameter outer circle only. Blood flow values 
were calculated for the temporal rim of the ONH based upon the radius area defined by the 
outer and inner circles placed and adjusted in diameter to define the outer and inner edge of 
the temporal neural rim, respectively. AFFPIA avoids any possible influence of larger retinal 
blood vessels by excluding Doppler signals that are outside the valid measurement range of 
the HRF photodetector and erroneous blood flow data due to eye movements are also 
excluded 22, 32, 33. 
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5.3.4.3 CLBF velocity waveform analysis 
CLBF analysis software was used to analyze each acquired velocity waveform. A 
standardized protocol was employed to remove aberrant portions of each waveform due to 
eye movements or improper vessel tracking. The maximum number of acceptable waveforms 
in each measurement was included for analysis (minimum of one complete cycle required). 
 
5.3.4.4 Statistical Analysis 
A Repeated Measures Analysis of Variance (reANOVA) with Greenhouse-Geisser correction 
was used to determine the significance of any change of each of the dependent variables 
using SAS version 9.1. The dependent variables for retinal capillary hemodynamics were 
ONH blood flow, macula nasal, foveal and macula temporal blood flow, while the dependent 
variables for retinal arteriolar hemodynamics were diameter, blood velocity and flow. In 
addition, separate ANOVAs were performed to determine the significance of any change of 
PETCO2, PETO2, respiration rate, pulse rate, systolic and diastolic blood pressure and oxygen 
saturation. Statistical significance was Bonferroni adjusted to a level of p<0.01 due to 
multiple reANOVAs performed on the gas, systemic and retinal hemodynamic parameters. 
The PETCO2 and PETO2 measurements of each subject at baseline and hypercapnia in both 
sessions were compared using reANOVA with session and condition as within factors. A 
Bland and Altman 34, 35 approach was used to assess the repeatability of the PETCO2 and 
PETO2 measurements across the study sessions during baseline and hypercapnic provocation.  
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5.4 Results 
Retinal arteriolar and capillary vascular reactivity increased during isoxic hypercapnia. There 
was a 3.3% (SD 2.0, p<0.001), 16.9% (SD 9.0, p<0.001) and 24.9% (SD 7.0, p<0.001) 
increase in retinal arteriolar diameter, blood velocity and blood flow in response to isoxic 
hypercapnia (Figure 5.3). Retinal capillary blood flow showed a 34.8% (SD 31.0, p<0.001) 
increase at the rim of the ONH (Figure 5.4) and a 21.6% (SD 15.4, p<0.001) and 24.9% (SD 
18.4, p=0.006) increase at the macula nasal and foveal areas (Figure 5.5), respectively. There 
was a non-significant 8.2% (SD 7.9, p=0.028) trend for capillary blood flow to increase in 
the macula temporal area. The combined percent change in flow of retinal capillary vascular 
reactivity (i.e. all 4 analyzed areas = 22.4%) was similar to the magnitude of arteriolar (= 
24.9%) vascular reactivity.  
 
Figure 5.3 Box plot represents the group mean: A) retinal arteriolar diameter; B) blood velocity; and C) blood 
flow at baseline, isoxic hypercapnia and recovery. 
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Figure 5.4 Box plot represents the group mean capillary blood flow at the temporal rim of the ONH at baseline, 




Figure 5.5 Box plot represents the group mean capillary blood flow at the macula nasal, foveal and macula 
temporal areas at baseline, isoxic hypercapnia and recovery. 
 
Participants were comfortable and were able to sustain hypercapnia during the study. A 
14.1% (SD 2.4) (p<0.001) and 14.6% (SD 2.2) (p<0.001) increase in PETCO2 was achieved 
during the first and the second study sessions, respectively. There was a 4.2% (p<0.001) and 
4.4% (p<0.001) concomitant increase in PETO2 at the first and second sessions, respectively. 
The group mean magnitude of end-tidal CO2 and O2 concentrations at baseline, hypercapnia 
and recovery across the two study sessions are shown in (Tables 5.1 & 5.2). 
 Pulse rate (p=0.002) and systolic blood pressure (p=0.005) showed an increase during 
hypercapnia at session 1 but only pulse rate showed a significant increase at session 2 
 184 
(p=0.003). There was no other change observed in any of the measured systemic parameters 
(Tables 5.1 & 5.2). 
 
The coefficient of repeatability (COR) in PETCO2 measurements across the two sessions at 
baseline was 2mmHg and during isoxic hypercapnia was 2.4mmHg relative to a group mean 
PETCO2 of 39mmHg and 44.5mmHg, respectively  (Figure 5.6). The COR in PETO2 
measurements across the two study sessions at baseline was 10.5mmHg and during isoxic 
hypercapnia was 7.7mmHg relative to a group mean PETO2 of 106.4mmHg and 110.6mmHg, 
respectively (Figure 5.6). Repeated measures ANOVA of the magnitude of change in 
PETCO2 and PETO2 measurements during hypercapnia did not show a significant difference 





Baseline Hypercapnia Recovery Re ANOVA 
PETCO2 (mmHg) 39.1 ± 1.1 44.6 ± 1.4 38.6 ± 1.1 p<0.001 
PETO2 (mmHg) 106.5 ± 5.8 110.7 ± 3.7 107.5 ± 5.0 p<0.001 
Respiration rate 
(breaths/min) 19.5 ± 5.4 22.5 ± 4.2 22.3 ± 5.1 
NS 
Pulse rate (beats/min) 74.4 ± 12.1 79.3 ± 13.8 77.0 ± 14.1 p=0.002 
Blood pressure 





71.1 ± 4.8 73.7 ± 5.1 72.6 ± 5.9 NS 
O2 saturation (%) 99.2 ± 0.6 99.2 ± 0.5 99.3 ± 0.4 NS 
 
Table 5.1 Group mean (± SD) end-tidal partial pressure of CO2 & O2, respiration rate, pulse rate, systolic & 
diastolic blood pressure and oxygen saturation across different breathing conditions (i.e., baseline, isoxic 










Baseline Hypercapnia Recovery Re ANOVA 
PETCO2 (mmHg) 38.9 ± 1.1 44.5 ± 0.9 38.6 ± 1.0 p<0.001 
PETO2 (mmHg) 106.2 ± 3.4 110.8 ± 3.1 107.6 ± 3.6 p<0.001 
Respiration rate 
(breaths/min) 22.0 ± 6.3 22.5 ± 5.0 22.4 ± 5.3 
NS 
Pulse rate (beats/min) 76.6 ± 11.7 80.8 ± 13.8 79.1 ± 12.4 p=0.003 
Blood pressure 
(Systolic) mmHg 111.5 ± 9.3 113.8 ± 8.6 112.0 ± 8.2 
NS 
Blood pressure 
(Diastolic) mmHg 69.9 ± 6.6 72.3 ± 6.0 72.4 ± 6.2 
NS 
O2 saturation (%) 99.0 ± 0.6 99.2 ± 0.5 99.3 ± 0.4 NS 
 
Table 5.2 Group mean (± SD) end-tidal partial pressure of CO2 & O2, respiration rate, pulse rate, systolic & 
diastolic blood pressure and oxygen saturation across different breathing conditions (i.e., baseline, isoxic 




Figure 5.6 Bland and Altman plot of the difference (V1-V2) (mmHg) plotted against the mean {[V1 + V2]} / 2 
(mmHg) across the two study sessions.  
A) PETCO2 (mmHg) at baseline; B) PETCO2 (mmHg) during isoxic hypercapnia; C) PETO2 (mmHg) at baseline; 
and D) PETO2 (mmHg) during isoxic hypercapnia.  
The solid line represents mean of the difference in the PETCO2 and PETO2 parameters. The dotted lines represent 




In this study, we provided an automated, standardized and repeatable isoxic hypercapnic 
stimulus to provoke retinal capillary and arteriolar vascular reactivity. Vascular reactivity 
was calculated as the change between baseline and effect in retinal diameter, velocity and 
blood flow for arterioles and retinal and ONH blood flow for capillaries, for a given change 
in PETCO2. Retinal arterioles and capillaries showed a significant increase in hemodynamics 
in response to an approximately 14% increase in PETCO2. The overall magnitude of retinal 
capillary vascular reactivity (i.e. all 4 analyzed areas = 22.4%) was comparable to the 
arteriolar (= 24.9%) vascular reactivity in terms of percentage change of flow.  
 
The results of the present study define the magnitudes of vascular reactivity with only 
minimal change in PETO2. The magnitude of isoxic hypercapnia induced using the computer 
controlled gas blender was repeatable.  Previous work in our laboratory showed a 13% 
increase in PETO2 using the manual addition of CO2 to inspired air 
13 and a 6% decrease in 
PETO2 concentration using a manually controlled partial re-breathing technique 
14. In the few 
studies that have given consideration to concomitant changes in PaO2 during hypercapnia, 
there has been a large concomitant change in PETO2 reported. Gugleta and co-workers 
36 
showed an approximately 23% increase in PaO2 as a result of 19% increase in PaCO2 using 
the addition of 5% CO2 to inspired air. To our knowledge, the current study is the first to 
have concomitantly assessed retinal arteriolar and capillary vascular reactivity using a highly 
repeatable hypercapnic provocation that reduces the disturbance of PETO2 to a minimum (i.e. 
+4%). Although statistically significant, the +4% change in PETO2 in this study is 
physiologically irrelevant. To explain, Gilmore and co-workers (2005) increased PETO2 from 
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15.1% to 86.2% whilst maintaining isocapnia; this provoked a reduction in retinal arteriolar 
blood flow of -4.3µL/min. Therefore, a +4% change in PETO2 would be anticipated to reduce 
retinal blood flow by approximately 0.24µL/min (assuming linear response characteristics) 
18.  
 
The improved control of PETO2 during hypercapnic provocation can be attributed to the 
combination of the sequential re-breathing circuit and the computer controlled gas blender. 
The use of the computer controlled gas blender permitted the normalization of all subjects’ 
baseline PETCO2 measurements to approximately 38mmHg, thereby facilitating a 
standardised increase in PETCO2 during hypercapnia. Another advantage of using the 
computer controlled gas blender is the ability to achieve target end-tidal gas values within a 
short period of time, thereby minimizing subject discomfort, and this resulted in a sustained 
“square wave” increase in PETCO2 levels. The isoxic hypercapnic provocation achieved 
using the computer controlled gas blender was repeatable. The COR was 5% of the average 
PETCO2 both at baseline and during isoxic hypercapnia. Similarly, the COR was 10% and 
7% of the average PETO2 at baseline and during isoxic hypercapnia, respectively. 
 
Breathing CO2 has been shown to increase blood pressure in healthy subjects 
37. In the 
present study, we observed an increase in systolic blood pressure during the first session and 
an increase in pulse rate at both sessions. The magnitude of increase in blood pressure during 
hypercapnia, however, was small and well within the range of autoregulation of the retinal 
vessels and would not be expected to have an influence on vascular reactivity 38, 39. Similar 
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changes in the magnitude of blood pressure and pulse rate have been observed in other 
studies during hypercapnia in healthy subjects and patients with vasospasm 3, 5, 36, 40, 41. 
 
Evidence from the cerebral vasculature suggests that smaller diameter vessels produce a 
relatively larger magnitude of vascular reactivity in response to gas provocations 42, 43. A few 
studies have found the same relationship between retinal vascular reactivity and vessel 
diameter in the retinal microvasculature 44-46. In addressing the primary aim of the present 
study, however, the magnitude of retinal capillary vascular reactivity in terms of change in 
blood flow was generally comparable to that of the retinal arterioles in percentage change. 
The results of our study might not be directly comparable to previous work due to the 
differences in both the provocation and methods of quantifying the hemodynamic responses. 
In addition, some studies have also failed to monitor and / or report concomitant changes in 
PETO2. Jeppesen and co-workers 
46 investigated the diameter response of retinal vessels to 
change in systemic blood pressure and showed that smaller diameter retinal arterioles have a 
larger magnitude of vascular reactivity.  
 
The magnitude of retinal vascular reactivity achieved in this study is in broad agreement with 
previous work. Harino and co-workers 16 used a subjective-based blue field entoptic 
methodology and a total re-breathing technique to induce hypercapnia and showed a 53% 
increase in leucocyte velocity. Dorner and co-workers 5 achieved a 21% increase in PETCO2 
and, as a result, retinal arteriolar diameter and venular diameter increased by 4.2% and 3.2%, 
respectively. Recent work in our laboratory showed a 3.2%, 26% and 35% increase in 
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arteriolar diameter, blood velocity and flow in response to hypercapnia, produced using a 
manually controlled partial re-breathing technique 14.  
 
Few studies have investigated retinal capillary vascular reactivity in response to hypercapnia 
using the SLDF technique. Chung and co-workers (1999) 8 observed an increase in supero-
temporal capillary blood flow with a 15% increase in PETCO2. Roff and co-workers 
2 showed 
a 39% increase in capillary blood flow in the supero-temporal retina. Previous research from 
our own laboratory showed a 10.2% increase in ONH, 18.9%, 15.8% and 16.9% in the 
macula nasal, foveal and macula temporal areas, respectively, using a partial re-breathing 
technique to induce hypercapnia 13. In the current study, we observed a similar magnitude of 
capillary vascular reactivity in the macula nasal and foveal areas and a relatively larger 
magnitude of change in the ONH. 
  
The SLDF is used typically to assess capillary blood flow in the anterior ONH but also in 
other retinal areas. The blood supply to the pre-laminar portion of the ONH is derived from 
the branches of short posterior ciliary arteries (SPCAs) 47, 48. The superficial nerve fiber layer 
of the ONH transitions from principally the SPCA supply next to the pre-laminar region to 
predominantly the central retinal artery supply at the level of the internal limiting membrane.  
The measured ONH vascular reactivity reported in this study primarily reflects the response 
of the SPCAs and the downstream branch arterioles. There is evidence that blood flow 
measured in the macular and foveal areas using the HRF might have a contribution from the 
underlying choroid 49. We were careful, however, to focus the HRF at the level of the retinal 
nerve fibre layer or superficial temporal rim of the ONH. Nevertheless, choroidal 
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contribution to the measured signal could possibly be the reason for the regional variations in 
the magnitude of capillary vascular reactivity. Previous studies have shown that the choroidal 
vessels fail to show any metabolic regulation. More recently, Lovasik and co-workers (2003) 
50 have demonstrated that choroidal vessels do indeed respond to changes in ocular perfusion 
pressure but to a lesser degree than the inner retinal vessels. As a result, the HRF-derived 
measurements of capillary vascular reactivity may represent the combined responses of the 
inner and outer retinal vessels. 
 
Recently, studies have shown that the HRF results might be influenced by extraneous factors 
including measurement position and sampling depth in the retina 49, 51, 52. The results of our 
study cannot be compared to any of these papers because the retinal area imaged was 
carefully chosen to avoid large diameter blood vessels. In addition, AFFPIA was used to 
obtain retinal and ONH perfusion values which effectively eliminated flow signals from large 
blood vessels (retinal vessel diameter >30 µm) and also removed data from image pixels 
influenced by eye movements. Optimal focus setting was established from tomographic 
depth measurements, thereby optimizing the sampling of the anterior ONH capillaries 29. 
  
In this study, the use of the computer controlled gas blender provided a standardised means 
of provoking isoxic hypercapnia in young, healthy subjects. This standardised stimulus could 
be used in a clinical setting to investigate diseases that are thought to result in vascular 
dysregulation such as glaucoma, diabetic retinopathy and age-related macular degeneration 




In this study, a computer controlled gas blender was utilized to induce isoxic hypercapnia 
and the magnitude of retinal capillary and arteriolar vascular reactivity was quantified. 
Retinal arterioles and capillaries showed an increase in hemodynamic parameters to 
approximately a 14% increase in PETCO2. The magnitude of retinal capillary vascular 
reactivity was comparable to the arteriolar vascular reactivity in terms of percentage change 
of flow, consistent with expectation based upon the fact that the retinal circulation is a closed 
system. The magnitude of isoxic hypercapnia induced using the gas flow controller was 
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6 Retinal Arteriolar Vascular Reactivity in Untreated and 
Progressive Primary Open Angle Glaucoma 
 
Venkataraman ST, Hudson C, Rachmiel R, Buys YM, Markowitz SN, Fisher JA, Trope GE, 
Flanagan JG. Retinal arteriolar vascular reactivity in untreated and progressive primary open 
angle glaucoma. Invest Ophthalmol. Vis. Sci. (Under review). 
 
6.1 Abstract  
Aim: The primary aim was to determine the magnitude of retinal arteriolar vascular 
reactivity to normoxic hypercapnia in patients with untreated primary open angle glaucoma 
(uPOAG), progressive POAG (pPOAG) and controls.  
Methods: The sample comprised 11 patients with uPOAG, 17 patients with pPOAG and 17 
age-similar controls. pPOAG patients manifested optic disc hemorrhage within the previous 
24 months. During the baseline 10 min phase, PETCO2 was maintained at approximately 
38mmHg. Normoxic hypercapnia (15% increase in PETCO2 relative to baseline and PETO2 
maintained as baseline ~105mmHg) was then induced for 15 mins using an automated gas 
flow controller (RespirActTM, Thornhill Research Inc. Toronto, Canada). A third 10 min 
recovery phase was then implemented. Retinal arteriolar hemodynamics were assessed using 
the Canon Laser Blood Flowmeter.   
Results: There was no difference in baseline arteriolar hemodynamics across groups. In 
healthy controls, diameter increased by +2.3% (Re-ANOVA p<0.001) and velocity and flow 
increased by +17.9% (p<0.001) and +22.4% (p<0.001), respectively, in response to normoxic 
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hypercapnia. There was no change in the hemodynamic parameters to normoxic hypercapnia 
in uPOAG. Retinal arteriolar diameter and blood velocity did not change in pPOAG but 
blood flow increased by +9.1% (p=0.030). The vascular reactivity to hypercapnia was 
different in terms of blood velocity (ANOVA p=0.004) and blood flow (p=0.013) across 
groups; the vascular reactivity was decreased in uPOAG and in pPOAG compared to controls 
(Fishers LSD post hoc test).  
Conclusions: The arteriolar vascular reactivity to normoxic hypercapnia was reduced in 
uPOAG and in pPOAG compared to healthy subjects.  
Keywords: Retinal arterioles, vascular reactivity, optic nerve head, normoxic hypercapnia, 
primary open angle glaucoma. 
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6.2 Introduction 
Glaucomatous optic neuropathy (GON) is characterized by the apoptotic loss of retinal 
ganglion cells and their axons 1. The factors responsible for the pathogenesis of primary open 
angle glaucoma (POAG) are not completely understood. Elevated intra-ocular pressure (IOP) 
has been identified as the primary risk factor in the development and progression of POAG. 
However, a subset of patients with POAG maintain a “normal” IOP, termed normal tension 
glaucoma (NTG), while many patients with ocular hypertension (OHT) fail to develop GON. 
In addition, some POAG patients manifest progression of GON, while other POAG patients 
remain stable over many years. 
 
Abnormal vascular regulation has been suggested to be involved in the development of 
POAG 1-6.  Previous studies have shown that optic nerve head (ONH) and retinal blood flow 
is decreased in patients with POAG and NTG measured using fundus fluorescein 
angiography 7, color Doppler imaging (CDI) 7-9 and the Canon Laser Blood Flowmeter 
(CLBF) 10. Histopathological evidence suggests that there is a decrease in the number of 
capillaries in the ONH in POAG 11. Atrophy of the peripapillary capillaries supplying the 
retinal nerve fibre layer (RNFL) has also been reported in POAG 12, 13. Using CDI, Liu and 
co-workers 14 have shown reduced peak systolic and end-diastolic velocities in the central 
retinal artery (CRA) and nasal posterior ciliary artery (PCA) and increased resistive index in 
the CRA in patients with advanced glaucoma compared to healthy controls and early 
glaucoma. In addition, there is also a reduction in the cerebrovascular blood velocities noted 
in POAG 15. However, the effect of IOP lowering medications on ocular blood flow remains 
poorly understood. In particular, treatment with carbonic anhydrase inhibitors has been 
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reported to increase aspects of ocular hemodynamics in POAG 16-21, while others have found 
no change 22, 23. However, previous studies have not assessed the effect of treatment on 
vascular reactivity in POAG patients. 
 
Increase in the arterial partial pressure of CO2 (PaCO2) above normal resting values 
(hypercapnia) results in vasodilation of retinal vessels in healthy volunteers 24-29. The retinal 
vascular reactivity response to inhaled CO2 in patients with POAG is not well established. 
Some studies have shown reduced vascular reactivity using CDI 9, 30, while another study has 
shown a normal magnitude of vasodilation of the short posterior ciliary arteries (SPCA) 31. 
An absence of vascular reactivity of the middle cerebral artery (MCA) to hyperoxia 
(increased amounts of inspired oxygen) in patients with POAG has also been reported 15 but 
recent work has shown an absence of MCA response to hyperoxia in healthy controls 32.  
 
Hypercapnia also results in hyperventilation leading to an unpredictable change in the arterial 
partial pressure of O2 (PaO2) 
33. Fisher and co-workers have developed hypercapnic 
provocations that simultaneously stabilize PaO2 
34 and this normoxic hypercapnic stimulus 
has been applied in our laboratory to assess retinal and ONH vascular reactivity in healthy 
volunteers 27, 29. In this study, we induced normoxic hypercapnia, such that the partial 
pressure of end-tidal O2 in exhaled breath (PETO2) was maintained at physiological resting 
levels throughout the provocation. The primary aim of this study was to assess the magnitude 
of retinal arteriolar vascular reactivity to normoxic hypercapnia in patients with untreated 
POAG (uPOAG) and progressive POAG (pPOAG) and healthy controls. The secondary aim 
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of the study was to quantify vascular reactivity in newly treated POAG (ntPOAG) patients 




The study was approved by the Research Ethics Boards of the University Health Network, 
University of Toronto, and the Office of Research Ethics of the University of Waterloo. All 
subjects provided signed informed consent prior to participation after explanation of the 
nature and possible consequences of the study according to the tenets of the Declaration of 
Helsinki. The sample comprised 11 patients with newly diagnosed previously untreated 
POAG (uPOAG), 17 patients with pPOAG and 17 healthy age-similar control subjects. 
Patients with pPOAG were identified as having an optic disc hemorrhage within the previous 
24 months. The uPOAG group were treated with one drop of 2% Dorzolamide twice daily for 
2 weeks to form the newly treated POAG (ntPOAG) group (n=11). 
 
All participants had a visual acuity of 20/40, or better, and a refractive error less than 
±6.00DS and ± 1.50DC. They were free of other ocular disease and were non-smokers. 
Participants with cardiovascular disorders, uncontrolled systemic hypertension and diabetes 
were excluded from the study. Healthy control subjects had no family history of glaucoma or 
diabetes. All participants were asked to abstain from caffeine containing food or drinks and 
were asked to adhere to a low nitrate diet for at least 12 hours before the study visit(s). An 
impact of caffeine on cerebral blood flow is well established 35, while a recent study also 
showed the influence of caffeine on retrobulbar blood velocity 36. Consumption of saturated 
fats are also known to influence vascular reactivity 37. 
 207 
6.3.2 Gas delivery system 
A sequential gas delivery (SGD) breathing circuit (Hi-Ox80, Viasys Healthcare, Yorba Linda 
CA) was modified by placing a rebreathing bag on the exhalation port of a commercial 3-
valve oxygen delivery system. This breathing circuit has been described in detail elsewhere 
27-29, 38, 39.  
 
6.3.3 Retinal blood flow assessment 
The principle and technical details of the Canon Laser Blood Flowmeter (CLBF; Model 100, 
Canon, Tokyo, Japan) have been detailed elsewhere and in Chapter-1 of this Thesis 27, 38, 40-45.  
  
6.3.4 Procedures 
All participants attended for 2 visits. Patients with uPOAG returned for an additional third 
visit and were then designated into the ntPOAG group. Both eyes were dilated using 
Mydriacyl 1% (Alcon Canada Inc., Mississauga, Canada) at visit 1 and only the study eye 
was dilated during subsequent visits. Visit 1 consisted of an assessment of visual acuity, 
central visual field assessment (24-2 SITA-standard, Humphrey Visual Field Analyser 740, 
Carl Zeiss Meditec, Dublin, CA), scanning laser tomography (Heidelberg Retina Tomograph 
2, v3, Heidelberg Engineering, Heidelberg, Germany) and stereo fundus photography 
(TOPCON, Model TRC-50VT, Japan) of the ONH and measurement of the IOP. Based on 
the results of the above tests and clinical assessment, the diagnosis was confirmed by a 
glaucoma specialist (YB or GT). One eye was randomly chosen as the study eye assuming 
both eyes met the study criteria. 
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During the second visit, IOP and blood pressure (BP) were assessed. The pupil of the chosen 
eye was dilated using Mydriacyl 1% (Alcon Canada Inc., Mississauga, Canada). Participants 
rested for an initial 15 minutes before the start of the breathing paradigm. They were then 
fitted with a face mask connected to the automated gas flow controller. During the first 10 
minutes, participants breathed air and baseline PETCO2 was standardised to approximately 
38mmHg. Following this, normoxic hypercapnia (consisting of a 15% increase in PETCO2 
from baseline and PETO2 maintained at resting levels) was induced and sustained for the next 
15 minutes. Participants were then allowed to breathe air for 10 minutes and re-establish their 
baseline end-tidal values (post-hypercapnia). At least, 3 CLBF measurements of either the 
superior or inferior temporal arteriole were obtained in each of the breathing phases. 
PETCO2, PETO2 and respiration rate were monitored by the automated gas flow controller 
(RespirActTM, Thornhill Research Inc., Toronto Canada). PETCO2 and PETO2 are accurate 
measurements of PaCO2 and PaO2, respectively, when breathing via a sequential gas delivery 
circuit 46. Pulse rate, oxygen saturation, heart rate and BP (every 2.5 minutes), were 
monitored using the rapid response critical care gas analyzer (Cardiocap 5, Datex-Ohmeda, 
Helsinki, Finland). 
 
Patients with uPOAG were then prescribed 2% Dorzolamide (Trusopt) (Merck Frosst, 
Canada Ltd), one drop every 12 hours in the study eye for two weeks. After 2 weeks, the 




6.3.5.1 Retinal Blood Flow Analysis 
CLBF analysis software was used to analyze the velocity waveforms. A minimum of one 
complete waveform was required to be included in the analysis. A standardised protocol was 
used in order to eliminate aberrant waveforms 40. Mean Ocular Perfusion Pressure (MOPP) 
was calculated using the formula:  
MOPP = 2/3 [diastolic + 1/3(systolic – diastolic)] – IOP 
 
6.3.5.2 Gas Parameters Analysis 
The gas parameters were analyzed using customized software (Labview, National 
Instruments, version 7.1). PETCO2 and PETO2 were calculated breath-by-breath as the 
maximum PETCO2 value and minimum PETO2 value, respectively, during exhalation. 
 
6.3.5.3 Statistical Analysis 
A repeated measures analysis of variance (reANOVA) with Greenhouse-Geiser correction 
was used to determine any significant change in retinal arteriolar diameter, blood velocity 
and blood flow across the breathing paradigm within each group. A one-way ANOVA was 
used to determine the significance of any difference in the baseline arteriolar hemodynamics, 
IOP, MOPP, age and the magnitude of change in vascular reactivity of arteriolar diameter, 
blood velocity and blood flow during normoxic hypercapnia across groups. Fishers least 
significant difference (LSD) post hoc test (SAS) was used for comparison between the 
groups. The Fisher’s LSD post hoc test identifies groups that are significantly different from 
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other groups at a significance level of p<0.05. It does not provide one specific p-value per se 
for each group that is significantly different. A separate reANOVA was performed to 
determine any significant change in pulse rate, systolic and diastolic BP, oxygen saturation, 





There was no difference in the baseline retinal arteriolar diameter, blood velocity and blood 
flow across groups.  
 
Figures 6.1A, 6.1B and 6.1C show the vascular reactivity to normoxic hypercapnia in terms 
of percentage change in diameter, velocity and flow, respectively. In healthy controls, 
diameter increased by +2.3% (ReANOVA p<0.001, Figure 6.1A), blood velocity increased 
by +17.9% (p<0.001, Figure 6.1B) and blood flow increased by +22.4% (p<0.001, Figure 
6.1C). There was no change in any of the hemodynamic parameters to normoxic hypercapnia 
in the uPOAG group (Figure 6.1). Diameter and blood velocity did not change in the pPOAG 
group (Figure 6.1) but blood flow manifested an increase of +9.1% (p=0.030, Figure 6.1C).  
 
The change in vascular reactivity in response to normoxic hypercapnia was different in terms 
of velocity (one-way ANOVA p=0.004) and blood flow (p=0.013) across groups. Velocity 
and flow were decreased in uPOAG and pPOAG compared to controls and ntPOAG (Fishers 
LSD post hoc test).  
 
Following Dorzolamide treatment, diameter increased by +3% (p=0.040, Figure 6.1A), 
velocity increased by +19% (p<0.001, Figure 6.1B) and flow increased by +26% (p<0.001, 




Figure 6.1 The percentage change from baseline in group mean A) retinal arteriolar diameter; B) blood velocity; 
and C) blood flow in response to normoxic hypercapnia in patients with uPOAG, ntPOAG, pPOAG and 
controls.  
Error bar represents standard deviation (%) (uPOAG, untreated POAG; ntPOAG, newly treated POAG; 
pPOAG, progressive POAG). Note: * represents significance when compared across the three breathing 
conditions (baseline, normoxic hypercapnia and post-hypercapnia) within the group at the level of p<0.05.
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The mean age, IOP and MOPP as a function of group is detailed in Table 6.1. The group 
average visual field mean deviation (MD) was -1.4 (SD 1.6) in uPOAG/ntPOAG, -2.1 (SD 
2.0) in pPOAG and -0.3 (SD 1.0) in controls. The group mean pattern standard deviation 
(PSD) in uPOAG /ntPOAG, pPOAG and controls was 2.6 (SD 2.7), 5.0 (SD 3.0) and 2.0 (SD 
0.4), respectively. 
 
Parameter uPOAG ntPOAG pPOAG Controls p-value 
Age (yrs) 54.0 ± 11.4 54.0 ± 11.4 65.0 ± 7.7* 55.0  ± 6.7 0.0022 
IOP (mmHg) 22.5  ± 2.2** 18.0  ± 2.0**† 12.1  ± 2.0 13.0  ± 2.1 <0.001 
MOPP (mmHg) 39.0 ± 8.2** 37.6 ± 4.5** 46.7 ± 7.8 44.9 ± 4.5 0.0010 
 
Table 6.1 The group mean ± SD of the age, IOP and MOPP in all the groups. 
(IOP, intra-ocular pressure; MOPP, mean ocular perfusion pressure; uPOAG, untreated POAG; ntPOAG, newly 
treated POAG; pPOAG, progressive POAG).  
p-value denotes significance across all groups using one-way ANOVA.  * denotes the group that is significantly 
different when compared to other groups. ** denotes the group that is significantly different when compared to 
pPOAG and controls. † denotes the group that is significantly different when compared to uPOAG. 
 
Tables 6.2, 6.3, 6.4 & 6.5 detail the systemic parameters measured during the breathing 
paradigm in all the groups. The mean percentage increase in PETCO2 during hypercapnia in 
all groups (i.e. uPOAG, pPOAG and controls) was 15.4% (SD 2.5, p<0.001) (Tables 6.2 to 
6.5). In ntPOAG, PETCO2 increased by 15.9% (SD 4.6, p<0.001). During normoxic 






Gas and Systemic 
parameters 
Baseline Hypercapnia Post-hypercapnia p-value 
PETCO2 (mmHg) 38.9 ± 0.7 44.9 ± 1.1 39.2 ± 0.9 <0.001 
PETO2 (mmHg) 105.4 ± 2.6 108.6 ± 2.7 107.4 ± 2.2 <0.001 
Respiration rate 
(breaths/min) 
17.2 ± 5.4 19.0 ± 3.6 19.0 ± 4.7 NS 
Pulse rate (beats/min) 71.9 ± 10.4 73.6 ± 11.3 72.7 ± 10.5 NS 
Systolic BP (mmHg) 133 ± 17.4 136.9 ± 17.7 134.0 ± 18.6 <0.001 
Diastolic BP (mmHg) 81.8 ± 8.7 83.8 ± 8.4 82.8 ± 9.3 NS 
O2 saturation (%) 97.8 ± 1.1 98.1 ± 1.0 98.0 ± 1.0 NS 
 
Table 6.2 The group mean ± SD of PETCO2, PETO2, respiration rate, pulse rate, systolic and diastolic BP and 
O2 saturation in uPOAG.  
(PETCO2, partial pressure of end-tidal carbon dioxide; PETO2, partial pressure of end-tidal oxygen, BP, blood 
pressure; O2 saturation, oxygen saturation). Note: The p-value denotes significance of each parameter across the 













Gas and Systemic 
parameters 
Baseline Hypercapnia Post-hypercapnia p-value 
PETCO2 (mmHg) 39.1  ± 1.4 45.2  ± 1.0 38.7  ± 1.4 <0.001 
PETO2 (mmHg) 103.9  ± 5.0 106.5  ± 4.6 106.5  ± 5.2 0.020 
Respiration rate 
(breaths/min) 
18.6  ± 5.9 19.4  ± 4.7 20.2  ± 7.1 NS 
Pulse rate (beats/min) 70.8  ± 8.7 72.5  ± 8.7 72.0  ± 9.1 NS 
Systolic BP (mmHg) 124.0 ± 12.3 131.1  ± 11.7 129.0  ± 13.2 0.009 
Diastolic BP (mmHg) 78.6  ± 10.8 78.9  ± 10.7 78.5  ± 10.9 NS 
O2 saturation (%) 98.1  ± 0.8 98.3  ± 0.5 98.6  ± 0.7 0.003 
 
Table 6.3 The group mean ± SD of PETCO2, PETO2, respiration rate, pulse rate, systolic and diastolic BP and 
O2 saturation in ntPOAG.  
(PETCO2, partial pressure of end-tidal carbon dioxide; PETO2, partial pressure of end-tidal oxygen, BP, blood 
pressure; O2 saturation, oxygen saturation). Note: The p-value denotes significance of each parameter across the 




Gas and  
Systemic parameters 
Baseline Hypercapnia Post-hypercapnia p-value 
PETCO2 (mmHg) 38.9 ± 1.2 45.0 ± 1.5 38.6 ± 1.0 <0.001 
PETO2 (mmHg) 104.8 ± 2.9 108.0 ± 2.9 106.8 ± 2.7 <0.001 
Respiration rate  
(breaths/min) 
19.9 ± 4.25 20.2 ± 4.8 20.3 ± 4.7 NS 
Pulse rate (beats/min) 66.0 ± 8.7 67.2 ± 8.1 67.8 ± 7.2 NS 
Systolic BP (mmHg) 128.9 ± 13.9 139.4 ± 12.5 134.6 ±14.9 <0.001 
Diastolic BP (mmHg) 80.9 ± 6.0 85.2 ± 6.8 83.1 ± 9.1 0.004 
O2 saturation (%) 98.5 ± 0.9 98.6 ± 0.8 98.8 ± 0.8 0.020 
 
Table 6.4 The group mean ± SD of PETCO2, PETO2, respiration rate, pulse rate, systolic and diastolic BP and 
O2 saturation in pPOAG.  
(PETCO2, partial pressure of end-tidal carbon dioxide; PETO2, partial pressure of end-tidal oxygen, BP, blood 
pressure; O2 saturation, oxygen saturation). Note: The p-value denotes significance of each parameter across the 
three breathing conditions using reANOVA. NS denotes not significant. 
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Gas and Systemic 
parameters 
Baseline Hypercapnia Post-hypercapnia p-value 
PETCO2 (mmHg) 39.0 ± 1.6 45.0 ± 1.4 38.9 ± 1.6 <0.001 
PETO2 (mmHg) 106.1 ± 4.8 109.1 ± 4.3 107.9 ± 4.7 <0.001 
Respiration rate 
(breaths/min) 
21.0 ± 4.8 21.2 ± 3.8 21.8 ± 3.9 NS 
Pulse rate (beats/min) 65.5 ± 7.9 67.5 ± 8.7 67.0 ± 8.9 0.020 
Systolic BP (mmHg) 118.5 ± 13.5 125.2 ± 15.7 124.2 ± 12.2 <0.001 
Diastolic BP (mmHg) 77.6 ± 7.7 80.7 ± 9.1 79.0 ± 6.6 0.007 
O2 saturation (%) 98.1 ± 1.0 98.5 ± 0.8 98.5 ± 0.9 0.005 
 
Table 6.5 The group mean ± SD of PETCO2, PETO2, respiration rate, pulse rate, systolic and diastolic BP and 
O2 saturation in controls.  
(PETCO2, partial pressure of end-tidal carbon dioxide; PETO2, partial pressure of end-tidal oxygen, BP, blood 
pressure; O2 saturation, oxygen saturation). Note: The p-value denotes significance of each parameter across the 
three breathing conditions using reANOVA. NS denotes not significant. 
 




The primary finding of this study was that retinal vascular reactivity was reduced in uPOAG 
and pPOAG compared to controls. A hypercapnic protocol that simultaneously maintained 
normoxia was undertaken to avoid additional vasoconstriction in what is a potentially 
vasospastic disease. The use of a sustained and stable normoxic hypercapnic stimulus was 
essential for the assessment of retinal arteriolar vascular reactivity so that repeated 
hemodynamic measurements could be obtained.   
 
Various studies have shown a decrease in homeostatic blood flow in POAG/NTG using the 
CLBF 10 color Doppler imaging 9, 47-49 and pulsatile ocular blood flowmeter (POBF) 50. In 
this study, however, there was no difference between baseline diameter, blood velocity and 
blood flow in uPOAG compared to the other groups. The techniques used in previous studies 
have limitations. CDI requires an experienced operator to obtain reliable measurements, is 
unable to quantify volumetric blood flow and it can be difficult to differentiate responses 
between the CRA and SPCA 51. Similarly, the results of the POBF can be influenced by 
ocular rigidity and the measurement is dominated by the choroidal circulation 52. The use of 
the CLBF in this study offered an alternative approach since it objectively quantifies 
volumetric retinal blood flow in real units. The results of this study are not directly 
comparable to earlier work in that the vascular reactivity was assessed in the retinal arterioles 
of untreated POAG patients, while in most other studies patients were already receiving IOP 
lowering medications. O’Brien and co-workers (1999) assessed blood flow using the POBF 
in a group of 28 NTG patients of which there were 12 previously treated patients (stopped 
treatment 1month prior to the study) and only 16 patients with newly diagnosed NTG. 
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However, the blood flow results of the two groups were not separated in the analysis of the 
study 50.   
  
Most previous studies have only assessed homeostatic blood flow in POAG or NTG patients, 
often using CDI 7-9, 14. The few studies that have assessed retinal and ONH vascular reactivity 
in POAG have found contradictory results. Gugleta and co-workers (2005) showed an 
increase in ONH blood flow in patients with vasospasm and a decrease in ONH blood flow in 
patients without vasospasm assessed using laser Doppler flowmetry in response to 
hypercapnia 53. In this study, a decrease in the magnitude of vascular reactivity to normoxic 
hypercapnia was noted in both uPOAG and pPOAG but all the groups, apart from uPOAG, 
showed evidence of increased retinal blood flow in response to normoxic hypercapnia. 
Similarly, a reduction in the vascular reactivity of the CRA using CDI has also been shown 
in patients with open angle glaucoma 30. Hosking and co-workers (2004) showed 
vasodilation of the retrobulbar vessels assessed using the CDI during hypercapnia in POAG 
31. Interestingly, Harris and co-workers (1994) have reported that patients with NTG showed 
an increase in the peak systolic velocity of the CRA and posterior ciliary artery (PCA) and 
also end-diastolic velocity of the OA during hypercapnia. There was no change in the 
velocities of the CRA and OA in controls in response to hypercapnia 9. Using the CLBF, 
Feke and co-workers (2007) also showed evidence of abnormal retinal arteriolar response in 
POAG to posture change compared to controls 54. This altered response was only seen in a 




As glaucoma is primarily characterized by either compromise of the ONH perfusion and / or 
mechanical compression of the lamina cribrosa, we also assessed the response of the 
capillaries at the temporal rim of the ONH to normoxic hypercapnia. Several studies have 
demonstrated a decrease in blood flow in the ONH in POAG using different assessment 
techniques 55-58. In this study, ONH capillary vascular reactivity was assessed in a sub-set of 
patients with POAG using the Heidelberg Retina Flowmeter (Heidelberg Engineering 
GmbH, Dossenheim, Germany, software version 1.03W). The vascular reactivity of the 
capillaries at the temporal rim of the ONH showed a +6%, +11% and +20% increase in blood 
flow to normoxic hypercapnic provocation in uPOAG (n=5), pPOAG (n=12) and controls 
(n=12), respectively (Figure 6.2). In ntPOAG (n=5), the magnitude of ONH vascular 
reactivity was +18%. We have previously shown that the percentage change of capillary 
vascular reactivity is comparable to arteriolar vascular reactivity in young healthy volunteers 
29. An interesting finding of the ONH sub-study was that the vascular reactivity of the ONH 
capillary bed was reduced in percentage terms in uPOAG and pPOAG, to a similar extent as 
that of the superior/inferior temporal arteriole. The vascular reactivity of the control group 
was similar between the arteriolar and ONH sites and the recovery of vascular reactivity 
following Dorzolamide treatment was also similar between ONH capillaries and retinal 
arterioles for the ntPOAG group. 
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Figure 6.2 The percentage change from baseline in group mean temporal rim ONH blood flow in response to 
normoxic hypercapnia in patients with uPOAG and ntPOAG, pPOAG and controls.  
Error bar represents standard deviation (%) (ONH, optic nerve head; uPOAG, untreated POAG; ntPOAG, 
newly treated POAG; pPOAG, progressive POAG). The sample comprised of 5 patients with uPOAG of mean 
age 54yrs (SD 8.6), 12 patients with pPOAG of mean age 65yrs (SD 7.5) and 12 healthy controls of mean age 
of 55yrs (SD 7.4). Normoxic hypercapnia was induced identical to the protocol described for retinal arteriolar 
vascular reactivity assessment. 
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A secondary finding of this study was that vascular reactivity improved to the level of the 
controls in the ntPOAG group, following 2 weeks of treatment with 2% Dorzolamide. 
Recently, a number of studies have focused on the assessment of the retinal blood flow after 
treatment with IOP lowering medications. It has been thought that carbonic anhydrase 
inhibitors, in particular, Dorzolamide might improve blood flow. However, many of these 
studies used an additional IOP lowering medication simultaneously with Dorzolamide 19-21 or 
used untypical methods of drug delivery 16. In this study, vascular reactivity was assessed in 
patients who had never undergone treatment with IOP lowering medications. The inclusion 
of previously untreated patients was essential to avoid any residual vascular effects of 
medication on the response of the vasculature. In addition, we also assessed vascular 
reactivity in patients with progressive disease (i.e. currently receiving treatment, have 
achieved target IOP reduction and have a history of optic disc hemorrhage) as there is 
evidence that this group of patients exhibit vascular dysregulation 59, 60. This study supports 
the previous findings since patients with pPOAG exhibited a reduced vascular reactivity 
reserve. 
 
Previous studies have assessed the effect of treatment on homeostatic retinal blood flow, 
rather than on vascular reactivity per se, in POAG. Retinal vascular reactivity in response to 
hypercapnia has been previously assessed using scanning laser ophthalmoscopy, fluorescein 
angiography and the blue field entoptic technique in healthy subjects after treatment with 
Dorzolamide and no change was found in vascular reactivity 61. This study is the first to 
investigate the effect of Dorzolamide on retinal vascular reactivity in patients with POAG. 
Vascular reactivity improved after short term treatment of POAG with Dorzolamide. 
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However, there was no difference across the groups in the baseline arteriolar hemodynamics 
after treatment. The controversy in terms of baseline hemodynamic findings of our study and 
previous reports is probably due to differences in experimental design and blood flow 
quantification techniques, including the concomitant use of other medications, and also due 
to variation in the duration of Dorzolamide administration. In the absence of a non-
pharmacological control group that exhibited a similar reduction in IOP, such as laser 
trabeculoplasty, it is not evident whether the improvement in vascular reactivity following 
treatment is due to the reduction in IOP or a direct effect of Dorzolamide on the vasculature. 
Nevertheless, in this study, there was no difference in the MOPP between uPOAG and 
ntPOAG, indicating that the improvement in retinal vascular reactivity seen in the uPOAG 
might be due, in part, to a direct beneficial effect of Dorzolamide on the retinal vasculature. 
Obviously, this finding needs to be interpreted with caution until an adequate control group is 
established. This work is in progress. 
 
In a related study 62 from our laboratory, plasma levels of biochemical markers of endothelial 
function, namely endothelin-1 (ET-1) and cyclic guanosine monophosphate (cGMP i.e. a 
surrogate marker of nitric oxide), were assessed in uPOAG, ntPOAG, pPOAG and controls at 
baseline and during the normoxic hypercapnic provocation. A relationship was found 
between the change in the magnitude of vascular reactivity and the change in biochemical 
markers during normoxic hypercapnia in the controls. ET-1 levels were found to be 
repeatedly lower at baseline in uPOAG and ntPOAG, suggesting that there is a systemic 
endothelial dysfunction in uPOAG that remained unaltered even after short-term treatment. 
In addition, there was also a strong association between baseline arteriolar blood flow and 
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baseline levels of cGMP in uPOAG and ntPOAG. These results further validate the 
functional vascular reactivity abnormalities seen in this study. 
 
Previous studies claim to have administered isoxic hypercapnia to provoke an increase in 
retinal blood flow in healthy subjects and in POAG 9, 24, 31, 63, 64. However, these studies have 
failed to report, and / or, monitor concomitant changes in PETO2. In addition, elevated 
PETCO2 levels were achieved by dynamic end-tidal forcing (DEF), an integral proportional 
feedback system to make breath-by-breath corrections to inspired gases, but this technique 
does not actually target the arterial concentration of CO2 (PaCO2). DEF requires a complex 
set-up including multiple large gas tanks and tubing.  In contrast, the Respiract™ system 
(automated gas flow controller) is about the size of a desk-top computer and supplies gas at 
about the subject’s minute ventilation to a relatively small fitted face mask.  An additional 
advantage of the Respiract™ over DEF is that it uses a sequential gas delivery breathing 
circuit whereby PETCO2 has been shown to be equal to PaCO2. This allows the provocative 
stimulus (PaCO2) to be known from exhaled gas (PETCO2) without the need for invasive 
arterial punctures. With DEF, there is a large variation between PETCO2 and PaCO2 so the 
latter is not precisely known from non-invasive measures 46, 65. 
 
A number of limitations exist in this study. There was a significant increase in systolic BP in 
uPOAG, and ntPOAG and in both systolic and diastolic BP in pPOAG and controls. The 
magnitude of increase in BP during normoxic hypercapnia, however, was small (≤8%) and 
well within the range of autoregulation of the retinal vessels and would not be expected to 
have a major influence on vascular reactivity 66, 67. In addition, there was a small increase in 
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peripheral O2 saturation (SpO2) (defined as the ratio of the amount of O2 that is bound to 
hemoglobin to the amount that can be potentially bound) in ntPOAG, pPOAG and controls 
during normoxic hypercapnia. To put this in perspective, one can typically measure 
physiologic responses to changes in SpO2 that reach about 70% 
68, 69.  There are no known 
physiological responses to changes of 1% in the range of nearly saturated hemoglobin (97-
99%). Also, the controls were not age-matched to the pPOAG group. The reason for this was 
that patients with pPOAG were those who had relatively long standing glaucoma compared 
to uPOAG and also those who showed progression of the disease. Previous work in our 
laboratory has shown negligible difference in the magnitude of the vascular reactivity in 
healthy subjects over the range of ages used in this study 70. Also, there was no significant 
difference noted in the baseline arteriolar hemodynamics across the groups. 
 
6.6 Conclusions 
Arteriolar vascular reactivity was reduced in uPOAG and in pPOAG compared to healthy 
subjects. Whether or not this functional deficit of vascular reactivity reflects endothelial 
dysfunction is equivocal. A normoxic hypercapnic protocol was undertaken that avoided 
additional and uncontrolled vasoconstriction in what is a potentially vasospastic disease. 
Vascular reactivity improved after short-term treatment of uPOAG with Dorzolamide. 
However, it is not clear whether this improvement was a direct effect of the medication or a 
secondary effect due to decrease in IOP. Based upon a sub-study, the ONH capillary bed 
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7 Plasma Endothelin-1 and Cyclic GMP in Response to 
Normoxic Hypercapnia in Primary Open Angle Glaucoma 
 
Venkataraman ST, Hudson C, Rachmiel R, Buys YM, Fisher JA, Vogl R, Tong J, Markowitz 
SN, Trope GE, Flanagan JG. Plasma endothelin-1 and cyclic GMP in response to normoxic 
hypercapnia in primary open angle glaucoma. Invest. Ophthalmol. Vis. Sci. (In submission). 
 
7.1 Abstract  
Aim: The aim of the study was to compare plasma endothelin-1 (ET-1) and cyclic guanosine 
monophosphate (cGMP) levels between patients with untreated primary open angle 
glaucoma (uPOAG), progressive POAG (pPOAG), newly treated POAG (ntPOAG) and 
controls at baseline and during hypercapnia. 
Methods: The sample comprised 11 patients with uPOAG (mean age 54yrs, SD 11), 12 
patients with pPOAG (63yrs, SD 9.0) and 16 healthy control subjects (55yrs, SD 7.0). The 
uPOAG group were treated with 2% topical Dorzolamide for 2 weeks to form the ntPOAG 
group. At each visit, blood samples were collected from the cubital vein (with PETCO2 
standardized to 38mmHg). ET-1 and cGMP levels were determined using immunoassay. 
Normoxic hypercapnia was then induced for 15 minutes and blood samples were collected 
during hypercapnia.   
Results: Baseline ET-1 levels were different between the groups (p=0.0012), being lower in 
uPOAG (1.21pg/mL ± 0.56) compared to pPOAG (p=0.040, 1.78pg/mL ± 0.54) and 
compared to controls (p=0.028, 1.77pg/mL ± 0.43). Similarly, ntPOAG exhibited lower ET-1 
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levels (1.13pg/mL ± 0.45) compared to the pPOAG (p=0.015) and controls (p=0.009). 
During normoxic hypercapnia, uPOAG and ntPOAG exhibited lower ET-1 levels than 
pPOAG and controls. cGMP at baseline and during normoxic hypercapnia was not different 
between the groups. Baseline cGMP in uPOAG and ntPOAG (r≥+0.65, p≤0.030) was 
associated with baseline blood flow. In the control group, reduced change in ET-1 from 
baseline to hypercapnia was associated with increased change in retinal blood flow (r=-0.52, 
p=0.04). The change in ET-1 and cGMP in response to normoxic hypercapnia did not differ 
between the groups.  
Conclusions: Plasma ET-1 levels were lower in uPOAG and ntPOAG groups at baseline and 
during normoxic hypercapnia. A relationship was demonstrated between biochemical 
markers of endothelial function and retinal blood flow and vascular reactivity in POAG and 
in controls. 




A transient reduction of optic nerve head (ONH) perfusion and retinal ischemia are thought 
to be implicated in the pathogenesis of primary open angle glaucoma (POAG), in addition to 
the established risk factor of increased intra-ocular pressure (IOP) 1-5. Endothelin-1 (ET-1) 
and nitric oxide (NO) are involved in the regulation of blood flow in the eye 6. ET-1 
receptors have been located in the retina and the ONH 7. ET-1 promotes vasoconstriction in 
the retina by the stimulation of the ET-A receptor that is present in the vascular smooth 
muscle cells and pericytes 8-11. In porcine eyes, ET-1 can also result in vasodilatation via the 
prostacyclin pathway, through the stimulation of ET-B receptors in the ophthalmic 
vasculature 9. Conversely, NO driven relaxation of the retinal smooth muscle cells is thought 
to occur via an increase in cyclic guanosine monophosphate (cGMP, i.e. a surrogate marker 
of NO) 8, 12, although other vasodilating factors such as cyclic adenosine monophosphate 
(cAMP) 13 and prostacyclin might also be responsible for vasodilation 14. A basal release of 
NO is essential for the regulation of retinal vascular tone 15-19. 
  
There is lack of information regarding the response of biochemical markers of endothelial 
function in POAG to systemic provocation. Nicolela and co-workers (2003) assessed plasma 
levels of ET-1 before and after cold provocation and showed an increase in ET-1 after 
provocation in patients with treated POAG 20. However, the study failed to show any 
significant correlation between change in biochemical markers of endothelial function and 
retinal capillary vascular reactivity. In addition, an abnormal decrease in ET-1 level has been 
found during posture change in NTG (from a supine to upright position) 21. 
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A number of limitations exist regarding previous research in this area. In particular: 1) 
Studies have often used patients who were being treated with IOP lowering medications or 
did not report the treatment status of patients 22-29 2) Studies have typically determined 
homeostatic ET-1 22-25, 30-32 and NO levels 26-29, 33, 34 in patients with glaucoma, rather than 
using some form of provocation to assess functional vascular regulation. 3) Only a few 
studies have adopted the approach of simultaneously assessing functional vascular regulation 
(Chapter 6) 35,20 and biochemical markers of endothelial function in POAG patients. The 
development of a combined vascular function and biochemical endothelial function approach 
is essential in order to further our understanding of the patho-physiology of POAG. 4) 
Patients with progressive (p)POAG are thought to be especially prone to vascular 
dysregulation 36-38 and the majority of studies have failed to look at this susceptible group. 
  
The ambiguity of the work to date in this area mandates further investigation to better 
understand some of the mechanisms involved in the pathogenesis of POAG. The aim of this 
study was to compare plasma ET-1 and cGMP levels between groups of patients with 
untreated primary open angle glaucoma (uPOAG), progressive POAG (pPOAG), newly 
treated POAG (ntPOAG) and controls. The effect of systemic hypercapnic provocation, 
whilst maintaining normoxia, on plasma ET-1 and cGMP was assessed in all the groups. We 
then followed-up on the uPOAG group after treatment with a single drop of 2% 
Dorzolamide, twice daily for 2 weeks (who then formed the ntPOAG group). The study also 
aimed to correlate biochemical markers of endothelial function and functional measures of 





The study was approved by the Research Ethics Boards of the University Health Network, 
University of Toronto, and the Office of Research Ethics of the University of Waterloo. All 
subjects provided signed informed consent prior to participation after explanation of the 
nature and possible consequences of the study according to the tenets of the Declaration of 
Helsinki. The sample comprised 4 groups, including 11 patients with uPOAG (i.e. newly 
diagnosed POAG) of mean age 54 yrs (SD 11; 3 males : 8 females) and 12 patients with 
progressive POAG (pPOAG) of age 63 yrs (SD 9.0,  6 males : 6 females). The uPOAG group 
were treated with 2% topical Dorzolamide for 2 weeks to form the newly treated POAG 
(ntPOAG) group.  Sixteen healthy control subjects of age 55 yrs (SD 7.0, 6males :10 
females) formed the control group. There was a significant difference in the mean age of the 
pPOAG group compared to the controls (p=0.003, one tailed, unpaired t-test). pPOAG 
patients were classified based on the occurrence of optic disc hemorrhage within the past 24 
months. 
 
All participants had a visual acuity of 20/40, or better, and a refractive error less than 
±6.00DS and ± 1.50DC. The participants were free of other ocular pathologies and were non-
smokers. Participants with cardiovascular disorders, uncontrolled systemic hypertension and 
diabetes were excluded from the study. Healthy control subjects had no family history of 
glaucoma and diabetes. All participants were asked to abstain from caffeine containing food 
or drinks and red meat at least 12 hours before the study visit. An impact of caffeine on 
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cerebral blood flow is well established 39, while a recent study also showed the influence of 
caffeine on retrobulbar blood velocity 40. Consumption of saturated fats is also known to 
influence vascular reactivity 41.  
 
7.3.2 Procedures 
7.3.2.1 ET-1 and cGMP assays 
The blood sample was collected and prepared according to the manufacturer’s instructions.  
ET-1 (R&D systems, Human Endothelin-1 Immunoassay, MN USA) and cGMP (Cayman 
Chemicals, Ann Arbor, MI USA) were assessed using immunoassay. The intra-assay 
Coefficient of Variation (CoV) of three samples of mean ET-1 of 14.4pg/mL, 32.8pg/mL and 
68.7pg/mL were 4.6%, 4.5% and 4.2%, respectively. The inter-assay CoV of three samples 
of mean ET-1 of 16.2pg/mL, 33.9pg/mL and 70pg/mL were 6.5%, 5.5% and 5.1%, 
respectively. The intra-assay CoV for cGMP in the mid-range 0.55 to 30 pmol/mL ranges 
from 2% (at 5pmol/mL) to 20% (at 0.3pmol/mL). The inter-assay CoV ranges from 7% (at 
5pmol/mL) to 28% (at 0.3pmol/mL). 
 
Further details of the blood preparation procedures and the ET-1 and cGMP assays are 
included in the thesis Appendix. 
 
7.3.2.2 Normoxic hypercapnia provocation 
The technique used to induce normoxic hypercapnia has been fully described in previous 
publications from our group 42, 43 35. Briefly, an automated gas flow controller (RespirActTM, 
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Thornhill Research Inc., Toronto Canada) was attached to a sequential rebreathing circuit to 
induce normoxic hypercapnia in all the groups 42, 43.  
 
7.3.3 Procedures 
Eligibility to participate in the study was assessed during the first visit. The diagnosis of 
POAG was confirmed by a glaucoma specialist (GT or YB). During the second visit, 
participants rested for 15 minutes before the start of the breathing paradigm. Following this, 
PETCO2 (partial end-tidal concentration of CO2) was normalized to 38mmHg for 10minutes 
and a blood sample was then collected from the cubital vein. Normoxic hypercapnia 
(consisting of a 15% increase in PETCO2 from baseline and PETO2 maintained at resting 
levels) was then induced and stabilized for 15 minutes while a second blood sample was 
collected when both PETCO2 and PETO2 were stable. Patients with uPOAG were then treated 
with a single drop of 2% topical Dorzolamide twice daily for 2 weeks. At the end of this 2 
week period, the procedures were replicated in the ntPOAG group. 
 
7.3.4 Statistical Analysis 
A one-way Analysis of Variance (ANOVA) was performed to compare ET-1 and cGMP 
levels at baseline and during hypercapnia in all the groups (Statistica, Statsoft version 7.0). 
Tukey’s honestly significant differences (HSD) post-hoc test was used to compare between 
patient groups. Any difference in the change of ET-1 and cGMP in response to normoxic 
hypercapnia was compared using a one-way ANOVA followed by Tukey’s HSD post hoc 
test for between groups comparison.  
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Correlation Analysis: The plasma ET-1 and cGMP results were correlated to functional 
measures of retinal arteriolar blood flow and vascular reactivity simultaneously assessed in 
response to normoxic hypercapnia in the same sample of patients (Chapter 6) 35. Pearson 
correlation analysis (GraphPad Prism version 5) was performed to correlate absolute ET-1 
and cGMP levels at baseline and during hypercapnia to absolute retinal arteriolar blood flow 
in all the groups. The change in ET-1 and cGMP in response to normoxic hypercapnia was 
also correlated to the vascular reactivity in all the groups. Only conservative correlations with 
an r>0.40 (represents 16% of the variance within the correlation) and a p<0.05 have been 




Baseline ET-1 levels were different across groups (p=0.0012) (Table 7.1). ET-1 levels were 
lower in uPOAG compared to pPOAG (p=0.040) and controls (p=0.028). Similarly, ntPOAG 
also showed lower ET-1 levels compared to pPOAG (p=0.015) and controls (p=0.009). The 
group mean baseline plasma ET-1 in the uPOAG and ntPOAG groups was 1.21pg/mL (SD 
0.56) and 1.13pg/mL (SD 0.45), respectively, while in the pPOAG group and in the controls 
it was 1.78pg/mL (SD 0.54) and 1.77pg/mL (SD 0.43).  
 
ET-1 levels during normoxic hypercapnia were also different across groups (p=0.0014) 
(Table 7.1). ET-1 levels in uPOAG were lower than the pPOAG (p=0.017) and controls 
(p=0.013). Similarly, the ET-1 levels were lower in ntPOAG compared to pPOAG (p=0.032) 
and controls (p=0.026) during hypercapnia. 
  
There was no difference in cGMP at baseline and during normoxic hypercapnia across the 
groups (Table 7.2). The group mean baseline cGMP in the uPOAG, and ntPOAG groups was 
3.23pmol/mL (SD 0.54) and 3.06pmol/mL (SD 0.98), respectively, while in pPOAG and 




Condition uPOAG ntPOAG pPOAG Controls p-value 
Baseline 1.21 ± 0.56* 1.13 ± 0.45* 1.78 ± 0.54 1.77 ± 0.43 0.0012 
Hypercapnia 1.09 ± 0.72* 1.13 ± 0.52* 1.78 ± 0.53 1.76 ± 0.41 0.0014 
 
Table 7.1 Represents group mean ± SD of the ET-1 values (pg/mL) at baseline and during normoxic 
hypercapnia in uPOAG (untreated POAG), ntPOAG (newly treated POAG), pPOAG (progressive POAG), and 
controls.  
The p-value represents significant difference across groups (One-way ANOVA.) * denotes the groups that were 
significantly different when compared between groups using Tukey’s honestly significant difference (HSD) 
post-hoc test (significance at the level of p<0.05). 
 
Condition uPOAG ntPOAG pPOAG Controls p-value 
Baseline 3.23 ± 0.54 3.06 ± 0.98 2.96 ± 1.06 2.92 ± 0.76 NS 
Hypercapnia 2.86 ± 0.88 2.97 ± 0.97 2.86 ± 1.03 2.62 ± 0.81 NS 
 
Table 7.2 Represents group mean ± SD of the cGMP values (pmol/mL) at baseline and during normoxic 
hypercapnia in uPOAG (untreated POAG), ntPOAG (newly treated POAG), pPOAG (progressive POAG), and 
controls.   
NS denotes not significant. 
 
A significant correlation between plasma cGMP and retinal arteriolar blood flow at baseline 
in uPOAG (r=+0.68, p=0.023) and ntPOAG (r=+0.65, p=0.030) was noted (Figures 7.1A & 
7.1B), suggesting that higher cGMP was associated with higher blood flow. Conversely, 
there was a relatively weak non-significant negative correlation between the ET-1 and 
arteriolar blood flow at baseline in uPOAG (r= -0.45, p=0.164) and a negative non-
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significant correlation in ntPOAG (r= -0.59, p=0.061) (Figures 7.2A & 7.2B), suggesting that 
higher ET-1 level was associated with lower blood flow. In ntPOAG, ET-1 during normoxic 
hypercapnia negatively correlated to blood flow (r= -0.65, p=0.043), suggesting that higher 
ET-1 was associated with lower blood flow, while there was no correlation in uPOAG (r=-
0.31, p=0.354) during hypercapnia (Figures 7.3A & 7.3B). 
 
In the control group only, there was a significant negative correlation between the change in 
ET-1 from baseline to normoxic hypercapnia and the change in arteriolar blood flow (r=-
0.52, p=0.04, Figure 7.4A), suggesting that as the change in ET-1 reduced, the change in 
blood flow increased. There was also a relatively weak non-significant positive correlation 
between the change in cGMP from baseline to normoxic hypercapnia and the change in 
blood flow in the control group (r=+0.45, p=0.08, Figure 7.4B), possibly indicating that as 




Figure 7.1 Correlation analysis of the baseline cGMP and retinal arteriolar blood flow in A) uPOAG (untreated 
POAG) and B) ntPOAG (newly treated POAG). 
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Figure 7.2 Correlation analysis of the baseline ET-1 concentration and retinal arteriolar blood flow in A) 
uPOAG (untreated POAG) and B) ntPOAG (newly treated POAG). 
 249 
 
Figure 7.3 Correlation analysis of the hypercapnic ET-1 and retinal arteriolar blood flow in A) uPOAG 
(untreated POAG) and B) ntPOAG (newly treated POAG). 
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Figure 7.4 Correlation analysis of the change in response to normoxic hypercapnia of A) ET-1 and B) cGMP to 
the change in arteriolar blood flow in controls.  
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There was no difference in the change in ET-1 and in cGMP in response to normoxic 
hypercapnia across groups (Figures 7.5 and 7.6, respectively). In terms of percentage change 
in ET-1, uPOAG showed a greater trend to decrease (-9.60%) in response to normoxic 
hypercapnia than the other groups (ntPOAG = -1.61%, pPOAG = +2.86% and controls = 
+2.84%). In uPOAG (-11.23%), the percentage change in cGMP also showed a greater trend 
to decrease compared to ntPOAG (+4.04%) and pPOAG (-0.88%). In the controls, however, 




Figure 7.5 Box plots represent change in plasma ET-1 in response to normoxic hypercapnia in uPOAG 
(untreated POAG), ntPOAG (newly treated POAG), pPOAG (progressive POAG) and controls.  
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Figure 7.6 Box plots represent change in plasma cGMP in response to normoxic hypercapnia in uPOAG 




This study found that baseline ET-1 levels were lower in the uPOAG and ntPOAG groups 
compared to the pPOAG group and controls. The ET-1 levels were repeatedly lower in the 
uPOAG and ntPOAG groups in response to normoxic hypercapnia. These results suggest that 
there is an overall reduction in ET-1 in uPOAG. This is the first study to show a reduction in 
ET-1 levels in uPOAG at baseline and after short-term treatment with 2% Dorzolamide. 
Interestingly, there was an improvement in functional retinal vascular reactivity after 
Dorzolamide treatment 35, possibly suggesting that Dorzolamide treatment does not 
immediately impact systemic measures of ET-1 and cGMP, although the functional 
assessment of retinal vascular reactivity had recovered at this point in time. Alternatively, 
this finding might indicate that the recovery of vascular reactivity following Dorzolamide 
treatment occurs as a result of IOP reduction. In addition, the correlation results in the 
controls showed that as the change in ET-1 reduced during normoxic hypercapnia, the 
change in blood flow increased. 
 
Previously, higher baseline plasma levels of ET-1 have been reported in patients with treated 
NTG 22, 23 and pPOAG 24. while others showed no difference in POAG 20, 21, 25, 30-32 and in 
untreated NTG 32. In our study, however, there was a reduced ET-1 in newly diagnosed, 
untreated patients compared to controls and pPOAG. The finding of higher levels of plasma 
ET-1 in pPOAG (patients on IOP lowering medications) than uPOAG in our study is 
consistent with previous reports of ET-1 levels in treated patients 21-24. Only one previous 
study has assessed ET-1 in patients with NTG without prior treatment and found no 
difference in baseline ET-1 levels compared to controls 32. Certain IOP lowering medications 
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have also been suggested to improve ocular blood flow via a mechanism that is independent 
of the change in ocular perfusion pressure 44, 45 and may improve retinal vascular reactivity in 
untreated POAG 46 35. In this study, we found evidence of the effect of treatment on the 
expression of biochemical markers of endothelial function. Based on the results of this study, 
it is likely that the findings of earlier studies are confounded by the influence of IOP 
lowering medications.  
 
A decrease in the baseline surrogate markers of NO in the aqueous of treated POAG has been 
reported 26, 29, 33 and also in the plasma of patients with treated NTG 34. However, there have 
also been reports of an increase in NO markers in the plasma 27 and aqueous 28 of treated 
POAG. In this study, we did not see any difference in cGMP levels at baseline and during 
normoxic hypercapnia in any of the POAG groups when compared to controls. The 
discrepancies seen between studies that measured biochemical markers of endothelial 
function might be due to the differences in assay procedures and their cross-reactivities. 
Furthermore, the role of NO in the patho-physiology of POAG is controversial and, due to its 
short half-life, direct assessment of NO is challenging. NO is thought to produce vasodilation 
by a decrease in intracellular Ca2+ and an increase in cGMP levels 9, 15, 47-49. Recently, a less 
pronounced decrease in retinal blood flow was reported in POAG compared to the controls 
after systemic inhibition of NO, suggesting that other biochemical vascular factors might be 
involved in effecting vaso-dilation 50. 
 
Previous studies have only assessed homeostatic blood flow in POAG and there is lack of 
work on the assessment of retinal vascular reactivity. In addition, patients with progressive 
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POAG have been suggested to be more susceptible to vascular dysregulation but studies have 
failed to look at retinal vascular reactivity and biochemical markers of endothelial function. 
In an earlier study, we showed a reduced magnitude of vascular reactivity in uPOAG and 
pPOAG compared to controls in response to normoxic hypercapnia. We also found that 
treatment with 2% Dorzolamide, for 2 weeks improved the magnitude of retinal vascular 
reactivity in ntPOAG (Chapter 6) 35. A decrease in extracellular pH has been suggested as a 
possible mechanism for a reported increase in homeostatic blood flow after Dorzolamide 
treatment 44, 51-53. Also, a reduced involvement of NO during acetazolamide induced 
vasodilation in humans has been reported 52. However, the mechanism responsible for the 
improvement in vascular reactivity after Dorzolamide treatment is still not clear and we 
continue to investigate this question in our on-going research. It is possible that the reduction 
in IOP would improve vascular reactivity, although a direct effect of Dorzolamide on the 
retinal vessels cannot be excluded. 
 
This study found significant correlations between homeostatic blood flow and biochemical 
markers of endothelial function. A strong relationship was noted between baseline cGMP 
levels and arteriolar blood flow in uPOAG and ntPOAG, suggesting an association between 
increase in cGMP and increase in blood flow. A negative correlation was noted in uPOAG 
and ntPOAG between ET-1 and baseline blood flow, while a stronger negative correlation 
was observed between ET-1 and blood flow during hypercapnia only in the ntPOAG. These 
associations suggest that increased expression of ET-1 inhibits blood flow in POAG; this 
association was repeated in response to hypercapnic provocation and after treatment with 
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Dorzolamide. These correlations show that ET-1 and cGMP are involved in the regulation of 
blood flow in POAG but clearly the situation is complex and much remains to be revealed. 
 
The study also correlated the functional vascular reactivity to biochemical markers of 
endothelial function. In healthy subjects, an association was found such that as the change in 
ET-1 from baseline to hypercapnia decreases, there is an increase in the vascular reactivity of 
arteriolar blood flow. In addition, as the change in cGMP increases, there is an increase in the 
change of arteriolar blood flow in healthy subjects. Previously, Nicolela and co-workers 
(2003) correlated the change in ET-1 levels to the change in finger blood flow after cold 
provocation in treated POAG patients and failed to show any significant relationship 20. To 
the best of our knowledge, this is the first study where an association between biochemical 
markers of endothelial function and functional vascular reactivity in response to hypercapnia 
has been established. This approach can be used to further our understanding about the 
patho-physiology of POAG. The correlation observed in healthy subjects in this study further 
validates the functional measures of vascular reactivity and provides evidence of the 
underlying physiological mechanisms responsible for the functional measures (Chapter 6) 35. 
 
There was no significant difference in the magnitude of change in ET-1 and cGMP between 
baseline and normoxic hypercapnia across groups. However, there was a trend towards a 
greater percentage decrease of ET-1 (i.e. 4 times greater) in response to normoxic 
hypercapnia in uPOAG than the other groups. In the ntPOAG group, there was no such 
decrease seen, possibly indicating an effect of Dorzolamide on the expression of ET-1. 
Similarly, a trend towards a greater percentage decrease of cGMP in response to normoxic 
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hypercapnia was seen in uPOAG that was not repeated after treatment with Dorzolamide, 
although in a related study functional vascular reactivity increased in response to normoxic 
hypercapnia after treatment with Dorzolamide (Chapter 6)35. Interestingly, the controls also 
showed a similar magnitude of decrease in cGMP during hypercapnia as the uPOAG group. 
  
It is possible that endothelium derived vasodilating factors other than cGMP might be 
involved in retinal vasodilation 8, 54. The role of NO during hypercapnic vasodilation in the 
cerebral vessels of animal models is established 13, 55-57. In the retinal circulation, however, 
the involvement of NO is still controversial 19, 58, 59. 
  
We noted some discrepancies in the correlation results between biochemical markers of 
endothelial function and functional vascular reactivity. A difference in the time of recovery 
of vascular reactivity in POAG after short term treatment with Dorzolamide compared to any 
measureable changes in the biochemical markers of endothelial function may well explain 
such discrepancy. That is, functional vascular reactivity could be decreased in pPOAG and 
uPOAG earlier than any quantifiable changes in the biochemical markers of endothelial 
function. Furthermore, it is not known whether systemic levels of ET-1 and cGMP can be 
related to the concentrations present in the ocular circulation. The blood flow in the retina 
and the ONH is regulated by locally mediated mechanisms 6, 54. Some of the earlier studies 
have assessed aqueous levels of ET-1 or cGMP in POAG and NTG which is also thought to 
represent expression of biochemical markers of endothelial function under local conditions. 
Nevertheless, a linear relationship has been reported between aqueous and plasma cGMP 26 
in POAG but any association for aqueous derived ET-1 remains elusive. 
 258 
Limitations: In this study, 2 patients in the uPOAG and 2 patients in the pPOAG groups 
were taking systemic anti-hypertensive drugs. Also, the patients in the pPOAG group were 
on topical IOP lowering medications including beta-blockers, carbonic anhydrase inhibitors 
and prostaglandin analogues, all of which potentially might influence the expression of 
endothelial derived vasoactive factors. The pPOAG group was older than the controls and 
uPOAG groups, primarily because patients with pPOAG had relatively long standing 
glaucoma. It has been suggested that ET-1 levels may increase with age 31. However, there 
was no difference in the baseline ET-1 and cGMP levels in pPOAG compared to the controls. 
Furthermore, the major limiting factor in the assessment of cGMP as a surrogate marker of 
NO is the influence of diet. Studies have shown increased variability of NO with 
uncontrolled diet, while a low-nitrate diet helps to accurately assess NO 60, 61. Apart from a 
single previous study 26, the majority of the studies have failed to control the dietary intake of 
participants.  In this study, patients avoided the intake of food rich in saturated fats and 




Plasma ET-1 levels at baseline and during normoxic hypercapnia were significantly lower in 
the uPOAG and ntPOAG groups compared to controls and pPOAG and this reduced 
expression of ET-1 was unaltered after short-term treatment. There was no difference in the 
baseline cGMP across groups. This is the first study to report a correlation between retinal 
vascular reactivity and biochemical markers of endothelial function. There was a negative 
correlation between the expression of ET-1 in response to normoxic hypercapnia and the 
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magnitude of vascular reactivity in controls. The assessment of ET-1, and to a lesser extent, 
cGMP in patients with POAG provides useful information about the function of retinal blood 
vessels at baseline and during hypercapnic provocation. Clearly, the relationship between 
functional vascular reactivity and biochemical markers of endothelial function is complex 
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8 General Discussion 
In this thesis, a safe, sustained and a repeatable normoxic hypercapnic stimulus was 
developed that was then used to assess the vascular reactivity of the retinal arterioles and 
change in the systemic biochemical markers of endothelial function in POAG. The 
maintenance of normoxia/isoxia during hypercapnic provocation is important for the 
assessment of vascular reactivity in order to avoid variable and uncontrolled confounding 
effects of O2 induced vasoconstriction. There is lack of comprehensive assessment of 
vascular reactivity in POAG, especially uPOAG. The assessment of retinal vascular 
reactivity without any influence of IOP lowering medications aided the better understanding 
of the pathophysiology of POAG. This is the first study to assess all aspects of retinal 
vascular reactivity (i.e. diameter, velocity and flow) to a standardised normoxic hypercapnic 
provocation. It was found that there was a decrease in vascular reactivity in uPOAG and 
pPOAG compared to controls. In addition, this work also showed that vascular reactivity 
improved after treatment with 2% Dorzolamide for two weeks in ntPOAG (newly treated 
POAG). Another major finding of this work was decreased levels of ET-1 in uPOAG at 
baseline, during normoxic hypercapnia and after short term treatment with Dorzolamide. 
This is the first study to also establish an association between functional vascular reactivity 
and biochemical markers of endothelial function.  
 
A number of limitations exist in terms of the previous studies that have assessed homeostatic 
blood flow and/or vascular reactivity in POAG. The majority of previous studies have 1) 
used non-standardised provocation techniques to assess retinal vascular reactivity; 2) used 
techniques that fail to comprehensively assess blood flow or vascular reactivity 3) included 
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patients who were already receiving IOP lowering medications 4) have not investigated 
patients with pPOAG, whom are thought to be more susceptible to vascular dysregulation 5) 
have not investigated the association between functional vascular reactivity and biochemical 
markers of endothelial function.  
 
Studies in the past have used a non-rebreathing circuit connected to a gas mixing chamber to 
induce hypercapnia. The manual addition of CO2 to room air (combined in a mixing 
chamber) to increase PETCO2 is known as Dynamic End-Tidal Forcing (DEF). Recently, it 
was shown that there is a wide variation between the arterial partial pressure of CO2 (PaCO2) 
and PETCO2 using the DEF in combination with a non-rebreathing circuit. The use of a 
sequential rebreathing circuit allows the intake of exhaled gas from the rebreathed reservoir 
during a decrease in the inspired air. This unique feature has been shown to closely match 
PETCO2 and PaCO2 and also reduce the intra-breath fluctuations in PETCO2. Accordingly, 
the objective of this thesis was to develop a safe, sustained and a repeatable normoxic/isoxic 
hypercapnic stimulus in order to ultimately assess retinal vascular reactivity in POAG. 
  
Chapter 3 describes the use of the manual addition of CO2 via a sequential rebreathing circuit 
to a controlled level of inspired air to achieve a 15% increase in PETCO2. The vascular 
response of the ONH and macular areas to normoxic/isoxic hypercapnia was assessed using 
the Heidelberg Retina Flowmeter (HRF) in young healthy subjects. A 14% increase in 
PETCO2 with a +13% concomitant increase in PETO2 was noted. A significant increase in the 
group mean macular nasal and foveal capillary blood flow was shown in response to 
normoxic/isoxic hypercapnia. There was no change in the blood flow of the temporal rim of 
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the ONH and macula temporal areas in response to normoxic/isoxic hypercapnia. Previous 
studies have also noted regional variation in the vascular reactivity to hypercapnia. This study 
concluded that there was a difference in the magnitude of vascular reactivity of the retinal 
areas assessed in response to normoxic/isoxic hypercapnia. Although the hypercapnic 
stimulus arguably resulted in a physiologically insignificant change, there was still a distinct 
increase in PETO2 during hypercapnia.   
   
In chapter 4, a new manual methodology was used to assess retinal arteriolar vascular 
reactivity in response to a modified normoxic/isoxic hypercapnic stimulus. In addition, the 
CLBF allowed a comprehensive assessment of the retinal hemodynamics in young healthy 
subjects. Normoxic/isoxic hypercapnia was induced by simply decreasing inspired air until 
subjects began to partially rebreathe expired air from the rebreathed gas reservoir, thereby 
elevating PETCO2 in a controlled manner. The modified hypercapnic stimulus resulted in a 
12% increase in PETCO2 while there was a concomitant 6% decrease in PETO2. A significant 
increase in the magnitude of retinal arteriolar diameter, blood velocity and blood flow in 
response to hypercapnia was noted. The changes in the retinal hemodynamics in this study 
were comparable to other research, however, to the best of our knowledge, this is the first 
study to comprehensively assess retinal hemodynamics. The partial rebreathing technique 
resulted in an improved control of PETO2 during hypercapnia compared to the manual 
addition of CO2 to inspired air. Nevertheless, there was still a statistically significant 
decrease in the magnitude of PETO2. The arteriolar vascular reactivity results of this study 
will serve as a reference point for future studies using the CLBF.  
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The results of Chapters 3 & 4 aided in the development of an automated gas flow controller 
(RespirActTM, Thornhill Research Inc., Toronto Canada). Chapter 5 describes the use of an 
automated gas flow controller in combination with the sequential rebreathing circuit to 
induce normoxic/isoxic hypercapnia. This stimulus was used to assess retinal arteriolar and 
ONH capillary vascular reactivity in young healthy subjects. Using this system, PETCO2 and 
PETO2 can be independently controlled and set values are robust to changes in respiration 
rate and tidal volume. A group mean 15% increase in PETCO2 with only a 2-3% increase in 
PETO2 was achieved. As a result, there was a significant increase in the retinal arteriolar 
diameter, blood velocity and blood flow and in capillary blood flow of the temporal rim of 
the ONH, nasal macula and foveal areas. The magnitude of changes noted in the ONH using 
the new normoxic/isoxic hypercapnic stimulus was greater when compared to the response to 
the previously described hypercapnic stimulus (Chapter 3). There was also an increase in 
nasal macula and foveal area blood flow and a non-significant trend towards increase in the 
temporal macular area in response to normoxic/isoxic hypercapnia. Theoretically the 
vascular reactivity of the retinal capillaries and the arterioles will be comparable as the retinal 
circulation is a closed system. However, this is the first study to show that the overall 
magnitude of capillary vascular reactivity in terms of percentage change of flow was 
comparable to the provoked change in arteriolar blood flow. In addition, the PETCO2 and 
PETO2 levels achieved using the automated gas flow controller were also repeatable. The 
study concluded that the use of an automated gas flow controller provided much improved 
control of end-tidal CO2 and O2 but still resulted in minimal changes in PETO2 during 
hypercapnia. For this reason the term “normoxic hypercapnia” (i.e. change that did not 
cause any measurable physiological impact) was used to describe the stimulus in the 
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following chapters of this thesis and in all subsequent publications. The vascular reactivity of 
the retinal capillaries and arterioles was comparable in terms of percentage change of flow. 
 
Chapter 6 describes the use of the standardised and repeatable normoxic hypercapnic 
stimulus to assess retinal vascular reactivity in patients with uPOAG, pPOAG and control 
subjects. The chapter also describes the effect of treatment with 2% Dorzolamide for 2 weeks 
in a ntPOAG group. The magnitude of retinal arteriolar vascular reactivity was reduced in 
uPOAG and pPOAG compared to controls. Treatment with 2% Dorzolamide for 2 weeks 
improved retinal vascular reactivity in ntPOAG. As glaucoma is a condition whose primary 
site of damage is at the ONH, a sub-study was undertaken to also assess the vascular 
response of the ONH using the HRF in a small sample. A decreased ONH capillary vascular 
response in uPOAG and pPOAG was observed. Similarly, in the ntPOAG group, treatment 
with 2% Dorzolamide for two weeks improved ONH vascular reactivity. Some of the 
previous studies have assessed retinal vascular reactivity in previously treated patients. The 
inclusion of previously untreated patients is essential to avoid any residual direct, or indirect, 
vascular effects of IOP lowering medications. In addition, this study also assessed vascular 
reactivity in patients with pPOAG (i.e. currently receiving treatment and currently 
manifesting optic disc hemorrhage) as there is increasing evidence that this group of patients 
are more susceptible to vascular dysregulation. This study revealed impairment of retinal 
vascular reactivity in uPOAG and pPOAG and that short term treatment with Dorzolamide 
improved retinal and ONH vascular reactivity in uPOAG. It is not very clear whether this 
improvement is a direct effect of treatment or due to the decrease in IOP in uPOAG. 
However, in our study there was no change in the mean ocular perfusion pressure (MOPP) 
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during pre- & post-treatment, suggesting that the improvement in vascular reactivity might 
be due to the effect of Dorzolamide. The magnitude of vascular reactivity of the arterioles 
and ONH capillaries was comparable in terms of percentage change of flow in POAG and 
controls subjects. 
 
Chapter 7 assessed systemic levels of biochemical markers of endothelial function (ET-1 and 
cGMP) in uPOAG, pPOAG and controls at baseline and during normoxic hypercapnia. 
Furthermore, the study also quantified biochemical markers of endothelial function after 
treatment with 2% Dorzolamide (ntPOAG). The study showed lower levels of ET-1 at 
baseline in uPOAG and ntPOAG compared to pPOAG and controls. This finding repeated 
during normoxic hypercapnia. These results suggest that there is an overall reduction in the 
endothelial constricting factors in uPOAG. The plasma cGMP level was positively associated 
with blood flow at baseline in both uPOAG and ntPOAG, suggesting that when there is an 
increase in cGMP there is also an increase in blood flow. Similarly, a weak negative 
association was noted between ET-1 and blood flow at baseline in uPOAG and ntPOAG that 
also repeated during normoxic hypercapnia in ntPOAG. These results suggest that an 
increase in ET-1 results in a decrease in blood flow. In the controls only, the change in 
plasma ET-1 during normoxic hypercapnia showed a negative association to the change in 
arteriolar blood flow. These associations further validate the functional vascular reactivity 
measures in Chapter 6. The study concluded that there was a decrease in endothelial derived 
vasoconstricting factor in uPOAG and this finding remained unchanged even after short term 
treatment with 2% Dorzolamide. A relationship was established between functional vascular 
reactivity and change in biochemical markers of endothelial function in response to 
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normoxic hypercapnia in controls. The assessment of ET-1 in patients with POAG provides 
useful information about the function of retinal blood vessels at baseline and during 
hypercapnic provocation. The relationship between functional vascular reactivity and 
systemic biochemical markers is complex and much remains to be revealed. 
 
8.1 Future work 
1. Future work will investigate the mechanism involved in the improvement of vascular 
reactivity in POAG after treatment with 2% Dorzolamide. It is not known whether the 
improvement of vascular reactivity in POAG after short term treatment of Dorzolamide is 
due to the direct effect of Dorzolamide or as a result of a decrease in IOP. Future study will 
determine retinal vascular reactivity in response to normoxic hypercapnia in uPOAG patients 
who were treated with primary Selective Laser Trabeculoplasty (SLT) to reduce IOP. The 
study will also assess biochemical markers of endothelial function in POAG pre-and post-
laser treatment. This work is in progress in our laboratory. 
2. Future studies should also quantify systemic levels of nitrates and nitrites (surrogate markers 
of the presence of nitric oxide). It is possible that endothelial derived biochemical factors 
other than ET-1 and NO might be responsible for the regulation of blood flow in the retina. 
In the cerebral literature, prostacyclin pathway induced vasodilation has been proposed 
during hypercapnia. There is a need for a complete understanding of the various biochemical 
markers of endothelial function in the retina in addition to ET-1 and cGMP. Furthermore, 
prostacyclin induced release of cyclic adenosine monophosphate (cAMP) should also be 
quantified to provide more information about the regulation of the retinal vasculature in 
POAG in response to normoxic hypercapnia. 
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3. There is increasing evidence for vascular dysregulation in patients with POAG and 
associated systemic vasospastic symptoms such as cold hands, cold feet and migraine. Future 
work should assess retinal and ONH vascular reactivity and also systemic biochemical 
markers of endothelial function in NTG. This work is in progress in our laboratory. 
4. Recently, oxidative stress has been proposed as an important factor responsible for the 
development of glaucomatous optic neuropathy (GON) in POAG. Glutathione (GSH) is a 
non-enzymatic antioxidant that also facilitates the bioavailability of NO (a vasodilator). The 
assessment of systemic GSH levels in POAG at baseline and during normoxic hypercapnia 
will provide a better understanding of the regulation of blood flow in the retina. 
5. Retinal vascular reactivity measurements can be combined with retinal oximetry assessment 
in POAG. This will provide information about the retinal oxygen saturation and metabolism 
in POAG that will help to better understand the pathophysiology of the disease.  
 
8.2 Summary of new knowledge and findings from this work 
1. This work resulted in the development of a novel and standardised normoxic hypercapnic 
stimulus. The new stimulus can now be safely used to also determine functional vascular 
response of other ocular and systemic conditions that exhibit vascular dysregulation.  
2. This is the first study to show that the magnitude of retinal capillary vascular reactivity was 
equivalent to the arteriolar vascular reactivity with respect to percentage change of flow. 
3. This work provides a comprehensive assessment of retinal vascular reactivity in POAG in 
response to normoxic hypercapnia. Patients with uPOAG and pPOAG revealed a reduced 
response to normoxic hypercapnia compared to controls. Treatment with 2% Dorzolamide 
for two weeks improved retinal vascular reactivity in the previously untreated group. 
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4. This work found an overall reduction in vasoconstrictive factor in uPOAG that remained 
unchanged during normoxic hypercapnia and after short term treatment with 2% 
Dorzolamide. In addition, the study also established an association between functional 
vascular reactivity and biochemical markers of endothelial function (i.e. ET-1 and cGMP) in 
POAG and controls. These findings further validate the assessment of retinal vascular 
reactivity assessment in patients with POAG and provide a better understanding of the 
pathophysiology of the disease. 
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9 Appendix A: Impact of Simulated Light Scatter on Scanning 
Laser Doppler Flowmetry 
 
 
Venkataraman ST, Hudson C, Harvey E, Flanagan JG. Impact of simulated light scatter on 
scanning laser Doppler flowmetry. Br.J.Ophthalmol. 2005; Sep, 89(9): 1192-1195. 
Reprinted by permission from BMJ publishing group. 
 
9.1 Abstract 
Aim: To determine the impact of simulated light scatter on scanning laser Doppler 
flowmetry (SLDF) assessment of retinal capillary blood flow and retinal image quality. 
Methodology: One eye of 10 normal subjects (mean age 24years, SD 1.7, range 22-27) was 
randomly selected. Varying concentrations of polystyrene microspheres (Polybead 
 Polysciences Inc., USA) were suspended in optically clear cells to simulate light scatter. 
The microsphere concentrations used were 0.05%, 0.03%, 0.02%, 0.01% and a cell 
containing only water. LogMAR visual acuity and contrast sensitivity was measured both 
with and without the cells. Optimal focus and alignment was established by acquiring 3 
SLDF images each of the optic nerve head (ONH) and of the macula using the Heidelberg 
Retina Flowmeter (HRF) with no cell in place. Subsequently, SLDF images were acquired 
with each of the light scatter cells mounted in front of the HRF. The group mean retinal 
capillary blood flow was compared using repeated measures Analysis of Variance 
(reANOVA) as a function of microsphere concentration. 
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Results: Retinal capillary blood flow was significantly higher in the ONH, nasal macula, 
fovea and temporal macula with increase in microsphere concentration (p<0.0001). Using 
Dunnett’s post hoc test, retinal capillary blood flow was found to be significantly increased 
relative to no cell for the 0.03% and 0.05% cell concentrations.  
Conclusions: Simulated light scatter produced an artifactual increase in retinal capillary 
blood flow. The impact of cataract on SLDF measurements has yet to be determined. 


















9.2   Introduction 
Cataract results in intra-ocular light scatter due to change in refractive index and 
opacification of the crystalline lens leading to degradation of retinal image quality 1, 2. In 
humans, the aggregation of lens crystallins form high molecular weight (HMW) aggregates 
of 300 to 500nm diameter resulting in cataract 3, 4. Degradation of retinal image quality and 
contrast in a cataractous eye is primarily due to forward light scatter 5.     
  
Non-invasive digital imaging techniques designed to improve the detection and clinical 
management of retinal disease are now used commonly. Assessment of the influence of 
ocular media opacities on the outcome of these new imaging techniques is important because 
cataract frequently occurs concomitantly with retinal disease. A number of reports have 
studied the influence of simulated light scatter on visual field performance and have shown a 
resulting decrease in visual field sensitivity 6-8. We have recently developed a simulated light 
scatter model and have demonstrated its’ impact on fundus visualization using a digital 
retinal camera 9.  
 
The purpose of the study was to determine the influence of simulated light scatter on 
scanning laser Doppler flowmetry (SLDF) assessment of retinal capillary blood flow and 
retinal image quality. 
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9.3 Materials and methods 
9.3.1 Sample 
The study protocol was approved by the University of Waterloo, Office of Research Ethics. 
Ten subjects of mean age 24 years (SD 1.7, range 22-27) participated in the study. All 
participants had a LogMAR visual acuity of 0.0, or better. Subjects with the following Lens 
Opacity Classification System (LOCS) III 10 grading were excluded from the study: Nuclear 
color > NC2, Nuclear opalescence > NO2; Cortical > C2; and Posterior sub-capsular ≥ P1. 
 
9.3.2 Scanning laser Doppler flowmetry 
The light reflected by moving red blood cells in the retina undergoes a frequency shift while 
light reflected from surrounding tissue remain unchanged. Using SLDF, the intensity of 
back-scattered laser light from the retina is measured as a function of time (to produce an 
intensity-time curve) for each pixel within the image. The two coherent components of light 
interfere resulting in an oscillation or “beat”, of the measured light intensity. The frequency 
of the intensity oscillation is equal to the Doppler frequency shift. Fast Fourier 
transformation of the intensity-time curve generates a power spectrum of the Doppler shift to 
derive parameters of blood flow, volume and velocity at each pixel within the image 11.  
 
SLDF measurements were undertaken using the Heidelberg Retina Flowmeter (HRF; 
Heidelberg Engineering GmbH, Dossenheim, Germany, version 1.03W). The HRF uses a 
780nm wavelength diode laser to measure the intensity, and thereby calculate the Doppler 
shift of back-scattered light. The instrument has a spatial resolution of approximately 10µm 
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and a depth resolution 300-400µm 12-14. The laser scanning system of the HRF enables the 
measurement of a 10° horizontal x 2.5° vertical (i.e. approximately 2.7mm x 0.7mm) field 
with a resolution of 256 pixels x 64 lines, respectively. Each line of 256 pixels is scanned 
128 times at a repetition rate of 4000Hz. The resulting image acquisition time is 2.048 sec. 
 
9.3.3 Simulated light scatter model 
Light scatter was induced using various concentrations of 500nm diameter polystyrene 
microspheres (Polybead  Polysciences Inc., USA) suspended in sterile water. The diameter 
of the microspheres was chosen to be similar to the diameter of HMW aggregates in a 
cataractous lens 4, 5, 8. Microsphere concentrations of 0.05%, 0.03%, 0.02% and 0.01%, and 
water only were prepared under sterile conditions (surfactant poloxamer 407 was included to 
prevent coagulation) 15. The stability of the light scatter model was determined by assessing 
HRF measurements against a plain white paper background for the 0.05% cell which had not 
been disturbed for 24hours and then after vigorous shaking. The mean value (3 repeats) for 
10x10 pixels was 47735 a.u. (SD 373) and immediately after shaking was not significantly 
different i.e. 47335 a.u. (SD 431). 
  
The various microsphere concentrations were injected into cells constructed from two 35mm 
removable CR39 plano lenses mounted on opposite ends of a plastic ring (inner diameter 25 
mm), with a spacing of 4.5mm between the lenses and a thickness of 2.04mm each. The total 
volume of each cell was 2.2mL. The cells were mounted to the objective of the HRF using a 
custom made adaptor that incorporated a 20° tilt to minimize surface reflections (Figure 9.1).   
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Figure 9.1 Schematic representation of the light scatter cell mounted in front of the objective of the HRF using a 
custom designed adaptor to produce a standard 20° tilt. 
 
9.3.4 Procedures 
All participants underwent a preliminary eye examination followed by dilation of the study 
eye with a single drop of 0.5% tropicamide. LOCS III grading was undertaken after dilation. 
Three SLDF images of the optic nerve head (ONH) and 3 images of the macula were 
acquired with no cell in place in order to establish optimal focus settings and image 
alignment. Subsequently, 3 SLDF images both of the ONH and of the macula were acquired 
with the various cells in place. The order of cells and also the measurement site were 
randomized between subjects and a constant focus setting and alignment was maintained 




Fundus photographs of the study eye of one subject were acquired for all conditions using a 
digital fundus camera (Canon CR6-45NM, Canon, Lake Success, New York), in order to 
illustrate the clinical relevance of the simulated light scatter model.  
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9.3.5 Analysis 
Automated full field perfusion image analysis (AFFPIA) software version 3.3 and HRF 
custom analysis were used to generate retinal capillary blood flow values. AFFPIA excludes 
erroneous blood flow values due to saccades and major blood vessels 16. The AFFPIA 
software was used to delineate the temporal neuroretinal rim of the ONH. In addition, a 2.5° 
circle was centred to delineate the foveal macular area. All points temporal to the circle 
delineated the temporal macular area while those nasal of the circle delineated the nasal 
macular area. Capillary blood flow values were derived for the temporal neuroretinal rim and 
the various macular areas.  
  
A custom analysis was developed partly due to the limitation of the AFFPIA software to 
generate blood flow values with the higher microsphere concentrations. The HRF custom 
analysis preserved sample size especially with the high concentration light scatter cells. The 
HRF custom analysis consisted of a 10 x 10 pixel measurement window that was placed 
within the areas of interest. Care was taken to place the 10 x 10 pixel window at the same 
location for all images of a given subject and also within the same area that was used for 
AFFPIA using a transparent sheet to mark the relevant land marks and the AFFPIA area. 
Capillary blood flow for each pixel of the area of interest was obtained along with the 
brightness index of the image (DC value). A total of 100 flow (with corresponding DC) 
values were produced for each area analysed. Flow values with a DC range of 70-200 
arbitrary units (a.u) were included in the analysis since this range is within the acceptable 
level of retinal image illumination 17-19. The data was then sorted in ascending order and any 
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artifactual zero flow values were excluded, along with an equal number of the highest flow 
values. Only images with at least 35 flow values were included. 
 
Repeated measures analysis of variance (reANOVA) of the retinal capillary blood flow 
values for all microsphere concentrations and all measurement regions were performed for 
both AFFPIA and HRF custom analyses using SAS (v.8.02). Since AFFPIA failed to 
generate blood flow values in the majority of the subjects for 0.05% microsphere 
concentration it was not included in the statistical analysis. It was assumed that there was 
minimal light scatter and degradation of retinal image quality without any cell in place. 
Dunnett’s post hoc test was performed to determine the microsphere concentration that 
resulted in a significant change. The DC values obtained using the HRF custom analysis for 
the various microsphere concentrations were also analysed in an identical manner. Pearson’s 
correlation procedure was performed to determine whether there was a significant linear 
relationship between blood flow values with no cell and with increase in microsphere 









The group mean baseline capillary blood flow with the AFFPIA and HRF analysis of the 














228.86 ± 62.84 
 





226.68 ± 191.63 
 
176.52 ± 39.46 192.65 ± 53.92 163.89 ± 83.11 
 
Table 9.1 Group mean baseline capillary blood flow values (± SD) of the ONH, nasal macula, fovea and 
temporal macula using the AFFPIA and HRF custom analysis. 
 
The reANOVA for the AFFPIA demonstrated a significant increase in capillary blood flow 
with increase in microsphere concentration for the ONH (p<0.0001), nasal macula 
(p=0.0003), fovea (p=0.0004), temporal macula (p=0.0003). The reANOVA for the HRF 
analysis also demonstrated a significant increase in capillary blood flow with increase in 
microsphere concentration for the ONH (p<0.0001), nasal macula (p<0.0001), fovea 
(p<0.0001) and temporal macula (p<0.0001). 
  
 Dunnett’s post-hoc analysis of the AFFPIA data revealed a significant increase in capillary 
blood flow with the 0.03% cell concentration while HRF custom analysis revealed a 
significant increase with both 0.03% and 0.05% cell concentrations for the ONH, nasal 
macula, fovea and temporal macula relative to baseline. Capillary blood flow values of the 
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ONH, nasal macula, fovea and temporal macula extracted using the AFFPIA and HRF 
custom analysis followed a similar trend for all light scatter cell situations (Figures 9.2A-D). 
 
Figure 9.2 Group mean capillary blood flow (+SD) with no cell, water only, 0.01%, 0.02%, 0.03%, 0.05% 
microsphere concentrations of the A) optic nerve head B) macula nasal C) foveal and D) macula temporal areas 
using SLDF (grey bars) and custom HRF (black bars) analysis. 
 
The re-ANOVA for the DC values obtained using the HRF custom analysis for all the 
measured regions demonstrated a significant difference across the various microsphere 
concentrations (p=0.0001) (Figure 9.3).  Dunnett’s post-hoc analysis of the DC values 
revealed a significant decrease in DC values with the 0.05% cell concentrations for the ONH, 
nasal macula, fovea and temporal macula relative to baseline.  Pearson’s correlation 
procedure did not show any significant linear association between blood flow values for the 
no cell situation and with increase in microsphere concentration. There was no consistent 
offset observed in the effect produced by the increasing microsphere concentration. 
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With no light scatter cell in place and with the cell containing only water, optimal fundus 
visualisation was achieved. Cells containing polystyrene microsphere concentrations of 
0.01% and 0.02% allowed a blurred outline of the ONH to be visible (Figure 9.4). With 
higher microsphere concentrations, visualisation of fundus details were increasingly difficult.  
 
The results of one subject were excluded due to excessive eye movement and poor image 
quality. AFFPIA failed to generate capillary blood flow values for ≤ 5 and 9 subjects with the 
0.03% and 0.05% microsphere concentrations, respectively. The HRF custom analysis 
resulted in incomplete sets of data only for the ONH measurement site (due to our 






Figure 9.3 Group mean DC values for all the measured regions with no cell, water only, 0.01%, 0.02%, 0.03%, 
0.05% microsphere concentrations.  





Figure 9.4 Fundus image of a normal subject acquired with various cell microsphere concentrations placed in 
front of a digital fundus camera. 




To the best of our knowledge, this is the first study to investigate the effect of artificial light 
scatter on retinal capillary blood flow and image quality using the HRF. AFFPIA and the 
HRF custom analyses both demonstrated a significant artifactual increase in capillary blood 
flow with increasing light scatter. Post-hoc analysis of the AFFPIA data revealed a 
significant increase in capillary blood flow with the 0.03% cell concentration while HRF 
custom data revealed a significant increase with both 0.03% and 0.05% cell concentrations 
for all the measured regions relative to baseline. There was a significant decrease in the DC 
values demonstrated with the 0.05% microsphere concentration relative to baseline. The cell 
with water only was included as one of the conditions because it would induce some degree 
of image degradation and light scatter; however, the analysis demonstrated that there was no 
significant difference between the no cell condition and the cell with water only. Although 
the increase in capillary blood flow with lower light scatter microsphere concentrations did 
not reach statistical significance it might have clinical implications.  
 
The HRF is sensitive to change in photodetector setting.  Change in image brightness has 
already been shown to impact SLDF derived estimates of retinal capillary blood flow 13, 17, 19, 
20. In the current study, increase in light scatter decreased the image brightness for all 
subjects leading to an increase in the HRF gain setting by the operator to optimise the view 
of various retinal structures, as would occur in a clinical situation. This produced a 
significant decrease in DC values with the highest microsphere concentration resulting in a 
significant increase in blood flow values. DC related error in HRF measurements has been 
observed in both in-vitro models and in images of the human fundus. Tsang and co-workers 
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(1999) suggested that darker backgrounds resulted in higher blood velocity values in an in-
vitro blood flow model using the HRF. Increase in retinal capillary blood flow as a result of 
DC changes has already been demonstrated in normal subjects using the HRF 20. However, it 
should be noted that both the AFFPIA and our custom HRF analyses attempted to eliminate 
unacceptable DC values from the raw HRF measurements. 
  
There was a light scatter induced shift observed in the y-axis of the power spectrum with 
0.03% and 0.05% artificial light scatter microsphere concentrations. Careful examination of 
the SLDF power spectrum is required to eliminate images with DC shifts beyond the valid 
measurement range of the HRF. The HRF has a high zero offset due to random variation of 
backscattered light and internal noise leading to change in flow values 12. In this study, 
increase in simulated light scatter exaggerated the high zero offset. This explains the 
significant artifactual increase in capillary blood flow with increasing light scatter.  
 
AFFPIA resulted in exclusion of a majority of subjects as it failed to generate blood flow 
values for higher light scatter cell concentrations due to invalid zero offset. On the other 
hand, our HRF custom analysis provided capillary blood flow values for nearly all possible 
cell situations with the operator defined acceptable range of DC values for all images. This 
feature of the HRF custom analysis produced apparently valid capillary blood flow values 
even for the higher light scatter cell concentrations. 
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9.6 Conclusion 
Simulated light scatter produced an artifactual increase in capillary blood flow in the ONH 
and in various macular regions of the retina. Artificial light scatter resulted in a shift in the y-
axis of the SLDF power spectrum. Both AFFPIA and our HRF custom analysis produced 
remarkably similar capillary blood flow values. SLDF images need to be analysed with 
caution to exclude unacceptable DC values and power spectrum shifts to derive accurate 
capillary blood flow values. The impact of cataract on SLDF measurements has yet to be 
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10 Appendix B: Endothelin – 1 (ET- 1) assay procedure 
10.1 Sample preparation 
1. Blood samples were collected in a K3 EDTA sprayed vacutainer and kept in ice for about 
30mins. 
2. The samples were then centrifuged at 1800 x g (gravity) and 4º C. 
3. 100µL of Aprotinin ((from bovine lung, Sigma-Aldrich, ST.Louis, MO) was added to each 
2mL plasma and stored at -70º C. 
4. A minimum of 2mL was required for the test. 
 
10.2 Principle of the assay 
The assay kit contains a microplate that is pre-coated with an antibody specific for ET-1. 
Standards, Samples, Control and Conjugate are pipetted into the wells and any ET-1 present 
is sandwiched by the immobilized antibody and the enzyme-linked antibody specific for ET-
1. Following a wash to remove any unbound substances from the plate, Substrate is added to 
the wells and color develops in proportion to the amount of bound ET-1. That is, the intensity 
of the color developed is directly proportional to the amount of bound ET-1. Table 10.1 






96 well microplate (12 strips of 8 wells) coated with rat 
antibody to human ET-1. 
ET-1 Standards 
6 vials of lyophilized synthetic human ET-1 containing 
blue dye. 
Sample Diluent 
20mL of buffered protein base, with blue dye and 
preservative. 
ET-1 Conjugate Concentrate 
0.3mL of antibody to ET-1 conjugated to horseradish 
peroxidase (HRP) in buffer. 
Conjugate Diluent 
11mL of diluent for HRP-Conjugate concentrate, with red 
dye and preservative. 
ET-1 Control 
1 vial of lyophilized human ET-1. The concentration of the 
control was within the range specified on the vial label. 
Wash Buffer Concentrate 
20mL of 25-fold concentrated buffered surfactant with 
preservative. 
Substrate 11mL of stabilized tetramethylbenzidine solution. 
Stop solution 11mL of hydrochloric acid (HCl) solution 2N. 
Plate sealers 8 adhesive plate sealers. 
 
Table 10.1 Details the various reagents in the endothelin-1 (ET-1) assay kit provided by the manufacturer that 
was used for the ET-1 assay procedure. 
 
10.3 Reagent preparation 
All reagents were prepared based on the manufacturer’s (R&D systems, MN USA) 
guidelines.  
1. 20mL of Wash Buffer Concentrate was diluted with deionized water to prepare 500mL of 
Wash Buffer 
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2. The ET-1 Standards and ET-1 Control was reconstituted immediately before use with 1.0mL 
of deionized water and was kept at room temperature. 
3. 250µL of Conjugate Concentrate (HRP) was transferred into the bottle of Conjugate Diluent 
and mixed gently by inversion. 
 
10.4  Assay procedure 
The samples, Standards and the ET-1 Control were assayed in duplicate according to the 
manufacturer guidelines. 
1. 100µL of diluted Conjugate was added to each microplate well (total of 96 wells). 
2. 100µL each of the Standard and Control were added to each well without any interruption 
and this procedure was completed within 10mins. 
3. The plate was covered with a plate sealer and then incubated for 1 hour at room temperature. 
4. The contents were then aspirated from each well and washed six times by adding 300µL of 
Wash Buffer in each well.  
5. 100µL of Substrate (tetramethylbenzidine) was added to each well and the plate was sealed 
using a new plate sealer and incubated at room temperature for 30mins. 
6. 100µL of Stop solution (HCl solution, 2N) was added to each well in the same order as the 
Substrate was added. 
7. The optical density of each well was determined using a microplate reader spectrophotometer 
(Spectramax Plus 384, Molecular Devices) set at 450nm wavelength.  
8. A standard curve was then generated with ET- 1 concentration on the x-axis and mean 
absorbance on the y-axis. The concentration for each unknown sample was calculated based 
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on the mean absorbance in the standard curve. The minimum detectable ET-1 was 0.3 
pg/mL. 
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11 Appendix C: 3’,5’ cyclic guanosine monophosphate (cGMP) 
assay procedure 
11.1 Sample preparation 
1. Blood samples were collected in a K3 EDTA sprayed vacutainer and kept in ice for about 
30mins. 
2. The samples were then centrifuged at 1800 x g (gravity) and 4º C. 
3. The centrifuged blood samples were aliquoted in test tubes and stored at -70 º C. 
4. A minimum of 1mL was required for the test. 
 
11.2 Reagents used for the assay procedure and other contents in the 
Enzyme Immunoassay (EIA) kit  
1. cGMP EIA Antiserum 
2. cGMP acetylcholinesterase (AChE) Tracer 
3. cGMP EIA Standard 
4. 10mL EIA Buffer Concentrate 
5. 5mL Wash Buffer Concentrate 
6. 3mL Tween 20 
7. Mouse Anti-rabbit antibody (IgG) coated Plate 
8. Plate Cover 
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9. Ellman’s Reagent (consists of acetylthiocholine and 5,5’-dithiobis-(2-nitrobenzoic acid)): 
Reconstitution of Ellman’s reagent was done before the development stage by adding 20mL 
of deionised water to the Ellman’s reagent vial. 
10. 2.5mL Acetic Anhydride 
11. Ethanol 95% 
12. Potassium hydroxide (KOH) 
13. EIA Tracer Dye 
14. EIA Antiserum Dye 
11.3 Principle of the assay 
The EIA is based on the competition between free cGMP and a cGMP- AChE Conjugate 
(cGMP tracer) for a limited number of cGMP specific rabbit antibody binding sites. The 
concentration of cGMP tracer is constant while the concentration of cGMP in the standard or 
samples varies. As a result, the cGMP tracer that is bound to the rabbit antibody is inversely 
proportional to the concentration of cGMP in the well. 
 
11.4 Definition of terminologies in the assay procedure 
Blank: background absorbance caused by Ellman’s Reagent. The blank absorbance was 
subtracted from the absorbance readings of all the other wells. 
Total Activity: total enzymatic activity of the AChE linked tracer.  
NSB (Non-Specific Binding): non-immunological binding of the cGMP tracer to the well. 
Even in the absence of an anti-serum a very small amount of cGMP tracer still binds to the 
well. NSB is the measure of this low binding. 
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B0 (Maximum binding): maximum amount of the tracer that the antiserum can bind in the 
absence of free analyte. 
%B/B0 (%Bound/Maximum Bound): ratio of the absorbance of a particular sample of 
standard well to that of the maximum binding (B0) well. 
Standard Curve: a plot of the %B/B0 values versus concentration of a series of wells 
containing various known amounts of analyte. 
 
11.5 Reagent preparation 
1. The EIA Buffer Concentrate in the kit was diluted with 90ml of ultra pure water and the vial 
was rinsed to dissolve any precipitated salts. 
2. The Wash Buffer Concentrate was diluted to a total volume of 5 liters with ultra pure water 
and 2.5ml of Tween 20 (Detergent, to decrease non-specific binding) was added. 
3. cGMP AChE tracer and cGMP antiserum were each reconstituted with 6ml EIA Buffer and 
stored at 4 º C. 
 
11.6 Sample preparation 
1. 500µL of each collected plasma sample was transferred into individually labelled test tubes. 
2mL of ice-cold ethanol was added to each tube and vortexed. 
2. The tubes were centrifuged at 3000rpm for 10minutes. 
3. The supernatant was transferred into labelled test tubes and dried using SPEED VAC rotor 
evaporator at medium drying rate. 
4. The residue was reconstituted in 500µL EIA Buffer. 
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11.7 Standard preparation 
1. cGMP Stock Standard: The cGMP standard (concentration 300pmol/mL) in the kit was 
reconstituted with 1mL of EIA Buffer. The stock standard was aliquoted in order to avoid 
repeated freezing and thawing. 
2. cGMP diluted Stock Standard: 100µL of stock standard (300pmol/mL) was aliquoted into 
9.9mL of EIA Buffer. The concentration of the diluted stock standard was 3pmol/mL. 
3. cGMP Working Standards: 500µL of EIA Buffer was added to each of 9 clean test tubes 
(labelled #1 to #9). The following concentrations of working standard were prepared before 
the acetylation procedure, 0.00, 0.023, 0.046, 0.093, 0.187, 0.375, 0.75, 1.5 and 3.0pmol/mL 
using serial dilution procedure (Table 11.1). 
Working Standard 






S9 500µL of 3.0pmol/mL - 3.0 
S8 500µL of 3.0pmol/mL 500 1.5 
S7 500 µL of S8 500 0.75 
S6 500 µL of S7 500 0.375 
S5 500 µL of S6 500 0.187 
S4 500 µL of S5 500 0.093 
S3 500 µL of S4 500 0.046 
S2 500 µL of S3 500* 0.023 
S1  500 0 
* after mixing S2,  the last 500 µL was discarded. 
Table 11.1 Details the serial dilution procedure that was followed to prepare various concentrations of working 
standards. 
 
11.8 Acetylation procedure 
Acetylation procedure was performed to improve the sensitivity of the assay to detect even 
lower amounts of cGMP (i.e. cGMP of less than 1pmol/mL). All samples and standards were 
acetylated individually. 100µL of prepared 4M (4 molar) KOH was added to 500µL of 
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standards and sample followed by 25µL of acetic anhydride in quick succession. After 
mixing for 15 sec on a vortex mixer, 25 µL 4 M KOH was added and all tubes were vortexed 
again. This procedure was repeated for all samples and standards. 
 
11.9 Assay procedure 
1. The pre-coated microtiter plate consists of 12 removable strips (Figure 11.1). The standards 
and samples were done in duplicates. 
2. 50 µL of acetylated EIA buffer (Standard 1) was added into each of the NSB wells, the Bo 
wells and the S1 wells.  
3. 50 µL of EIA buffer was added into each of the NSB wells followed by addition of 50 µL of 
standards and samples into the appropriate wells. 
4. 50µL of sample was added to the corresponding wells in duplicate. cGMP AchE Tracer was 
added to each well except the TA and the Blank wells. 
5. cGMP antiserum was added to each well except TA, NSB and Blank wells. The microplate 
was then covered and incubated at room temperature for 18hours. 
6. The wells were then rinsed six times with wash buffer and reconstituted Ellman’s reagent 
was added to each well. The development of the plate was obtained in the dark using an 
orbital shaker. The assay typically develops in 60-90mins.  
7. The plate was read at a wavelength of 405nm using a spectrophotometer (Spectramax  Plus 




 1 2 3 4 5 6 7 8 9 10 11 12 
 BLK S 2 S 6 1 5 9 13 17 21 25 29 33 
B NSB S 2 S 6 1 5 9 13 17 21 25 29 33 
C NSB S 3 S 7 2 6 10 14 18 22 26 30 34 
D Bo S 3 S 7 2 6 10 14 18 22 26 30 34 
E Bo S 4 S 8 3 7 11 15 19 23 27 31 35 
F TA S 4 S 8 3 7 11 15 19 23 27 31 35 
G S 1 S 5 S 9 4 8 12 16 20 24 28 32 36 
H S 1 S 5 S 9 4 8 12 16 20 24 28 32 36 
 
Figure 11.1 Map of the microplate wells used for cGMP assay procedure.  
Blk; blank NSB; non-specific binding, B0; maximum binding, TA; total activity, S1-S9 
denotes standards in duplicates with concentrations ranging from 0 to 3.0pmol/mL. # 1-36 
represents samples with unknown concentration. 
 
11.10 Calculation of results 
A standard curve was generated using the concentration of acetylated cGMP in the x-axis and 
the percentage of Standard (or sample) bound/maximum bound (i.e. cGMP/maximum bound) 
in the y-axis to calculate the concentration of cGMP. The %B/B0 value for each sample was 
calculated and the concentration of each sample (pmol/mL) was calculated by identifying the 
%B/B0 on the standard curve and reading the corresponding values on the x-axis.  
  
